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“Do not go where the path may lead, 
Go instead where there is no path 
And leave a trail.” 
 
Ralph Waldo Emerson 
  
iv 
  
v 
Agradecimentos 
A minha jornada na ciência e na Investigação durante os últimos anos não 
teria sido a mesma sem cada uma das pessoas que fizeram parte da minha 
vida e a marcaram para melhor! Apenas a vida me dará a oportunidade para 
agradecer a cada uma delas da melhor maneira possível, mas eu vou 
aproveitar a oportunidade para vos agradecer aqui também, no início deste 
manuscrito que resume todo o trabalho durante estes últimos anos. 
Em primeiro lugar, eu gostaria de agradecer à Fundação para a Ciência e 
a Tecnologia for financiar o meu projeto de doutoramento bem como agradecer 
a todas as instituições e respetivas equipas/departamentos por me terem 
recebido e providenciado todas as condições necessárias para que eu pudesse 
desenvolver o meu trabalho: Grupo de Imunologia Molecular e Celular do 
Departamento de Promoção da Saúde e Prevenção de Doenças Não 
Transmissíveis, Instituto Nacional de Saúde Doutor Ricardo Jorge, I.P (INSA, 
Lisboa; Portugal); Departamento de Biologia Vegetal, Faculdade de Ciências 
da Universidade de Lisboa (FCUL, Lisboa, Portugal); Équipe 34 do Institut de 
Chimie et Substance Naturelles (ICSN, Gif-sur-Yvette, França); Équipe 
Génétique et Régulation du Métabolisme du Fer do Centre de Physiopathologie 
de Toulouse-Purpan (CPTP, Toulouse, França). Em particular, gostaria de 
agradecer ao Doutor Jean-claude Drapier no ICSN, Doutora Marie-Paule Roth 
e Doutora Hélène Chopin at CPTP por me terem recebido nas suas equipas e 
respetivos laboratórios durante as minhas estadias profissionais em França. 
Gostaria de agradecer aos meus orientadores Doutora Luciana Costa 
(INSA, Lisboa, Portugal), Doutor François Canonne-Hergaux (ICSN em Gif-sur-
Yvette até 2011, CPTP em Toulouse de 2011 até à atualidade, França) e Prof. 
Doutora Rita Zilhão (FCUL, Lisboa, Portugal) por todo o apoio e orientação ao 
longo de todos estes anos. Em especial, gostaria de agradecer a constante 
disponibilidade da Prof. Rita para me ajudar a todos os níveis sempre que 
precisei da sua ajuda e também pelo seu entusiasmo contagiante em todos os 
nossos encontros! E um agradecimento muito especial para a Luciana e para o 
François que foram não só meus orientadores, mas também se tornaram meus 
amigos durante estes anos. Eles partilharam comigo não só a sua visão da 
Ciência com tudo o que isso acarreta de bom e menos bom, mas partilharam 
também a sua sincera amizade. Posso dizer que acima de tudo o que foi o 
nosso caminho conjunto da Ciência e na Vida com todas as suas alegrias e 
dificuldades, são muitos os momentos e conversas que guardarei com carinho 
no meu coração! 
Gostaria de agradecer à Doutora Anne Negre-Salvayre (Inserm/UPS UMR 
1048-I2MC, Toulouse, França) pela sua colaboração durante os últimos meses 
em Toulouse. A sua preciosa partilha de conhecimento, recursos e inclusive de 
vi 
reagentes foi essencial para uma parte fulcral do trabalho aqui apresentado, 
pelo que eu gostaria de expressar a minha profunda gratidão pela sua 
constante disponibilidade e apoio. 
Gostaria também de agradecer, sem qualquer ordem específica, a todos 
os colegas com quem partilhei a vida no laboratório: Vânia, Tânia, Rita, João, 
Alexandra G., Arminda, Bárbara, Flávia, Inês S., Helena, Inês C., Catarina C., 
Sara, Sónia, Ana M., Ana Margarida M., Ana Isabel, Catarina A, Cláudia B., 
Ângela C, Bruno S., Rute, Paulo, Bruno A., Nuno, Fátima, Sofia N., Alexandra 
W., Anne, Sérgio, Ioana, Cendrine, Nora, Sahar, Cristina, Lorenne, Aurélie, e 
Céline.  
Um grande obrigada ao João por me ter ajudado a dar os “primeiros 
passos” no laboratório e por me ter iniciado na cultura celular e por convencer 
de como a proteína é tão importante, tudo isto sempre acompanhado de boa 
música! Um grande obrigada às minhas queridas amigas Vânia, Tânia, Rita, 
Bárbara, Ana, Flávia e Arminda por todo o apoio sempre que precisei de um 
ombro amigo para chorar, um abraço para celebrar ou apenas uma mente 
brilhante que me ajudasse a perceber o que fazer nas minhas experiências! 
Um grande obrigada à Alex, Anne, Lorenne, Céline e Aurélie por me terem 
recebido tão bem e me terem ensinado e ajudado sempre que eu “caí” nos 
seus laboratórios em Gif-Sur-Yvette e em Toulouse! E um grande obrigada à 
Nora, Sahar e Cristina por me fazerem sentir em casa durante a minha estadia 
em Toulouse! 
Um obrigada muito especial à Vânia, à Tânia e à Nora! Vânia, tu tens sido 
uma presença constante na minha vida, em todos os altos e baixos e em todas 
as minhas frustrações de trabalho (e pessoais) sem te queixares e sempre com 
o teu melhor sorriso e o abraço mais forte! Foste tantas vezes a pessoa com 
quem eu discuti o meu trabalho, a pessoa que me animava nos dias menos 
bons ou que simplesmente lidava com o meu (ocasional) mau humor. Tu sabes 
o quão especial tens sido na minha vida, por isso obrigada pela tua amizade, 
pelo teu apoio incondicional durante todos estes anos e por me dares a 
conhecer o Carnaval de Torres Vedras todos os anos! Tânia, nós demorámos 
algum tempo até entrarmos na vida uma da outra, mas convidar-te para ires 
connosco a Londres foi das melhores ideias que eu e a Vânia tivémos já que foi 
assim que demos os primeiros passos para nos tornarmos grandes amigas e, 
sem saber, para nos tornarmos família! E como não mencionar que és ainda a 
minha melhor parceira de dança e coreografias?! Obrigada pela tua amizade e 
por fazeres parte da minha vida! E Nora, tu entraste na minha vida 
recentemente, mas foste a minha salvação em Toulouse! Obrigada por todos 
os dias, noites, fins-de-semana partilhados, por todos os almoços e jantares 
improvisados no lab (os nossos inesquecíveis noodles picantes!), as nossas 
longas caminhadas de regresso a casa pela noite dentro quando já não haviam 
vii 
transportes, os nossos preciosos e raros momentos de lazer, as nossas 
eternas conversas filosóficas sobre a vida e, acima de tudo, obrigada por 
partilhares comigo estes meses difíceis no final dos nossos doutoramentos e 
por me teres dado força para aguentar e seguir em frente! Nunca me irei 
esquecer da tua citação de Winston Churchill “Se estás a passar no inferno, 
continua a andar”. E é tão verdade! 
Um grande obrigada às minhas “meninas” Filipa, Raquel,Sílvia, Taia e 
Rita por fazerem parte da minha vida durante todos estes anos e pela bonita 
amizade que partilhamos. Foi na vossa companhia que descobri e partilhei a 
minha paixão pela Ciência! E ainda hoje, sempre que nos encontramos, toda a 
distância física que nos separa desaparece e é como se nunca nos tivéssemos 
separado e ainda andassemos pelos corredores da universidade todos os dias! 
E agora com os novos membros da nossa “família” que vieram para nos roubar 
os nossos corações e sorrisos: a Caterina e o Simão! 
E para a minha verdadeira família: a minha mãe, o meu pai e o meu 
irmão... não há palavras para vos agradecer ou para descrever o quão 
importantes vocês são na minha vida! Vocês os três são a razão pela qual, por 
mais difícil que por vezes possa ser, eu me levanto todos os dias e coloco o 
meu melhor sorriso para iniciar o novo dia! Foi o vosso amor que fez de mim 
quem eu sou hoje e que continua a guiar-me a todos os níveis! E foi a vossa 
força que me ajudou em todos os momentos difíceis da minha vida! Cada um 
de vocês tem um papel único e incomparável na minha vida! Obrigada a todos 
por me terem recebido na vossa família e casa pois eu não consigo imaginar a 
minha vida sem vocês ou uma melhor família a quem pertencer! Amo-vos com 
todo o meu coração! 
E finalmente, eu dedico este trabalho à minha avó Ângela de quem eu 
tenho tantas saudades e que me perguntava durante todos estes anos quando 
é que eu terminaria os meus estudos para poder finalmente começar a minha 
própria família! Avó, eu não sei o que a vida me reserva, mas aqui estou eu a 
terminar o meu doutoramento e prestes a iniciar um novo e desconhecido 
capítulo da minha vida, e espero sinceramente que te faça sentir orgulhosa de 
mim onde quer que estejas!  
  
viii 
  
ix 
Acknowledgements 
My journey in Science and in Research over the last years would have not 
been the same without every single person who took part of my life and marked 
it for better! Only life will give me the opportunity to thank each one of you in the 
best possible way, but I will take the chance to thank you here, at the very 
beginning of this manuscript that sums up all the work of these last years. 
In the first place, I would like to thank Fundação para a Ciência e a 
Tecnologia for funding my PhD work and to thank all the different institutions 
and respective teams/departments which received me and provided all the 
conditions necessary so that I could perform my research work: Grupo de 
Imunologia Molecular e Celular at Departamento de Promoção da Saúde e 
Prevenção de Doenças Não Transmissíveis, Instituto Nacional de Saúde 
Doutor Ricardo Jorge, I.P (INSA, Lisbon; Portugal); Departamento de Biologia 
Vegetal at Faculdade de Ciências da Universidade de Lisboa (FCUL, Lisbon, 
Portugal); Équipe 34 at Institut de Chimie et Substance Naturelles (ICSN, Gif-
sur-Yvette, France); Équipe Génétique et Régulation du Métabolisme du Fer at 
Centre de Physiopathologie de Toulouse-Purpan (CPTP, Toulouse, France). In 
particular, I would like to thank Doctor Jean-Claude Drapier at ICSN, Doctor 
Marie-Paule Roth and Doctor Hélène Chopin at CPTP for having received me in 
their teams and respective laboratories during my periods of work in France.  
I would like to thank my supervisors Doctor Luciana Costa (INSA, Lisbon, 
Portugal), Doctor François Canonne-Hergaux (ICSN at Gif-sur-Yvette until 
2011, CPTP in Toulouse from 2011 until today, France) and Prof. Doctor Rita 
Zilhão (FCUL, Lisbon, Portugal), for all the support and guidance through all 
these years. A sincere thank you to Prof. Rita for her constant availability to 
help me at all levels whenever I needed her assistance and for her contagious 
enthusiasm during all our meetings! A special thank you to Luciana and to 
François who were not only my supervisors, but who also became close friends 
during these years. They shared with me not only their view of Science with all 
the good and bad that comes with it, but also their sincere friendship. I can say 
that above all that was our joint path in Science and Life with all the joys and 
difficulties, there were many moments and many conversations that marked me 
as I am today and which I will cherish in my heart! 
I would like to thank Doctor Anne Negre-Salvayre (Inserm/UPS UMR 
1048-I2MC, Toulouse, France) for all her cooperation during the last months of 
my stay in Toulouse. Her precious share of knowledge, resources and even 
reagents was essential for a vital part of my work, so I would like to express my 
sincere gratitude for her constant availability and support.  
x 
I would also like to thank, with no particular order, to all the colleagues 
with whom I shared my life in the lab: Vânia, Tânia, Rita, João, Alexandra G., 
Arminda, Bárbara, Flávia, Inês S., Helena, Inês C., Catarina C., Sara, Sónia, 
Ana M., Ana Margarida M., Ana Isabel, Catarina A, Cláudia B., Ângela C, Bruno 
S., Rute, Paulo, Bruno A., Nuno, Fátima, Sofia N., Alexandra W., Anne, Sérgio, 
Ioana, Cendrine, Nora, Sahar, Cristina, Lorenne, Aurélie, e Céline.  
A big thank you to João who helped me giving my first steps in the lab and 
who taught me about cell culture and how protein is so important, all this always 
at the sound of great music! A big thank you to my dear friends Vânia, Tânia, 
Rita, Bárbara, Ana, Flávia, and Arminda for being there whenever I needed a 
shoulder to cry on, a hug to celebrate or a cleaver mind to help me figure out 
what to do next in my experiments! A big thank you to Alex, Anne, Lorenne, 
Céline and Aurélie for welcoming me so well, teaching me and helping me out 
whenever I “fell” in their labs at Gif-sur-Yvette and Toulouse! And a big thank 
you to Nora, Sahar and Cristina for making me feel like home during my stay in 
Toulouse! 
A special thank you to Vânia, Tânia and Nora! Vânia, you’ve been there 
for me during all these years, in all the ups and downs and all my lab (and life) 
frustrations without complaining and always with your best smile and strongest 
hug! You were so many times the person with whom I discussed my work, the 
person who would cheer me up in a bad day or just handle my (occasional) bad 
mood. You know how special you have been and continue to be in my life, so 
thank you for your friendship, for your support all these years and for taking me 
to Carnival at Torres Vedras every year! Tânia, we took some time to get into 
each other’s lives, but I’m glad we had the idea to invite you to come to London 
as that was the first step for us to become close friends and, without a clue, for 
us to become family! And how could I not to mention that you are also my best 
choreography dance partner?! Thank you for your friendship and for being part 
of my life! And Nora, we met recently, but you were my salvation in Toulouse! 
Thank you for all the days, nights, weekends, for our improvised lunches and 
dinners at the lab (oh our unforgetable instant spicy noodles!), our long walks 
home late at night, our precious and so rare relaxing moments, our eternal 
philosophical discussions about life and, above all, thank you for sharing with 
me these difficult months at the very end of our PhD’s and for giving me the 
strength to hold on and just do it! I will never forget your quote on Winston 
Churchill: “If you’re going through hell, keep going”. And it is so true!  
And a big thank you to my girls Filipa, Raquel, Sílvia, Taia, and Rita for 
being in my life all these years and for the beautiful friendship that we share! It 
was in your company that I discovered and shared my passion for Science! And 
even today, whenever we meet, all the distance disappears and it feels like we 
were never apart and as if we were still walking through the university corridors 
xi 
everyday! And now with the newest members of our “family” who came to steal 
our smiles and hearts: Caterina and Simão! 
And to my true family: my mother, my father and my brother… there aren’t 
enough words to thank you or to describe how important you are in my life! The 
three of you are the reason why, no matter how hard it might be, I will always 
wake up every day and put up my best smile to face the new day! It was your 
love that made me who I am today and that keep guiding me in every possible 
way! And it was your strength that ultimately helped me in all the difficult 
moments of my life! Each one of you plays a unique and incomparable role in 
my life! Thank you all for having received me in your family and in your home as 
I can’t imagine my life without you or a better family to belong to! Love you all 
with all my heart!  
And finally, I dedicate this work to my grandmother Ângela who I miss so 
much and who kept asking me during all these years when would I finish my 
studies so that I could finally start my own family! I don’t know what life has 
reserved for me, but here I am finally finishing my PhD and about to start writing 
a new and unknown chapter of my life, and sincerely hoping that I can make 
you proud of me wherever you are!  
  
xii 
  
xiii 
Resumo 
A aterosclerose (AT) é uma doença inflamatória caracterizada pela 
formação de lesões designadas “placas ateroscleróticas” na parede de vasos 
sanguíneos. A formação destas lesões tem início na disfunção endotelial 
decorrente da ação de vários fatores de risco e que resulta na acumulação e 
modificação de partículas de lipoproteína de baixa densidade (LDL) 
(nomeadamente LDL oxidado (oxLDL)). A acumulação subendotelial de oxLDL 
promove a ativação das células endoteliais e o consequente recrutamento de 
células imunitárias, incluindo monócitos e linfócitos do sangue periférico. Os 
monócitos infiltrados diferenciam-se em macrófagos que, por ingestão de 
oxLDL, acumulam lípidos no seu interior e se diferenciam nas chamadas 
“células esponjosas” (do inglês “foam cells”), que são características das placas 
ateroscleróticas. 
Vários autores observaram a acumulação de ferro em placas 
ateroscleróticas, frequentemente associada a “células esponjosas” derivadas 
de macrófagos. Em 1981, Sullivan propôs a chamada “hipótese do ferro” na 
qual o nível de ferro armazenado no organismo poderia constituir um fator de 
risco no desenvolvimento e progressão da AT. De acordo com esta hipótese, a 
reduzida frequência de desenvolvimento de AT em doentes com 
hemocromatose hereditária – caracterizados por macrófagos deficientes em 
ferro apesar da elevada sobrecarga de ferro sistémica – sugere que a retenção 
de ferro no macrófago promovida pela hepcidina (Hepc) poderá constituir um 
mecanismo pró-aterogénico crucial na possível associação do ferro à 
aterogénese. De facto, estudos recentes indicam que a Hepc pode 
desempenhar um papel pró-aterogénico e que a promoção da saída de ferro 
mediada pela ferroportina-1 (Fpn1) poderá constituir um mecanismo de 
resistência do macrófago à diferenciação em “células esponjosas”. Por outro 
lado, e apesar do seu potencial papel como ferroxidase envolvida na saída de 
ferro em macrófagos, a ceruloplasmina (Cp) é também capaz de oxidar outros 
substratos tais como as partículas de LDL. Adicionalmente, visto que a sua 
expressão é fortemente induzida em condições pró-inflamatórias, a Cp tem sido 
proposta como um potencial fator pró-aterogénico. Neste contexto, o principal 
objetivo do presente estudo foi clarificar a regulação da expressão de proteínas 
envolvidas no metabolismo do ferro nas células imunitárias que infiltram as 
placas ateroscleróticas, com particular interesse na proteína exportadora de 
ferro Fpn1 e na Cp como sua potencial parceira neste processo. 
Numa primeira fase, o objetivo do estudo foi caracterizar a expressão das 
duas isoformas da Cp em linfócitos, monócitos e macrófagos bem como avaliar 
o seu potencial envolvimento como ferroxidase na saída de ferro no macrófago 
mediada pela Fpn1. Os resultados obtidos demostraram que, para além da 
isoforma solúvel da Cp (sCp) já descrita em outros estudos, os linfócitos, 
xiv 
monócitos e macrófagos expressam também uma isoforma membranar desta 
proteína. A diminuição da expressão da Cp membranar após o tratamento com 
PIPLC – uma enzima que corta especificamente proteínas com âncoras GPI – 
demonstrou que pelo menos parte da Cp associada à membrana corresponde 
à isoforma GPI-Cp nestas células. Adicionalmente, os resultados obtidos pelo 
nosso grupo de investigação permitiram concluir que a regulação da expressão 
da Cp em células imunitárias varia de acordo com o tipo de célula, com o seu 
estado de ativação e inclusivé com o tipo de isoforma. De facto, neste estudo 
observou-se que condições de stress oxidativo promoveram a diminuição do 
nível de mRNA de ambas as isoformas da Cp, ao passo que condições pró-
inflamatórias induziram o aumento significativo e exclusivo do nível de mRNA 
da isoforma solúvel (sCp). A expressão da Cp nas células imunitárias que se 
encontram envolvidas na formação e desenvolvimento das placas 
ateroscleróticas (monócitos/macrófagos e linfócitos) pode constituir uma fonte 
de Cp na placa e, consequentemente, um mecanismo adicional para a 
oxidação de partículas de LDL em condições pró-inflamatórias, o que é 
corroborado pela co-localização da Cp e oxLDL anteriormente descrita em 
áreas pró-ateroscleróticas na parede do vaso. Efetivamente, a hipótese da Cp 
constituir um fator pró-aterogénico é apoiada por vários estudos que 
observaram uma associação entre o elevado nível de Cp sérica e o risco de 
desenvolvimento da AT.  
Contudo, a expressão da Cp em células imunitárias pode estar também 
associada ao efluxo de ferro nestas células. Estudos recentes demonstraram 
que após estimulação com ferro, a expressão de Fpn1 em macrófagos 
aumenta significativamente em macrófagos, sendo recrutada para a membrana 
plasmática, onde se encontra enriquecida em microdomínios denominados de 
“jangadas lipídicas” (do inglês “lipid rafts”). Neste estudo, o padrão pontilhado 
da distribuição da Cp observado à superfície celular de monócitos, macrófagos 
e hepatócitos imortalizados (HepG2) é indicativo de que esta proteína se 
encontra concentrada em domínios membranares. Os resultados obtidos 
confirmaram que parte da Cp expressa em macrófagos bem como em células 
HepG2 se encontra localizada nas “jangadas lipídicas” e demonstraram ainda 
uma co-localização parcial entre a GPI-Cp e a Fpn1 em macrófagos 
estimulados com uma elevada concentração de ferro, o que sugere que a Cp 
poderá participar como ferroxidase no efluxo de ferro mediado pela Fpn1. 
Contudo, dado o caráter parcial da co-localização da GPI-Cp e Fpn1, é 
possível que a sCp ou uma outra ferroxidase possam estar também envolvidas 
no transporte de ferro pela Fpn1 em macrófagos estimulados com sobrecarga 
de ferro. Um estudo recente sugere que a proteína precursora do péptido β-
amilóide (APP) poderá estar envolvida no efluxo de ferro mediado pela Fpn1 
em neurónios, o que é corroborado pela acumulação de ferro nestas células 
em ratinhos App-/-. Os resultados aqui apresentados confirmaram a expressão 
da APP em macrófagos e demonstraram que condições de elevada 
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concentração de ferro promovem o aumento da expressão da APP bem como 
a sua co-localização com a Fpn1 nas “jangadas lipídicas”. Estes resultados 
estão de acordo com a hipótese de que a APP possa colaborar com a Fpn1 no 
efluxo de ferro em macrófagos estimulados com sobrecarga de ferro. Deste 
modo, é proposto um modelo no qual ambas as isoformas da Cp bem como a 
APP poderão estar envolvidas no efluxo de ferro mediado pela Fpn1 em 
macrófagos, podendo apresentar papéis sobrepostos mas também 
complementares.  
Numa segunda fase, propusemo-nos a clarificar o efeito da presença das 
partículas de oxLDL na expressão de algumas proteínas-chave no metabolismo 
do ferro em macrófagos. Os nossos resultados demonstraram que a 
estimulação de macrófagos com oxLDL levou à polarização do fenótipo Mox 
descrito por Kadl et al, bem como à acumulação intracelular de lípidos. A 
análise da expressão génica revelou que a exposição às partículas de oxLDL 
promoveu o aumento significativo da transcrição da heme oxigenase-1 (HO-1, 
gene Hmox1) e da Fpn1. Este aumento da transcrição de Hmox1 e Fpn1 não 
foi observado na presença de partículas de LDL nativo ou acetilado, o que 
sugere que este efeito é específico da modificação oxidativa das partículas de 
LDL. Tratamento de macrófagos Nrf2-/- e Nrf2+/+ com oxLDL mostrou que o 
aumento do nível de mRNA da Hmox1 e da Fpn1 induzido por oxLDL é 
mediado, pelo menos em parte, pelo fator de transcrição Nrf2. A exposição dos 
macrófagos a oxLDL conduziu ainda ao aumento significativo da transcrição da 
Hamp1 (gene da Hepc), interleucina-6 (IL-6, gene Il6) e da cadeia pesada da 
ferritina (H-Ft, gene Fth1), bem como a diminuição significativa da transcrição 
de ambas as isoformas da Cp. Contudo, e ao contrário do observado na HO-1, 
o aumento significativo do nível de mRNA da Fpn1 induzido por oxLDL não foi 
traduzido num aumento significativo a nível proteico. Este resultado sugere que 
a síntese da Fpn1 se encontra limitada no fenótipo Mox, provavelmente através 
de um mecanismo de regulação pós-transcricional influenciado pelo nível 
intracelular de ferro. Estes resultados sugerem ainda que, apesar da forte 
indução da transcrição da Fpn1, o efluxo de ferro nos macrófagos Mox se 
mantém provavelmente residual devido ao nível proteico basal da Fpn1. 
Contudo, como uma consequência a longo prazo da redução da transcrição da 
Cp e/ou do aumento da Il6 e Hamp1, é possível que o efluxo de ferro possa 
estar diminuído nos macrófagos Mox.  
Por outro lado, a estimulação simultânea de macrófagos com oxLDL 
(ativador do fenótipo Mox) e com lipopolissacarídeo combinado com interferão-
γ (LPS/IFNγ, ativadores do fenótipo M1) induziram a diferenciação de um 
fenótipo misto entre Mox e M1 (Mox/M1), o que demonstrou que o fenótipo Mox 
não é predominante sobre o fenótipo M1 nestas condições. Os macrófagos 
Mox/M1 apresentaram acumulação intracelular de lípidos à semelhança dos 
macrófagos Mox, sendo caracterizados por um aumento significativo da 
xvi 
transcrição da Hmox1, Il6, Fth1 e Cp (especificamente a isoforma sCp) e por 
uma diminuição significativa da transcrição da Fpn1 à semelhança dos 
macrófagos M1. Estes resultados sugerem que macrófagos expostos a um 
ambiente rico em oxLDL e em condições pró-inflamatórias como LPS/IFNγ 
promovem a acumulação intracelular de lípidos e de ferro em conjunto com o 
aumento da produção de sCp e de citocinas pró-inflamatórias tais como a IL-6, 
provavelmente contribuindo para a oxidação das partículas de LDL e para a 
inflamação local, o que poderá ter um papel pró-aterogénico.  
De acordo com estudos recentes, é o aumento de expressão de Fpn1 que 
desencadeia um mecanismo que conduz ao transporte reverso de colesterol e 
consequente resistência ao desenvolvimento de “células esponjosas”. Deste 
modo, podemos assumir que a expressão basal (Mox) ou diminuída de Fpn1 
(M1, Mox/M1) não confere proteção contra a formação das “células 
esponjosas”, o que é apoiado pelos resultados de elevada acumulação 
intracelular de lípidos observada em macrófagos Mox e Mox/M1. 
Concluindo, os resultados apresentados neste estudo estão de acordo 
com a “hipótese do ferro” proposta por Sullivan e indicam potenciais 
mecanismos quer para a acumulação de ferro em macrófagos, quer para a 
oxidação de LDL, ambos favorecendo a diferenciação de “células esponjosas” 
nas placas ateroscleróticas, o que contribui para o desenvolvimento e 
instabilidade das lesões e consequentemente para a progressão da AT.  
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Abstract 
Atherosclerosis is an inflammatory disease characterized by the formation 
of vessel wall plaques, initiated by oxidized LDL (oxLDL) accumulation and 
infiltration of immune cells. Iron accumulation in atherosclerotic plaques was 
proposed to constitute a risk factor in atherogenesis and immune cells could 
contribute to this risk. Herein, we studied the iron homeostasis of lymphocytes, 
monocytes and macrophages in a context of atherogenic conditions. 
Particularly, we investigated the expression and regulation of the iron exporter 
ferroportin-1 (Fpn1) and its potential functional partner ceruloplasmin (Cp). 
We demonstrated that lymphocytes, monocytes and macrophages 
express both a soluble Cp and a membrane GPI-Cp. Through oxidation of LDL, 
Cp expressed by immune cells could contribute to the reported association 
between high Cp levels and increased cardiovascular risk. We showed that 
GPI-Cp partially co-localizes with Fpn1 in lipid rafts of iron-treated macrophages 
and could participate in Fpn1-mediated iron export. However, we proposed that 
besides Cp, the β-amyloid precursor protein (APP) could be a functional partner 
of Fpn1 in macrophages that needs to be further studied.  
The effect of oxLDL on the iron homeostasis was investigated in 
macrophages. Despite oxLDL-driven Nrf2 activation and increased heme 
oxygenase-1 expression, Mox macrophages were not protected from foam cell 
formation like Mhem/M(Hb) macrophages, showing lipid accumulation, basal 
levels of Fpn1 at cell surface along with upregulation of interleukine-6 and 
hepcidin. Simultaneous exposure to oxLDL and LPS/IFNγ induced a Mox/M1 
phenotype closer to M1 than Mox, with increased interleukine-6 and H-ferritin 
expression along with decreased Fpn1 expression. Our results suggest that 
macrophages exposed to a microenvironment rich in oxLDL and pro-
inflammatory cytokines are prone to accumulate both lipids and iron while 
secreting high levels of pro-inflammatory cytokines and Cp, which will further 
promote the local inflammation and LDL oxidation. In summary, our results 
support the “iron hypothesis” in atherogenesis proposed by Sullivan. 
Keywords 
Iron, atherosclerosis, ceruloplasmin, ferroportin-1, β-amyloid precursor protein, 
immune cells. 
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3 
1. Iron 
 
1.1. Iron: a micronutrient essential to life 
Iron is one of the most abundant elements on Earth, constituting 
approximately 5% of its crust and almost entirely its nucleus. It is a metal 
commonly used in our society, but few know that iron is a trace element 
essential for most living organisms. It is a functional component of oxygen-
carrying proteins, cytochromes, DNA polymerase, and enzymes involved in 
electron transfer. However, given its high chemical reactivity, iron can be very 
toxic by generating free radicals through the Fenton reactions and contributing 
to oxidative stress and cell damage 1. The challenge for most organisms is to 
acquire adequate iron supply and simultaneously avoid its toxicity. Thus, highly 
regulated mechanisms were developed by complex organisms in order to 
control iron absorption, its distribution and storage in cells and tissues 2.  
Iron is a transition metal that exists in two reversible redox states: reduced 
ferrous (Fe2+) and oxidized ferric (Fe3+) iron. Under an oxygen-rich atmosphere, 
the most stable form of iron commonly found in nature is Fe3+, which is 
insoluble and thus poorly available for human and animal intake. In our diet, iron 
can be found in the form of heme (meat, poultry, and fish) or non-heme iron 
(mostly found in cereals and some vegetables), this latter one corresponding to 
the major source of dietary iron for humans (90%) 3. However, despite being the 
most predominant source of iron, non-heme iron has low absorption efficiency. 
In fact, human populations with a predominantly vegetarian diet are commonly 
associated with high prevalence of iron deficiency 4.  
The iron content in human body is 3-4 g, with iron daily losses of 
approximately 1-2 mg in adults (0.1% of total iron) that must be replaced by 
dietary iron in order to maintain iron balance. Apart from menstruation in adult 
women, iron losses occur predominately through desquamation of epithelial 
cells at the intestine and skin as well as through minor bleedings. There is no 
efficient iron excretion and thus the losses of iron cannot significantly increase 
in response to excessive iron intake and storage. 
The major portion of human iron content (70%) is contained in erythroid 
precursors and mature erythrocytes as key component of hemoglobin (Hb), 
20% is stored as ferritin (Ft) and hemosiderin in hepatocytes (liver) and in tissue 
macrophages (kupffer cells in the liver, splenic and bone marrow macrophages) 
while 10% is found in myoglobin in muscles cells or used by several iron-
dependent enzymes in several tissues 5. The major destination of iron in human 
body is the bone marrow, where erythroid precursor cells incorporate iron atoms 
into heme during Hb synthesis. The liver has first access to dietary nutrients 
and can readily uptake iron for storage in hepatocytes. Tissue macrophages are 
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responsible for elimination of senescent erythrocytes and recycling of Hb-
associated iron. The lifespan of human erythrocytes is 120 days, meaning that 
every day about 0,8% of all erythrocytes are recycled by macrophages. The 
recycling of heme is an essential process as the erythropoietic daily needs are 
about 20 mg/day, of which only 1-2 mg are daily absorbed (Figure I.1) 5,6.  
Despite large flows of iron in the plasma compartment, iron circulates 
mostly associated to transferrin (Tf) and its concentration is maintained in the 
range of 10-30 µM under normal homeostatic conditions. Low plasma iron 
concentration restricts iron uptake by erythroid precursors, limiting Hb synthesis 
and oxygen-transport, causing anemia. On the other hand, high plasma iron 
concentration that exceeds Tf binding capacity will lead firstly to iron 
accumulation at the liver and secondary iron accumulation in other tissues. 
However, excessive iron accumulation potentiates cell and tissue damage 
possibly by iron-mediated generation of reactive oxygen species (ROS) 1. Thus, 
a tight control must be kept between dietary iron absorption, iron recycling and 
iron losses in order to prevent iron homeostasis disorders.  
Figure I.1 - Distribution of iron in 
adults. In a balanced state, the human 
body has 3-4 g of total iron with a daily 
iron intake and loss of 1-2 mg (0,1%). Iron 
is absorbed at the duodenal enterocytes, 
being then loaded onto the plasma iron 
carrier Tf. Tf delivers iron to most 
cells/tissues, with bone marrow being the 
major destination for Hb synthesis at 
erythroid precursors and mature 
erythrocytes, followed by muscles fibers 
for myoglobin synthesis and other tissues. 
Excess of iron in circulation can be stored 
in Ft molecules in hepatocytes (liver) or at 
tissue macrophages as result of iron 
recycling from senescent erythrocytes. 
Without an efficient iron excretion 
mechanism, the regular daily iron loss is 
modest and occurs mainly by blood loss 
(menstruation and others) and by 
desquamation of epithelial and intestine 
mucosal cells. Image adapted from the 
original published at NC Andrews 
5
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1.2. Iron metabolism: absorption, transport, storage 
and recycling 
 
1.2.1. The intestinal iron absorption 
The absence of an efficient mechanism for iron excretion makes the 
control of iron absorption extremely important for insuring iron homeostasis. In 
mammals, the absorption occurs at the intestinal mucosa level, on the proximal 
portion of the duodenum, and it is an extremely controlled process that is 
modulated in agreement with the changes in body iron stores, tissue hypoxia 
and erythropoietic demand for iron. In that portion of the duodenum, polarized 
cells named enterocytes are organized on fingerlike villi that protrude into the 
intestinal lumen to maximize absorptive surface area. Duodenal enterocytes are 
the cells responsible for iron absorption, migrate from the crypt toward the tip of 
the villus (maturation axis) as they become polarized during their maturation 
process. Each absorptive enterocyte is a polarized cell with a microvillous brush 
border at the apical membrane that faces the intestinal lumen where cellular 
iron uptake takes place. Subsequently, iron is either stored in Ft molecules or 
transferred across the cell to the basolateral membrane where it is exported into 
plasma. Ft iron will be shed along with the senescent enterocytes (short life 
cycle of 2-3 days) and eliminated through the gastrointestinal tract 5-7. 
Iron absorption is a complex process that involves many proteins for the 
iron uptake at the apical membrane (importers), transport across the cytoplasm 
(chaperones), storage (Ft), transport across the basolateral membrane 
(exporter) and change of redox state of iron associated with import (reductase) 
and export (oxidase) activity.  
Routes of iron import at the apical membrane of enterocytes vary 
according to the type of iron source: inorganic iron, heme and Ft (Figure I.2). 
1.2.1.1. Inorganic iron apical uptake 
Non-heme iron, also referred as inorganic iron, corresponds to Fe3+ and is 
transported by the divalent metal transporter 1 (DMT1, originally named 
Nramp2) localized at the apical membrane of enterocytes 8,9. This transporter is 
not exclusive to iron, but animal models as well as human patients carrying 
mutations in DMT1 showed severe microcytic anemia evidencing the key role of 
this protein as the main iron importer involved in iron absorption10,11. DMT1 
transports only divalent metals, meaning that Fe3+ ions must be reduced to Fe2+ 
prior to transport by DMT1 at the apical membrane. Although there is some 
controversy on the topic 12,13, so far such reduction has been attributed to the 
duodenal cytochrome b (Dcytb) which is also expressed at the apical 
membrane of enterocytes, and that may use ascorbic acid as a co-factor for 
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Fe3+ reduction 14. Both DMT1 and Dcytb show increased expression at the 
apical membrane of enterocytes under iron deficiency and hypoxia conditions 
9,14,15. Some work suggests that DMT1 expression in enterocytes could also be 
downregulated by the master regulator of iron metabolism Hepcidin (Hepc) in 
conditions of iron overload 16 (see section 1.3.2.1).  
1.2.1.2. Heme apical uptake 
Two heme transporters have been reported in mammalian cells: heme 
carrier protein 1 (HCP-1, potential heme importer localized at the apical 
membrane of enterocytes) and heme responsive gene 1 (HRG1, potential heme 
exporter localized at the basolateral membrane and/or endosome membrane in 
polarized cells) 17-19. The mechanisms underlying heme absorption are not very 
clear, but it is believed that heme is imported at the apical membrane either by 
HCP-1 or through receptor-induced endocytosis, with HRG1 possibly exporting 
heme out of the endosome into the cytoplasm. Once in the cytoplasm, heme 
could be catabolized by heme oxygenase-1 (HO-1, also known as HMOX1), 
generating free iron that would join the intracellular labile iron pool (LIP) 18,20.  
1.2.1.3. Ferritin apical uptake 
Dietary Ft has also been shown to be absorbed at intestinal level by a yet 
unknown, but independent mechanism from the ones involved in duodenal 
uptake of heme and inorganic iron 21, constituting another source of iron 
absorbed by enterocytes.  
1.2.1.4. The basolateral iron export 
After uptake in the enterocytes, intracellular iron can then be either 
incorporated into Ft molecules for storage or carried to basolateral membrane. 
At that site, ferroportin-1 (Fpn1, also known as SLC40A1), which is the only 
known iron exporter in mammals, transports iron to plasma in cooperation with 
the membrane multicopper oxidase hephaestin (Heph) 22-25. The involvement of 
the circulating plasma multicopper oxidase ceruloplasmin (Cp) in such process 
was also reported under conditions of bleeding-induced acute anemia 26. In 
addition, it was recently proposed the existence of a third unidentified soluble 
ferroxidase expressed in enterocytes 27.  
Fpn1 expression at the basolateral membrane of enterocytes is also 
induced by iron deficiency and hypoxia, being downregulated by post-
translational mechanisms involving Hepc under systemic iron overload 
conditions as well as inflammation and infection, blocking iron absorption 28. In 
addition to export of iron by Fpn1, intracellular heme in the enterocytes can be 
also exported at the basolateral membrane by HRG1, entering the plasma 
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where it forms complexes with other macromolecules such as hemopexin 
(Hpx)18. 
 
Figure I.2 - Schematic illustration of the different pathways for iron intestinal absorption. 
The enterocyte is a polarized cell, presenting microvillosities at the apical membrane that 
contacts the intestinal lumen and a smooth side at the basolateral membrane which contacts 
with the plasma. Iron can be absorbed in various forms: inorganic iron (Fe
3+
) through DMT1 
coupled with the reductase Dcytb; heme through HCP1 and/or endocytosis followed by export 
to the cytoplasm and at the basolateral membrane through HRG1; iron associated with Ft 
through a yet undisclosed mechanism. Depending on the body iron requirement, the absorbed 
iron can be stored in Ft molecules or exported to the plasma through the iron exporter Fpn1 
coupled with the oxidase Heph and circulating Cp. The free iron can then be transported by Tf 
in plasma while heme circulates associated with Hpx. 
1.2.2. Iron distribution and general cellular uptake 
Once in plasma and given its high redox reactivity, iron circulates mostly 
associated with other molecules and subsequently enters cells through different 
mechanisms (Figure I.3), of which some are exclusive of specific cells/tissues.  
1.2.2.1. The transferrin cycle 
Under physiological conditions, Fe3+ in plasma circulates mostly 
associated with Tf, corresponding to approximately 30% of total circulating Tf. 
This protein is considered to be the main plasma iron carrier with high affinity to 
Fe3+ and it is mostly secreted by liver hepatocytes. Tf can circulate dissociated 
from iron as apo-transferrin (apo-Tf, iron dissociated Tf) or associated to one 
Fe3+ atom (monoferric Tf) or two atoms of Fe3+ (diferric Tf), both designated as 
holo-transferrin (holo-Tf, iron associated Tf) 29. Cells can uptake holo-Tf through 
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a Tf specific receptor denominated Tf receptor 1 (TfR1), which is expressed in 
most cells, with variable degree of expression according to the cell iron 
requirements 30. One important destination for circulating holo-Tf is the bone 
marrow, where erythroid precursors express high levels of TfR1, importing most 
of plasma holo-Tf for incorporation into heme during Hb synthesis 31.  
All cells, including erythroid precursors, uptake holo-Tf complexes through 
an endocytosis process known as “Tf cycle”. Diferric-Tf has higher affinity to 
TfR1 than monoferric Tf, favoring the maximum uptake of iron per TfR1 
molecule. After holo-Tf binding to TfR1, an endocytosis process is triggered and 
a clatherin vesicle is formed containing the complex TfR1-Tf. Acidification (low 
pH) inside the vesicle favors conformational changes in Tf that lead to the 
release of the iron atoms 32. Free Fe3+ atoms are then reduced into Fe2+ by a 
reductase (STEAP3 in erythroid precursors, macrophages and hepatocytes) 
and then transported out of the vesicle into the cytoplasm by DMT1 33. Apo-Tf 
then returns to the cell surface, completing its cycle as it is released for iron 
reload in plasma while TfR1 remains at cell surface. One molecule of TfR1 can 
perform up to 100-200 endocytosis cycles during its lifespan.  
1.2.2.2. Non-transferrin bound iron uptake 
Under systemic iron overload conditions in which the plasma iron level 
exceeds the iron-binding capacity of Tf (Tf saturation), a significant amount of 
free Fe3+, usually referred as non-Tf bound iron (NTBI), may circulate in plasma 
usually complexed with citrate, acetate and albumin molecules 34. Despite its 
association with these carriers, NTBI can easily participate in Fenton reactions 
and subsequent formation of ROS 1,34. NTBI can be absorbed by hepatocytes in 
the liver and other cells through the transport activity of DMT1 coupled with a 
reductase.  
1.2.2.3. Heme and hemoglobin uptake 
Free heme can also be taken up by cells, in particular hepatocytes and 
tissue macrophages 35,36. However, as a consequence of intravascular 
hemolysis of erythrocytes, free heme and Hb also circulate in plasma and are 
usually associated with other macromolecules such as Hpx and haptoglobin 
(Hp), respectively. The complexes heme-Hpx and Hb-Hp will be recognized and 
internalized through CD91 and CD163 receptor-mediated endocytosis in 
macrophages and hepatocytes, protecting the organism and the cells against 
the toxic effect of heme and Hb 37-39. 
1.2.2.4. Ferritin uptake 
Recently, Ft was reported to deliver iron to cells and that the iron delivery 
was significantly higher when heavy chain-Ft (H-Ft) was used compared with 
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light chain-Ft (L-Ft), which suggests that the mechanism of Ft uptake preferably 
binds H-Ft and not L-Ft 40. T cell immunoglobulin-domain and mucin-domain-2 
(Tim-2) is an H-Ft specific receptor expressed in immune and non-immune 
cells. H-Ft was shown to be taken up by Tim-2 through a pathway distinct from 
that of Tf cycle, followed by iron delivery at the cytoplasm confirming that Ft 
uptake may constitute an efficient way of iron delivery to the cells 41. 
Additionally, besides Tf, TfR1 was recently reported to also specifically binding 
to H-Ft, which could constitute an alternative receptor for Ft uptake 21,42. 
 
Figure I.3 - Scheme illustrating the different pathways for cellular iron uptake from 
circulation. Most cells uptake circulating iron through the Tf cycle, in which the holo-Tf binds to 
TfR1 and the complexes TfR1-Tf are endocytosed, releasing the iron from Tf. Dissociated iron is 
then pumped by DMT1 into the cytoplasm where it joins the LIP. Free Fe
3+
 may circulate in 
conditions of iron overload, in which it is mostly uptaken by hepatocytes through DMT1 coupled 
with a reductase. Another source of iron mostly used by macrophages and hepatocytes is 
heme, which can circulate: 1) associated with Hpx (heme:Hpx); 2) incorporated in circulating Hb 
molecules that may result from hemolysis and are mostly associated with Hp (Hb:Hp); 3) 
incorporated in Hb molecules inside erythrocytes. While heme-Hpx and Hb-Hp can be uptaken 
through receptor-mediated endocytosis, senescent erythrocytes can be phagocytosed 
exclusively by macrophages. In all three cases, the resulting heme iron is then likely pumped by 
HRG1 into the cytoplasm, where HO-1 catabolizes heme, releasing the Fe
3+
 atoms that will join 
the LIP. Ft was also reported to be uptaken by some cells through an independent mechanism 
involving Tim-2 and/or TfR1 as receptors. 
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1.2.3. Cellular iron trafficking, storage and mobilization 
Once in the cytoplasm and independently of its uptake mechanism, free 
intracellular iron will enter the LIP, which consists of iron complexed with low 
affinity ligands and is therefore highly reactive. The LIP is kept at its minimum, 
corresponding to about 5% of total cellular iron and, given its reactivity, it is 
considered to be a good marker for cell iron-derived oxidative stress 34. Once in 
the LIP, iron can be used for different purposes (Figure I.4): 
 Directed towards the mitochondria for heme synthesis in specific 
cells;  
 Used by iron and heme-dependent enzymes; 
 Stored associated with Ft or hemosiderin molecules; 
 Exported outside of the cells by the transporter Fpn1 in collaboration 
with an oxidase. 
1.2.3.1. Intracellular iron trafficking 
Given the high reactivity and toxicity of iron, its intracellular transport is 
thought to be mediated by metallochaperones that would safely deliver iron to 
be incorporated in iron-depending enzymes, heme synthesis, iron storage or 
export. However, little is currently known about iron chaperones apart from 
some likely candidates. For instance, poly (rC)-binding protein 1 (PCBP1) was 
recently identified as a chaperone that delivers iron to Ft 43. The authors 
showed that PCBP1 bound to Ft in vivo and in vitro, also facilitating iron loading 
into Ft in vitro. PCBP1 and its homologue PCBP2 play a role in iron delivery to 
the iron-dependent prolyl hydroxylases that are involved in the regulation of 
hypoxia transcription factors 44, suggesting that PCBPs proteins may be 
involved in iron delivery to other cytosolic proteins besides Ft. Another protein 
with possible iron chaperone function is frataxin, which binds and transfer iron 
atoms and was shown to play an important role in the assembly of iron-sulfur 
complexes at the mitochondria 45. 
1.2.3.2. Intracellular iron storage 
Whenever cellular iron exceeds its iron requirement, the excessive iron is 
stored in a bioavailable form as Ft, which protects cells from potentially toxic 
iron reactions 1. Ft is the main molecule involved in iron storage and is 
composed of a total of twenty-four subunits of H-Ft and L-Ft, with a variable 
ratio of H-Ft and L-Ft. This protein has high affinity to Fe3+ atoms, being capable 
to oxidize Fe2+ atoms into Fe3+ (activity associated to H-Ft) and to bind up to 
4000-4500 iron atoms per molecule 46. Ft expression is controlled by 
intracellular iron levels as well as by inflammatory conditions 47. Hemosiderin, a 
product of Ft degradation, is also a form of iron storage in cells commonly found 
in conditions of iron overload 46. 
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1.2.3.3. Intracellular iron mobilization 
In condition of high body iron demand, iron can be mobilized from the LIP 
and iron storage molecules such as Ft, in order to be exported from the 
cytoplasm of cells into the plasma through the activity of the iron transporter 
Fpn1. Indeed, low level of systemic iron or increased erythropoietic demand is 
thought to induce Ft degradation by lysosomal proteolysis and release of stored 
iron 48,49. Iron is then exported from the cells and loaded onto Tf molecules, 
entering circulation for distribution throughout the organism.  
In addition to free iron export by Fpn1, secretion of iron-loaded Ft from 
cells (particularly from macrophages) has been described 50. Besides holo-Tf, 
circulating iron-loaded Ft could be more important in iron homeostasis than 
expected as discussed recently 41,42,50.  
 
Figure I.4 - Intracellular iron trafficking pathways and its mobilization. Once inside the cell, 
according to the cell type and under conditions of low body iron demands, the iron can be 
stored in Ft, consumed in the activity of enzymes and in synthesis of heme to be used in 
enzymes (hepatocytes), Hb (erythrocytes) and myoglobin (muscle cells). In conditions of high 
body iron demand, the Ft in iron stores such as macrophages and hepatocytes can be 
degraded and the released iron can be exported through Fpn1 coupled with a membrane 
oxidase and/or circulating Cp, entering circulation. In addition, macrophages and hepatocytes 
were also shown to secrete Ft to plasma.  
 
The oxidase Cp, and in particular its secreted soluble isoform, has been 
reported to be the ferroxidase associated with Fpn1 export of iron in both 
hepatocytes and macrophages 51. However, its role is not completely 
understood and depending of the cell types, other oxidases associated to the 
membrane or secreted to the circulation could also be important. This topic on 
Fpn1 ferroxidase partners will be further discussed in section 1.4.3.  
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1.2.4. Specialized cellular iron trafficking 
 
1.2.4.1. The erythroid precursors and heme metabolism 
Erythroid precursors have a strong requirement for iron in order to produce 
an important amount of heme and Hb, uptaking iron from the circulation mostly 
via the Tf cycle (Figure I.5). Therefore these cells express high level of TfR1 
and DMT1. In addition, erythroid precursors can also express the heme 
exporter feline leukemia virus subgroup C receptor (FLVCR), which appears to 
be vital for erythrocyte maturation and survival. Export of heme by erythroid 
cells likely corresponds to an intracellular iron homeostasis regulatory 
mechanism in order to protect these cells from the toxicity of high intracellular 
heme concentration 52. In addition, it was recently reported that erythroid cells 
express HO-1 and that its expression is upregulated during erythroid 
differentiation having an immediate impact on heme and Hb levels, which points 
to an important role of HO-1 on the tight control of the regulatory heme pool at 
appropriate levels during the different stages of erythroid differentiation 53. 
1.2.4.2. The hepatocytes and iron storage 
One of the main human cells involved in iron storage is the hepatocyte in 
the liver (Figure I.5). Hepatocytes express high levels of TfR1 and Ft, both 
proteins being regulated through a post-transcriptional mechanism according to 
intracellular iron levels. In addition to iron uptake through Tf cycle, hepatocytes 
express DMT1 and avidly uptake circulating NTBI in conditions of iron overload, 
storing it mostly associated to Ft molecules in the cytoplasm. The hepatocytes 
can also uptake the complex heme-Hpx from circulation as well as to synthesize 
heme 36,54 in order incorporated in heme-containing enzymes such as the 
cytochrome P-450. Heme can also be degraded in hepatocytes and the derived 
iron stored in Ft molecules. Interestingly, despite Fpn1 expression, hepatocytes 
clearly favor the storage of iron even in conditions of high intracellular iron 
content 55, which may explain why the liver is the main organ for iron storage 
and is also the first target for iron toxicity in disorders involving iron overload.  
Nonetheless, under conditions of high body iron demand, the stored iron in 
hepatocytes can be mobilized by degradation of Ft and iron export through 
Fpn1 in association with a ferroxidase, likely Cp. In addition, hepatocytes also 
secrete a form of Ft to plasma circulation that is usually more enriched in L-Ft 
chains than intracellular Ft 56,57. Despite its unclear function, the level of 
circulating Ft is proportional to intracellular Ft levels in iron store cells and is 
thus considered as a plasma marker for body iron store level 56. In addition, 
although minor than intracellular Ft, the iron content of circulating Ft is 
significant and also proportional to the body iron store level 58. Ft is also an 
acute phase protein with its levels being upregulated by inflammation and 
infection 47.  
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1.2.4.3. The macrophages and iron recycling 
Erythropoietic daily requirements are approximately 20-22 mg, but only 1-
2 mg of iron is absorbed in the duodenum during this period, which would be 
clearly insufficient. Thus, macrophages have developed specialized iron uptake 
and recycling mechanisms in order to fulfill the organism needs.  
Indeed, most of the daily iron requirement in mammals is provided by a 
highly efficient recycling of Hb-derived iron from senescent erythrocytes through 
a process denominated erythrophagocytosis (EP) 31. This specific process of 
EP occurs at a rate of 5x106 erythrocytes per second 59 in macrophages mostly 
concentrated in the liver (Kupffer cells), spleen and bone marrow 60. As they 
reach the terminal age (120 days in humans), erythrocytes undergo 
modifications at cell surface that are specifically recognized by tissue 
macrophages, leading to their phagocytosis 59. After engulfment, inside the 
erythophagosome, heme is released from erythrocyte-Hb by proteolytic activity 
and likely transported outside the erythrophagosome into the cytoplasm by the 
heme transporter HRG1 61,62. Indeed, HRG1 was reported as being expressed 
at the erythrophagosome membrane, while HO-1 is located outside the 
erythrophagosome, either at the cytoplasm or associated to the cytosolic side of 
the erythrophagosome membrane. On the other hand, DMT1 is perfectly co-
localized with TfR1 and not with erythrophagosomal membrane marker, which 
supports the proposal that heme is transported by HRG1 through the 
erythrophagosomal membrane into the cytoplasm 61,62, where it is then 
catabolized by HO-1, leading to the release of iron, carbon monoxide (CO), and 
biliverdin/bilirubin 59. The precise cytosolic compartment where HO-1 activity 
takes place is still under investigation. Additionally, in some conditions like 
intravascular hemolysis, macrophages can also directly uptake Hb and the 
complexes Hb-Hp and heme-Hpx through CD163- and CD91-mediated 
endocytosis, respectively 35. After endocytosis, heme is likely transported by 
HRG1 to the cytoplasm for subsequent catabolism by HO-1 and iron release.  
Once in the cytoplasm, free iron enters the LIP in the macrophage and can 
be either incorporated into Ft for iron storage or exported by Fpn1 in 
cooperation with a ferroxidase according to the body iron demand 31.The 
macrophage ferroxidase involved on iron efflux is not completely identified, but 
Cp has been proposed. Patients with aceruloplasminemia, that do not produce 
Cp, present strong iron accumulation in the liver in both hepatocytes and 
Kupffer cells (resident liver macrophages), among other organs 51,63. In addition 
to Fpn1 iron export, a recent study suggests that circulating Ft is derived 
primarily from macrophages, and not from hepatocytes, through a non-classical 
secretory pathway constituting an additional and Fpn1-independent pathway for 
macrophage iron export 50. The heme exporter FLVCR was also reported to be 
expressed at macrophage plasma membrane, showing that heme can also be 
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exported by macrophages in a mechanism that is Hpx-dependent and that 
constitute another mechanism of macrophage iron export 52,64.  
Summing up, macrophages recycle iron mainly from senescent 
erythrocytes, but also from other sources such as circulating Hb or heme, and 
can store it or export iron in different physiological forms: free Fe3+, Ft, and 
heme (Figure I.5).  
Figure I.5 - Overview of iron metabolism in the human body and in the different 
organs/cells. The central portion of the figure depicts the flow of iron throughout the human 
body, from intestinal absorption to blood circulation associated with Tf (holo-Tf) which delivers 
iron throughout the body, including its major site of utilization - the bone marrow - where it is 
incorporated into Hb during erythrocytes maturation process. As erythrocytes become 
senescent, they are phagocytosed by tissue macrophages located at the spleen, liver (Kupffer 
cells) and bone marrow. Macrophages recycle the iron contained in Hb, storing it in Ft 
molecules or releasing it back to the circulation via Fpn1. In addition, both erythroid precursors 
and macrophages express the heme exporter FLVCR and are therefore capable of exporting 
heme to circulation. Together with tissue macrophages, the hepatocytes in the liver are the 
main cells of iron storage in Ft molecules. In conditions of systemic iron deficiency, Ft molecules 
in hepatocytes and macrophages are degraded and the iron is released and exported by Fpn1 
back to blood circulation, re-starting the cycle.  
 
  
15 
1.3. Iron homeostasis: cellular and systemic regulation 
The main mechanism developed for controlling iron homeostasis in 
mammals is based on a strict control of dietary iron absorption as well as 
controlling the availability of stored and recycled iron accordingly to the body 
iron demand 5,6. Regulation of iron homeostasis occurs at two different but 
interconnected levels: cellular and systemic iron homeostasis. Iron homeostasis 
is maintained by the regulation of the expression of the proteins involved in 
cellular iron uptake, storage and export in agreement with the levels of 
intracellular iron levels. These regulatory mechanisms occur at both 
transcriptional and post-transcriptional level and are modulated by anemia 
hypoxia, iron deficiency, iron overload and inflammation. 
1.3.1. Cellular iron homeostasis 
 
1.3.1.1. Hypoxia and iron metabolism genes 
Under conditions of low oxygen (hypoxia) and low iron level (iron 
deficiency), hypoxia inducible factors (HIFs) are induced, affecting the 
transcription of many genes involved in iron metabolism. Under these 
conditions, the transcription of HIF-1α and HIF-2α subunits is upregulated along 
with protein stabilization. Indeed, HIF-1α and HIF-2α proteins are targets of 
ubiquitination and proteosomal degradation triggered by iron-depending 
enzymes. For this reason, besides transcription upregulation triggered by 
hypoxia, low intracellular iron levels also prevent HIF-1α and HIF-2α 
degradation, stabilizing these subunits that, together with the constitutively 
expressed HIF-1β and HIF-2β, originate the heterodimers HIF-1 and HIF-2. 
HIFs are transcription factors that bind to specific hypoxia-response elements 
(HRE) and promote transcriptional induction or suppression depending on the 
gene target. HIFs have been reported to suppress Hepc transcription while 
inducing transcription of several genes such as Tf, TfR1, Fpn1, DMT1, Dcytb, 
HO-1, and Cp among others, clearly promoting iron cellular uptake as well as 
iron export 31,65. From a systemic point of view, the regulation of these proteins 
in hypoxic conditions could correspond to increased iron absorption at intestinal 
level as well as mobilization from iron stores in order to increase systemic iron 
levels in response to erythropoietic iron demand. 
1.3.1.2. Cytokines and iron metabolism genes 
Another transcriptional regulatory mechanism of iron cellular homeostasis 
is controlled by cytokines such as interferon -γ (IFNγ), tumor necrosis factor-α 
(TNFα) and interleukins (IL), namely IL-1β, IL-2, IL-6. These cytokines have 
been reported to bind to specific receptors, triggering specific signaling 
cascades that will lead to either induced or repressed transcription of cytokines-
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regulated genes in a cytokine and gene specific manner. As an example, IL-6 
and IL-1 induce Ft and Cp among others genes in hepatocytes and 
monocytes/macrophages, while combined IFNγ and lipopolysaccharide (LPS) 
induce HO-1, Cp, Ft and downregulate Fpn1 and TfR1 transcription in 
monocytes 31,66. Noteworthy, the master regulator of iron homeostasis Hepc is 
transcriptionally upregulated by pro-inflammatory cytokines such as IL-6 67. 
1.3.1.3. The IRE/IRP system 
The post-transcriptional regulation of iron metabolism genes is considered 
to be major mechanism underlying the maintenance of cellular iron 
homeostasis. Indeed, a post-transcriptional regulation is a faster, easier and 
more efficient way of controlling protein expression than a transcriptional one 6. 
The main cellular post-transcriptional iron regulation system is the IRP/IRE 
regulatory network.  
This system comprises two RNA binding proteins named iron regulatory 
protein 1 and 2 (IRP1 and IRP2) and cis-regulatory RNA elements named iron 
responsive elements (IREs) to which IRP1 and IRP2 bind specifically. The IREs 
are stable RNA hairpins with a characteristic secondary structure that exist in 
the untranslated regions (5’-UTR or 3’-UTR) of mRNA of some genes involved 
in iron metabolism. The position of IREs at the 5’-UTR or at 3’-UTR of a specific 
mRNA leads to opposite effects on translation. Binding of both IRPs to IRE on 
5’-UTR interferes with the recruitment of the small ribosomal subunit to the 
mRNA, thereby blocking the translation of mRNA. On the other hand, IRPs 
binding to IRE at the 3’-UTR blocks the activity of endonucleases, protecting the 
mRNA from degradation (stabilization) and promoting its translation.  
i. Iron and IRPs activity 
Iron levels modulate the binding of IRP1 and IRP2 to the IRE, leading to 
the post-transcriptional regulation of IRE-containing mRNAs expression 68. IRP1 
is a protein presenting two different and mutually exclusive activities: one as 
aconitase and the other as a RNA binding protein. This protein contains an iron-
sulfur cluster that is responsible for the aconitase activity and that requires the 
binding of iron atoms to be active. In iron-deficient conditions, the iron-sulfur 
cluster is not formed, leading to the absence of IRP aconitase activity as well as 
to the exhibition of a conformation that allows IRP1 to bind to the IREs, 
promoting (3’-UTR IRE) or blocking (5’-UTR IRE) the IRE-containing mRNAs 
translation. On the other hand, under iron-replete conditions, the iron-sulfur 
cluster is formed and IRP1 undergoes conformational changes that lead to the 
release of this protein from the IRE and to the gain of aconitase activity, thus 
counteracting the previous effect of IRP1 on the translation of IRE-containing 
mRNAs.  
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Unlike IRP1, IRP2 does not present any aconitase activity and acts as a 
RNA binding protein only. This protein is rapidly targeted for proteosomal 
degradation by an iron-dependent mechanism involving ubiquitination. Under 
iron-deficient conditions, this degradation mechanism is prevented and IRP2 
accumulates in the cytosol and binds to IRE, blocking or promoting the 
translation of the respective mRNA depending on the UTR position of the IRE. 
In the presence of iron-replete conditions, the degradation mechanism is 
triggered, IRP2 is degraded and its effect on IRE-containing mRNAs translation 
is prevented 69,70.  
ii. Iron genes and the IRE/IRP system 
Many proteins involved in iron metabolism present IREs on its mRNA 3’-
UTR (TfR1, DMT1) and 5’-UTR (H-Ft, L-Ft, and Fpn1 among others) and a 
typical model for this IRP/IRE regulatory network is the TfR1/Ft post-
transcriptional regulation by intracellular iron levels 70. Through the IRP/IRE 
regulation network, low intracellular iron promotes translation of DMT1 and TfR1 
(iron uptake) and blocks translation of proteins involved in iron storage (Ft), 
utilization (ALAS2 involved in heme synthesis, among others) and export (Fpn1) 
while high intracellular iron induce the opposite regulation of these proteins 
(Figure I.6). IRPs were also reported as being regulated by other stimuli besides 
iron, but currently the available data are contradictory and the mechanisms 
involved are still not completely understood. 
Figure I.6 - IRP/IRE Regulatory 
Network. IRP1 and IRP2 bind to IRE in 
iron-deficient conditions (- Fe), mediating 
the repression of the translation of 
mRNAs with 5’-UTR IRE (Ft, Fpn1, 
ALAS2, ACO2, HIF2α, APP) or mRNA 
stabilization and translation of mRNAs 
with 3’-UTR IRE (TfR1, DMT1). In iron 
overload conditions (+Fe), IRP1 binds to 
iron, releasing the IRE and gaining 
aconitase activity while IRP2 is targeted 
for proteosomal degradation. In both 
cases, once dissociated from the IRPs, 
the target mRNAs will be either translated 
(5’-UTR IRE) or targeted for degradation 
(3’-UTR). ALAS2: erythroid- specific 
delta-aminolevulinate synthase; ACO2: 
aconitase-2; HIF-2α: hypoxia inducible 
factor 2 alpha; APP: β-amyloid precursor 
protein. Image adapted from the book 
Iron Metabolism (2012) InTech 
70
. 
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1.3.2. Systemic iron homeostasis: the hepcidin/ferroportin-1 
axis 
Systemic iron homeostasis results from the balance between iron 
absorption, recycling and mobilization and it is regulated by four major factors: 
systemic iron status (stores regulator), iron demand for erythropoiesis 
(erythropoietic regulator), hypoxia and inflammation (inflammatory regulator). 
Over the last decade, evidence showed that regulation of systemic iron 
homeostasis in response to all these factors is mostly orchestrated by the iron-
regulatory hormone Hepc and its cellular target Fpn1 71.  
1.3.2.1.  Mechanisms of hepcidin action 
Hepc is a small peptide that is mostly produced and secreted by 
hepatocytes (liver), but also in a lesser extent in other organs/cells such as the 
kidney 72, heart 73, lymphocytes 74, monocytes 75, and macrophages 76. 
Nonetheless, a recent study suggests that the hepatocyte constitutes the 
predominant reservoir for systemic Hepc and that the production of Hepc by 
other tissues is unable to compensate the lack of Hepc production by the liver77.  
Hepc is synthesized as an 84-amino acid (aa) pre-propeptide that is 
processed into 60-aa prohepcidin by removal of the signal peptide. The mature 
and biologically active Hepc comprises 25-aa and results from removal of the 
pro-region by the pro-hormone convertase furin 78. Hepc is a negative regulator 
of iron homeostasis that blocks iron flow from enterocytes, hepatocytes, and 
macrophages, impairing iron absorption and mobilization from iron stores, thus 
leading to decreased plasma iron availability 79. To date, Fpn1 is the only known 
target for Hepc and it was demonstrated that Hepc promotes Fpn1 
internalization and degradation through an ubiquitination process, blocking iron 
export 28,80. This Hepc-dependent downregulation of Fpn1 has been reported in 
cell lines overexpressing Fpn1 80 as well as in primary hepatocytes 55, 
macrophages 76, monocytes 75, and lymphocytes 74.  
However, this mechanism of Hepc-induced internalization of Fpn1 in 
enterocytes is still in debate. On one hand, in vivo expression of duodenal Fpn1 
is upregulated in mouse models of Hepc downregulation or downregulated in 
models of Hepc overexpression, suggesting that Fpn1 could be the target of 
Hepc also in enterocytes 81-84. On the other hand, Fpn1 was reported to be 
resistant to Hepc in intestinal cells and DMT1 was proposed to be the direct 
target of Hepc by these cells being downregulated 85. Moreover, it was recently 
shown that Hepc induces DMT1 degradation shortly after treatment with 
physiological concentrations of Hepc in both duodenal segments (ex vivo) and 
intestinal cell line while Fpn1 expression remains unaffected at that time point 
16.  
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1.3.2.2.  Regulation of hepcidin expression  
Hepc regulation occurs at the transcriptional level, being upregulated by 
inflammation/infection and by high iron status, while increased erythropoietic 
demand, hypoxia, anemia and low iron status suppress Hepc expression 
(Figure I.7).  
i. Hepcidin regulation by iron 
Hepc is regulated by plasma iron levels as well as by the intracellular iron 
level in stores. This regulatory mechanism involves a negative feedback loop, in 
which increased iron concentration at both plasma and iron stores induce Hepc 
expression by hepatocytes and its release into circulation, blocking iron 
absorption and iron release from stores (liver and recycling macrophages). This 
mechanism modulates Hepc expression at transcription level since its mRNA 
level usually correlates with the level of Hepc peptide at both plasma and urine 
31,86.  
Human genetic iron disorders such as Hereditary Hemochromatosis (HH) 
and iron-refractory iron deficiency anemia as well as murine knockout models 
presenting impaired iron homeostasis were vital to identify key proteins involved 
in the modulation of Hepc expression by iron. In addition to the basal 
transcriptional level promoted by the liver-enriched transcription factor C/EBPα 
87, the iron-dependent upregulation of Hepc transcription is promoted by the 
small mothers of decapentaplegic (SMAD) transcription factors 1, 5 and 8 and 
its mediator SMAD4. This SMAD signaling pathway is controlled by two known 
parallel and likely interconnected pathways: 1) bone morphogenetic protein 6 
(BMP6), BMP receptor and its co-receptor hemojuvelin that control the SMAD 
signaling cascade; 2) TfR1, Tf receptor 2 (TfR2) and hereditary 
hemachromatosis protein (HFE) that are presumed to act as a complex sensor 
for holo-Tf level (extracellular iron), triggering the SMAD signaling cascade 31,88.  
ii. Hepcidin regulation by erythropoiesis and hypoxia/anemia 
Low iron status also promotes erythropoiesis impairment, which will lead to 
the low production of mature erythrocytes (anemia) and subsequent impaired 
oxygen transport in tissues (hypoxia). Therefore, increased erythropoietic 
demand is often the result of hypoxia/anemia, suppressing Hepc and 
subsequently promoting iron absorption and mobilization from stores 
(hepatocytes and tissue macrophages), all resulting in a greater supply of iron 
for Hb synthesis.  
The regulation of Hepc by erythropoietic factors is the regulatory 
mechanism currently less understood. Besides the known dominance of 
erythropoietic iron demand (erythropoietic regulator) over the body iron status 
20 
(stores regulator), leading to Hepc suppression independently of the iron stores 
status, the exact molecules involved in this regulation are not fully 
characterized. These molecules/factors are believed to be produced at the level 
of the bone marrow and enter plasma circulation to reach liver and inhibit Hepc 
production. To this date, some molecules have been proposed: erythropoietin, 
growth differentiation factor 15, twisted gastrulation protein homologue 1 47, and 
recently erythroferron 89, all of them upregulated by increased erythropoietic 
demand.  
On the other hand, some studies suggest that Hepc suppression in the 
hepatocytes is not directly mediated by anemia, but by tissue hypoxia-derived 
erythropoietic demand 90, possibly mediated by Hepc transcriptional regulation 
through HIFs 65.  
iii. Hepcidin regulation by inflammation/infection 
Almost every bacterial pathogen requires iron for multiplication. As a 
consequence, natural selection has favored mechanisms that induce iron 
sequestration under inflammatory/infectious conditions and Hepc is believed to 
play a key role in this process. During inflammation and infection, IL-6 is highly 
upregulated along with other cytokines, and was shown to upregulate Hepc 
transcription through the STAT3 signaling pathway 67. Besides IL-6, activin 
B was shown to have an unexpected, but crucial role in the induction of Hepc in 
inflammatory conditions 91.  
As a result of Hepc upregulation, Fpn1 internalization leads to impaired 
iron efflux, blocking its absorption while promoting cellular iron retention in iron 
stores. This iron sequestration will rapidly lead to decreased plasma iron levels 
(hypoferremia), limiting iron availability to pathogens, but also to Hb synthesis 
92,93. Diseases characterized by a chronic inflammation lead to impaired 
erythropoiesis due the limited iron availability, developing the so-called anemia 
of inflammation or anemia of chronic disease 94. 
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Figure I.7 - Systemic regulation of iron metabolism by hepcidin. Circulating Hepc is mostly 
produced by the liver (hepatocytes), being induced by iron overload or by inflammation/infection 
while suppressed by high erythropoietic demand (iron deficiency, anemia, hypoxia). The 
upregulated Hepc is secreted into circulation, reaching different tissues and promoting Fpn1 
downregulation, which leads to impaired iron export from stores (recycling macrophages in liver, 
spleen and bone marrow as well as hepatocytes in the liver) and from intestine (enterocytes), 
resulting in decreased systemic iron levels. On the contrary, suppressed Hepc synthesis favors 
iron intestinal absorption and mobilization from stores, increasing circulating iron levels in order 
to respond to the high erythropoietic demand. 
 
1.4.  The iron exporter ferroportin-1: the cellular target 
of hepcidin 
Fpn1 is the sole iron exporter identified in mammals 24,95,96, being highly 
expressed at the plasma membrane of duodenal enterocytes (basolateral 
membrane), macrophages and hepatocytes, where it contributes to iron 
absorption and mobilization from stores 55,97. Mutants with complete lack of 
Fpn1 in zebrafish and mammals were shown to be embryonic lethal, unless 
rescued with iron injections 96. The surviving newborns presented severe iron 
deficiency and were unable to absorb dietary iron 96, showing the extreme 
importance of this transporter in iron metabolism and homeostasis 98.   
Fpn1 has an approximate molecular weight of 62 kDa, but it varies 
according to the cell/tissue due to post-translational modifications such as 
glycosilation. For instance, Fpn1 in murine duodenum, spleen and liver presents 
a molecular weight of 70, 65 and 63 kDa, respectively whereas Fpn1 presents a 
molecular weight of 65 kDa in murine macrophages differentiated in vitro 99.  
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The topology of Fpn1 is not fully defined, but the current model proposes 
that this protein has twelve transmembrane domains, with both N-terminal and 
C-terminal extremities in an intracellular position 100. As a transporter, Fpn1 has 
been proposed to act as a monomer 100-102 as well as a dimer 103. Although this 
topic is still under debate, the dominant inheritance of Fpn1 mutations in genetic 
disorders such as the negative effect of Fpn1 mutations in HH type 4 (also 
known as “ferroportin disease”) suggests that Fpn1 acts as a dimer. However, 
there are other possible explanations for the dominant effect such as haploid 
insufficiency or a multimeric structure of Fpn1 104,105. Fpn1 mutations can be 
classified as class I or “gain-of-function” which cause Fpn1 resistance to Hepc-
dependent internalization, or as class II or “loss-of-function” which affect the 
transporter activity of Fpn1 106.  
Fpn1 expression is regulated at multiple levels: transcriptional, post-
transcriptional, translational and post-translational in response to different 
stimuli and mechanisms.  
1.4.1. Regulation of ferroportin-1 mRNA expression 
At transcriptional level, Fpn1 is upregulated in response to heme 107 and to 
hypoxia 65. Upregulation of Fpn1 by hypoxia is mediated HIF-2α 108, while heme 
upregulates Fpn1 transcription through a dual mechanism. Heme binds to the 
transcriptional repressor Bach1, dissociating it from the small Maf proteins at 
the MARE/ARE sequence motif upstream of Fpn1 promoter, triggering Bach1 
ubiquitination and degradation. Simultaneously, heme stabilizes the 
transcription factor NFE2-related factor 2 (Nrf2), promoting its accumulation in 
the nucleus. Nrf2 dimerizes with the small Maf proteins at the MARE/ARE, 
forming a complex that promotes Fpn1 transcription 109. Noteworthy, the 
protoporphyrin ring of heme devoid of iron is capable of triggering Fpn1 
transcription to a less extent than heme, but not Fpn1 translation which is 
dependent on the presence of iron 107,109.  
Pro-inflammatory cytokines such as IFNγ and TLR4-activation by LPS as 
well as by pathogens (P. aeruginosa) induce severe downregulation of Fpn1 
mRNA 110-112. Remarkably, Fpn1 downregulation by LPS  in vivo was reported 
to occur also through an Hepc-independent mechanism that remains to be 
clarified 113. However, recent publications report opposite regulation of Fpn1 
induced by infection 114,115, which adds some controversy to the transcriptional 
regulation of Fpn1 by infection.  
Additionally, a novel mechanism of post-transcriptional downregulation of 
Fpn1 mRNA level was reported in response to iron deficiency through a specific 
micro-RNA (miR-485-3p) 116. 
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1.4.2. Regulation of ferroportin-1 protein expression 
 At translational level, Fpn1 mRNA presents an IRE element on its 5’-UTR 
sequence to which IRP protein binds, blocking its translation. Only in the 
presence of iron, IRP dissociates from Fpn1 mRNA unblocking its translation. 
Noteworthy, Zhang et al reported a novel Fpn1 transcript lacking the 5’-UTR 
IRE, being expressed exclusively in the duodenum and erythroid precursors 117.  
Post-translational regulation of Fpn1 occurs mainly through an Hepc-
dependent mechanism in which Hepc binds to Fpn1 at cell surface inducing its 
internalization and degradation in response to inflammation, infection or iron 
overload 28. Auriac et al reported that Fpn1 is localized in lipid raft microdomains 
in murine macrophages and demonstrated that this feature is essential for 
Hepc-mediated endocytosis and subsequent Fpn1 degradation in these cells118. 
Another mechanism controlling Fpn1 level at cell surface was reported in 
murine macrophages, in which Fpn1 in mostly localized in intracellular vesicles 
under basal conditions, being enriched at cell surface upon iron stimulation 119. 
Additionally, de Domenico et al and other authors reported that Fpn1 stability at 
cell surface during iron export was dependent on the activity of a ferroxidase 
(Cp) that converted Fe2+ into Fe3+, preventing Fpn1 internalization and 
degradation 120-122.  
However, it is worth mentioning that de Domenico – which is one of the 
researchers whose recent publications focused mostly of Fpn1 and significantly 
contributed to the current knowledge on this protein – was recently subject of an 
investigation of research misconduct carried by the University of Utah. As stated 
by the Salt Lake Tribune, the conducted investigation concluded that significant 
errors were found in ten of the eleven publications by de Domenico which were 
subject of analysis and recommended that those publications should be either 
corrected or retracted. Therefore, any publication by de Domenico in the iron 
metabolism area should be considered cautiously and its reproducibility by 
other groups should be evaluated. In summary, it is important to re-evaluate 
and confirm the knowledge on the axis Hepc/Fpn1/ferroxidases to which de 
Domenico significantly contributed over the last years 123. 
1.4.3. Ferroportin-1 partners for iron export 
To date, four proteins were reported to have ferroxidase activity and/or to 
promote iron export in mammalian cells: Heph, Cp, zyklopen (Zp), and β-
amyloid precursor protein (APP). 
Heph, Cp and Zp are multicopper oxidases and were shown to oxidize 
Fe2+ into Fe3+ in addition to oxidation of organic substracts, promoting iron efflux 
in different cells/tissues 124.  
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Heph is a transmembrane oxidase firstly identified in the sex-linked 
anemia (sla) mice bearing a mutation in Heph gene. These animals presented a 
microcytic hypochromic anemia which resulted from impaired iron export from 
enterocytes to the plasma due to impaired Heph activity 25. Heph main role in 
iron metabolism appears to be mostly linked to intestinal iron absorption, but its 
expression was also reported other tissues/organ 125-127, indicating that Heph 
may also act as ferroxidase outside of the intestine.  
Recently, Zp was identified as a transmembrane multicopper oxidase as 
Heph, being highly expressed at the placenta 128. Zp expression was also 
detected in the murine embryo (brain, bladder, eye and brown fat) as well as in 
the adult mice (brain, kidney, testes and retina) 128. An unidentified ferroxidase 
referred to as a Cp homolog was previously reported in BeWO cells, a placental 
choriocarcinoma cell line, likely corresponding to Zp 129,130. This ferroxidase is 
downregulated by copper deficiency as observed for Zp 128,129, and its 
downregulation was associated with iron accumulation in these cells, 
suggesting that Zp ferroxidase activity might be involved in iron export from the 
placental cells to the fetus circulation 129.  
Cp was first isolated from the plasma by Holmberg and Laurell and was 
literally named as the “blue substance from plasma” 131. Cp ferroxidase activity 
combined with its abundant level in plasma lead to the recognition of Cp as an 
important anti-oxidant plasma component, preventing Fe2+ participation in 
Fenton reactions and subsequent formation of ROS 132,133. Unlike Heph and Zp, 
Cp is not a transmembrane multicopper oxidase and can be expressed either 
as a soluble protein secreted to extracellular milieu (sCp) or as a membrane 
protein anchored to cell surface by a glycosylphosphatidylinositol (GPI) motif 134-
136. Interestingly, while hepatocytes express and secrete high levels of sCp, 
GPI-anchored Cp (GPI-Cp) was never reported in the liver and it was shown 
that this isoform corresponds to the predominant form of Cp expressed in the 
brain, where it plays a crucial role in iron homeostasis and anti-oxidant defense 
in the central nervous system 134,137. The ferroxidase activity of both Cp 
isoforms was previously reported to be essential to Fpn1 iron export in different 
cells/tissues. Impaired Cp expression in Cp-/- mice and aceruloplasminemia 
patients is associated with iron accumulation in different tissues/organs, in 
particular liver (hepatocytes and Kupffer cells), spleen (macrophages), brain 
(astrocytes and neurons), β-cells in the pancreas, and retina 138. 
APP is the precursor of β-amyloid peptide, which is linked to the 
development of Alzheimer disease. Recently, Duce et al reported that the E2 
domain in APP presents ferroxidase activity 139. In this study, APP was shown 
to co-localize with Fpn1 in neurons, where its ferroxidase activity was essential 
for Fpn1 iron export. Accordingly, APP-/- mice showed brain iron accumulation 
mostly associated with neocortical and hippocampal neurons, but also in other 
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organs such as the liver (hepatocytes) and kidney 139. However, posterior 
publications by another research group question APP ferroxidase activity and 
report that APP E2 domain has no such activity 140,141. In agreement, another 
research group recently showed that sAPP (a soluble form that results from 
APP cleavage) modulates iron efflux from brain microvascular endothelial cells 
by promoting Fpn1 stabilization levels at cell surface, but does not promote iron 
oxidation 142. In conclusion, while APP putative ferroxidase activity is still 
unsure, its interaction with Fpn1 and the subsequent effect on iron efflux has 
been reported by different groups and in different cells, reinforcing its 
involvement in iron metabolism. 
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2. Iron and the Immune System 
 
2.1.  Crosstalk between immune cells and iron 
 
2.1.1. The immune system 
Immune system is composed by a network of cells, tissues, and organs 
that protects the body (host) against infections caused by pathogens like 
bacteria, virus, and parasites by preventing and limiting their entry and their 
growth inside the body. It can be divided in two interactive systems: the innate 
immunity and the adaptive immunity. The innate immunity mobilizes a response 
against invading pathogens, toxin or allergen by distinguishing self from non-
self. It is the first line of defense, being activated rapidly and responding in a 
stereotypic manner against any threath. It is mostly composed of cells of 
myeloid origin including neutrophils, monocytes/macrophages, and natural killer 
(NK) cells, involving the release of cytokines, chemokines, ROS and reactive 
nitrogen species (RNS).  
On the other hand, adaptive immunity is involved in the elimination of 
pathogens during the late phase of infection and it consists on a targetted 
response against a specific antigen. The key cell of adaptative immunity is the 
lymphocyte, which can be classified in several subtypes, including the two 
major subpopulations B and T lymphocytes. The response of this type of 
immunity depends mostly on the activation, proliferation and differentiation of 
antigen specific B and T lymphocytes that will be involved in antibody- and cell-
mediated response against the recognized antigen. The antigen receptors result 
from a very complex DNA rearragement that recognize a wide range of potential 
antigens 143.  
2.1.2. Links between iron homeostasis and immunity 
The interaction between the immune system and iron homeostasis has 
been studied for decades. Multiple evidences support this complex interaction, 
varying from limiting the bioavailability of iron to invader pathogens (“nutritional 
immunity”) to the effect of iron deficiency or overload on the host immune 
response. Indeed, the key process of iron recycling that is vital for 
erythropoiesis is performed by an immune cell: the macrophage. It is also at the 
macrophage level that a major part of iron sequestration takes place during 
infection.  
Infection and inflammatory processes affect iron homeostasis and, 
conversively, the disruption of iron homeostasis affects the immune system and 
its capacity to protect the body against pathogens 144.  
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2.1.2.1.  Iron deficiency effect on the immune system 
Iron deficiency was reported to be associated with suppressed immunity 
that may predispose the body to infection, affecting both innate and adaptive 
immunity. Some of the iron-deficiency effects on the immune system include: 
reduced neutrophil function by affecting the activity of iron-dependent enzymes 
such as myeloperoxidase and possibly impaired intracellular bactericidal 
activity; impaired NK cell activity; decreased T lymphocyte counts; impaired 
cytokines production by lymphocytes and macrophages; defective T 
lymphocyte-induced proliferative response; decreased production of 
macrophage migration inhibition factor 144-146.  
2.1.2.2.  Iron overload effect on the immune system 
Iron overload compromises the function of many immune cells. For 
instance, in iron overload conditions as observed in thalassemia patients that 
suffer from severe anemia and blood transfusion-dependent iron overload, there 
is an increased susceptibility to infection that has been associated with iron 
accumulation in tissue macrophages along with defective immune function. 
These patients present decreased NK cells activity as well as defective 
chemotaxis and phagocytosis by neutrophils and macrophages 147,148. On the 
other hand, in HH type I (mutations in Hfe gene) patients, iron depletion from 
macrophages despite systemic iron overload seems to protect against infection 
by intracellular pathogens such as Mycobacterium tuberculosis 149. However, 
patients with HH type I present increased susceptibility to infection by Yersinia 
enterecolitica and Vibrio vulcanicus (extracellular pathogens) that proliferate 
systemically, taking advantage of the systemic iron overload condition in HH 
150,151. It was also reported that HH type I patients present impaired cytokine 
response (low TNFα and IL-6) that has been associated with impaired Toll-like 
receptor 4 (TLR4) signaling and is corrected by treatment with iron or Hepc 152. 
This suggests that the low intracellular iron concentration in HFE-deficient 
macrophages is at the origin of TLR4 signaling impairment. Also, HH patients 
show decreased CD8+ T lymphocytes numbers, both in peripheral blood and 
infiltrated in the liver. The cytotoxic activity of CD8+ T lymphocytes is also 
compromised and an inverse correlation was found between the CD8+ T 
lymphocytes counts and the severity of iron overload in HH 153-157. Altogether, 
these data support the intrinsic dependence between the immune system and 
iron homeostasis in such a way that impairment in one of these systems is 
reflected in the other’s function and balance. 
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2.2.  Iron and Infection 
Iron is an essential element for pathogen growth, in particular bacteria and 
parasites. In fact, a significant part of bacteria’s genome codify genes involved 
in iron handling, clearly showing how iron is essential for their survival. As a 
consequence, as both host and pathogen compete for access to iron, the 
resistance to infection will rely in part on the outcome of this competition and will 
determine the regulation of mammalian iron homeostasis under inflammatory 
and infectious conditions. As described before, Fpn1 is downregulated at both 
mRNA and protein level by inflammatory and infection-related conditions. 
Indeed, pro-inflammatory cytokines such as IL-6 as well as LPS itself (TLR4 
activation) upregulate Hepc production and secretion by the liver, promoting 
Fpn1 internalization and degradation. Downregulation of Fpn1 at cell surface 
leads to iron retention in the iron stores (hepatocytes and macrophages) and 
block of the iron absorption, reaching hypoferremia within hours after infectious 
or inflammatory stimuli 158.  
The expression of acute phase proteins such as Tf, Ft, and Cp at the liver 
is upregulated by pro-inflammatory cytokines, favoring iron storage as well as 
promoting iron loading onto Tf through the ferroxidase activity of circulating Cp. 
Indeed, in normal conditions, Tf saturation is usually maintained close to 30-
40% so that no iron remains free in circulation not only to protect against iron 
toxicity, but also as a first line of defense against infection 159. Another acute 
phase protein that plays an important role scavenging serum iron is lactoferrin 
(Lf). Lf is a host glycoprotein that, like Tf, binds to iron with high affinity. It is 
highly concentrated in mucosal secretions, being also secreted by the liver as 
an acute phase protein and also a component of neutrophils granules, being 
released at site of infection. Noteworthy, unlike Tf, Lf still binds iron with high 
affinity at acidic pH, constituting an advantage for the host at the site of infection 
160,161.  
Some pathogens cause hemolysis as a strategy to promote iron 
availability in the form of Hb and heme. The upregulation of both Hp and Hpx as 
acute phase proteins is also very important for sequestering any circulating Hb 
and heme, again insuring that no form of iron is available in circulation for 
pathogen growth 162,163. This mechanism of iron sequestration by the host is 
such a vital tool against infection that, under conditions of prolonged infection or 
inflammation, the host still favors this strategy of iron withhold despite severe 
limitation of erythropoiesis. The overall cost of such strategy is the development 
of the so-called anemia of inflammation or anemia of chronic disease 158,164. 
In face of such battle for iron, pathogens also evolved by developing 
escape strategies to compete for iron. The expression and release of 
siderophores and hemophores that bind free iron and heme with high affinity, 
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constitute an important iron uptake strategy by the pathogens 165. Given the 
ability of siderophores to scavenge iron so efficiently, it is not surprising that the 
host also evolved mechanisms to overcome siderophores synthesis by the 
pathogen. Lipocalin-2 (Lcn2), also known as siderocalin, is an acute phase 
protein expressed mostly by neutrophils able to bind to bacterial siderophores, 
sequestering them and making them unavailable to the pathogen 166. Therefore, 
the host responds to infection by upregulating Lcn2 expression via TLR 
signaling in order to sequester bacterial siderophores and thus limit microbial 
access to iron.  
Besides all these strategies to restrain the growth of pathogens, the innate 
immune response through professional phagocytes such as neutrophils and 
macrophages constitute the first line of defense to eliminate these invaders. In 
addition, Hepc production by neutrophils, macrophages, monocytes and 
lymphocytes in response to inflammatory/infectious stimuli could be of extreme 
importance to secure local iron withhold in these cells at site of infection, 
particularly in macrophages as iron store cells 74,75,112.   
2.3.  Macrophages, iron and immunity 
The macrophage is a key cell of innate immunity that plays also a crucial 
role in the maintenance of iron homeostasis. Interestingly, several polarized 
macrophage phenotypes have been described under the influence of different 
microenvironments 167. Among those polarized phenotypes, two particular ones 
were associated with opposite inflammatory conditions: M1 and M2 
macrophages. M1 phenotype corresponds to the classically activated 
macrophages, presenting a pro-inflammatory phenotype while M2 phenotype 
corresponds to alternatively activated macrophages, presenting an anti-
inflammatory phenotype. Until now, the best tool to distinguish between these 
two phenotypes has been the cytokine profile of expression, with M1 being IL-
12high IL-10low whereas M2 are IL-12low IL-10high among others. Interestingly, 
gene expression profiles are strikingly polarized in these two macrophage 
phenotypes, with over 60% of genes associated with iron metabolism being 
differentially expressed between human M1 and M2 macrophages 111,168 (Figure 
I.8). 
2.3.1. Inflammatory macrophages M1 
M1 macrophages are classically activated by IFNγ, TNFα and bacterial 
products (like LPS), being characterized by high expression of inducible nitric 
oxide synthase (iNOS), pro-inflammatory cytokines (IL-1β, TNFα, IL-6, IL-12) 
and chemokines (CXCL9, CXCL10, CXCL11) as well as low expression of the 
anti-inflammatory cytokine IL-10, arginase-1 (Arg-1), CD163, and mannose 
receptor (MR, also known as CD206) 111,169.  
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M1 macrophages are potent effector cells with enhanced microbicidal 
capacity, producing great amount of ROS and RNS along with high expression 
of apoptosis genes, altogether increasing their killing capacity. They also recruit 
other immune cells by expression of chemokines, in particular monocytes and 
lymphocytes (T and NK cells), promoting their activation, proliferation and killing 
capacity 169. Pro-inflammatory cytokines and TLR4-activation induce Fpn1 
downregulation in monocytes and macrophages both transcriptionally (TLR4-
activation) and post-translationally by autocrine Hepc upregulation and 
secretion, promoting iron retention in such infectious and pro-inflammatory 
conditions 75,111,112,170. Interestingly, increased intracellular iron has also been 
reported to induce expression of pro-inflammatory cytokines in macrophages 
lacking Fpn1, likely through NF-κB activation by iron 171,172.  
Hb-Hp, heme-Hpx and holo-Tf uptake in M1 macrophages is impaired by 
downregulation of CD163, CD91 and TfR1, respectively. M1 macrophages also 
promote storage of intracellular iron through upregulation of Ft 111,168,173,174. 
DMT1 expression in M1 macrophages is controversial, with some authors 
reporting upregulated DMT1 in response to LPS alone 175 or combined with 
IFNγ 176, while others reported that DMT1 is significantly upregulated in M2 
macrophages when compared with M1 macrophages 177. In infected 
macrophages, the expression of Nramp1 at the phagolysosomal membrane, 
exporting iron out of this compartment containing the pathogen, is crucial for 
overcoming intracellular infection 178.  
In addition, the multicopper oxidase Cp is also highly induced and 
secreted by M1 macrophages. Cp is an acute phase protein mostly associated 
with its anti-oxidant role in oxidizing Fe2+ into Fe3+, promoting extracellular iron 
loading in Tf and Lf locally produced by immune cells 111. Noteworthy, 
macrophage-derived Cp was reported to be crucial for protection against 
inflammation and tissue injury in Cp-/- mice 179. Interestingly, M1 macrophages 
also express high levels of copper importers (SLC31A2 and CTR1), supporting 
the high expression of Cp as well as the known copper bactericidal properties 
169,180.  
Previous studies on HO-1 expression in M1 macrophages have reported 
contradictory results, with some authors reporting LPS-dependent upregulation 
of HO-1 while others showed downregulation in M1 macrophages 111,170,181-183. 
However, M1 macrophages have been associated with increased 
erythophagocytic activity which would support a role for HO-1 upregulation in 
this polarized phenotype 170,184. 
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2.3.2. Alternatively activated macrophages M2 
 
Alternatively activated macrophages (M2) correspond to a polarized 
phenotype of macrophages driven by immune stimuli including IL-4, IL13, 
transforming growth factor β (TGF-β) and glucocorticoids. M2 macrophages 
express high levels of the anti-inflammatory cytokine IL-10, Arg-1, CD163, MR 
as well as low levels of iNOS and pro-inflammatory cytokines (IL-1β, TNFα, IL-
6, IL-12) 168,169. 
M2 macrophages are characteristic of the resolution phase of 
inflammation in which the pathogens have already been cleared, dampening 
pro-inflammatory cytokine levels, secreting components of the extracellular 
matrix (fibrinogen, fibronectin) and promoting tissue repair at the site of 
infection/injury 169. M2 macrophages express high levels of scavenger 
receptors, which will contribute to clearing surrounding tissue of cell debris. 
Amongst these scavenger receptors, CD163 and CD91 promote uptake of Hb-
Hp and heme-Hpx that may exist at the site of infection/injury as a result of 
hemolysis often associated with these conditions 111,168,174. As a consequence, 
M2 macrophages express a cell machinery of proteins involved in Hb and heme 
recycling, namely high HO-1 and Fpn1. One particularity of M2 macrophages is 
the low expression of Ft and high expression of Fpn1, suggesting that these 
macrophages promote iron recycling for clearing the site of infection/injury, but 
mostly for supplying iron to the surrounding cells and tissues, promoting 
collagen synthesis, fibroblast proliferation and tissue repair 111,168. Indeed, it has 
been shown that switch from M1 to M2 phenotype is essential for muscle 
regeneration, a condition in which high levels of iron are essential for building 
new and functional myofibers 185. In addition, the intracellular iron content of M1 
macrophages may also affect the switch into M2 phenotype, thereby 
compromising the healing of the injured sites 184.  
Interestingly, extracellular medium of M2 macrophages was reported to 
promote proliferation of tumor cells, supporting their role in the promotion of 
injury repair 111. Curiously, tumor associated macrophages (TAM) present a M2-
like phenotype, supporting the hypothesis that TAM, like M2, may be involved in 
iron supply to tumor cells, promoting their survival and proliferation 186. In fact, it 
was shown that Fpn1 levels in breast cancer cells were inversely correlated with 
tumor malignancy, showing how Fpn1 levels and consequent iron retention in 
cancer cells is vital for their proliferation and could constitute a therapeutical 
target in cancer research 187. Accordingly, another study confirmed an “iron 
retention” profile in breast cancer epithelial cells with increased Hepc, TfR1 and 
lower H-Ft expression when compared with non-cancerous mastectomy 
samples, which is compatible with the high proliferation status of cancer cells. 
Moreover, both lymphocytes and macrophages in cancerous mastectomy 
samples presented an “iron-donor” profile with high Fpn1 and H-Ft expression 
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along with an activation profile characterized by increased Hepc and TfR1. The 
“iron-donor” profile by lymphocytes and macrophages support the potential role 
of immune cells in supplying iron essential for the proliferation of the tumor cells 
188. 
 
Figure I.8 - Iron metabolism in polarized macrophages M1 and M2. M1 macrophages 
express low TfR1, CD163 and CD91 limiting the uptake of iron sources. These cells also 
present increased phagocytic capacity for both pathogens and damaged erythrocytes at the 
local. Secretion of Hepc by M1 macrophages in response to infection/inflammation leads to low 
levels of Fpn1 at cell surface, promoting the iron retention and storage in Ft, in a clear strategy 
for promotion of pathogen iron starvation. M1 macrophages are also characterized by 
expression of pro-inflammatory cytokines and chemokines for recruitment of other immune cells. 
On the other hand, M2 macrophages are characterized by expression of anti-inflammatory 
cytokines and high expression of CD163 and CD91, promoting uptake of Hb and heme, 
subsequent iron recycling through HO-1 activity and export by Fpn1 to the extracellular medium. 
Iron supply by M2 macrophages is crucial for matrix remodeling and tissue repair at the 
resolution phase of inflammation, but has also been associated with promotion of tumor cells 
proliferation. 
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2.4. Lymphocytes and iron 
Over the decades, the immune system was described as a complex 
network orchestrated only for protection of the organism from external threats 
(pathogens) and for self and non-self (transformed cells) recognition. However, 
in 1978, close observation of lymphocyte trafficking and positioning within tissue 
lead Professor Maria de Sousa to postulate that the immune system could also 
play an important role in the surveillance of iron toxicity in the organism 74,189. 
The author proposed that lymphocytes could be recruited to sites of high iron 
concentration by sensing a gradient of iron-proteins such as Ft, Lf and Tf. By 
expressing receptors for these iron-carrier proteins at their cell surface, 
circulating T lymphocytes would sense the iron-carrier proteins gradient and 
migrate towards the site of iron deposition, where they would contribute to iron 
detoxification 189,190.  
Despite the fact that, since 1978, many studies showed the close 
interaction between the immune system and iron homeostasis, the mechanism 
by which the lymphocytes could monitor and protect against local iron toxicity 
remains unclear. However, some pieces of the puzzle may already have been 
found:  
1) activated lymphocytes present high levels of TfR1 for efficient holo-Tf 
uptake that is crucial for DNA synthesis and cell division, both important 
steps for lymphocyte proliferation 191;  
2) both activated and non-activated lymphocytes synthesize Ft with high 
content of H-chains 192.  
It is therefore pertinent to propose that lymphocytes could constitute a 
“mobile” iron compartment that would be recruited towards sites of high iron 
deposition, where these cells could store iron in the form of Ft while consuming 
it during active proliferation, explaining also the high number of lymphocytes 
found at sites of high iron deposition. On the other hand, one can hypothesize 
that as a potential mobile iron store compartment, lymphocytes could also be 
recruited to sites with high iron demand where they could supply iron, in a 
similar manner as polarized M2 macrophages during tissue repair. 
Attesting the relevance of iron metabolism in lymphocytes, Pinto et al 
reported that human lymphocytes express basal levels of endogenous Hepc in 
all lymphocytes subpopulations, with CD4+ and CD19+ cells expressing the 
highest mRNA levels of human Hepc gene (HAMP) 74. In these studies, upon 
treatment of human lymphocytes with high concentration of holo-Tf or iron 
citrate (NTBI), HAMP transcription was significantly upregulated in a 
mechanism that was neither HFE/TfR2-dependent nor BMP6-dependent. 
Analysis of cytokine expression profile showed that treatment with holo-Tf 
specifically upregulated TNFα and that TNFα silencing would impair HAMP 
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mRNA upregulation by holo-Tf. In addition, the author reported that HAMP 
transcriptional upregulation mediated the internalization of overexpressed GFP-
Fpn1 in these cells, impairing iron export and promoting cellular iron retention. 
Since iron is extremely important for activated lymphocytes proliferation, the 
effect of cell activation on transcription of HAMP was tested. As expected, 
lymphocyte activation upregulated IL-2, IFNγ, TNFα and Hepc. It was also 
demonstrated that Hepc upregulation in activated lymphocytes is crucial for cell 
proliferation, probably by promoting intracellular iron retention to be used for 
DNA synthesis and cell division, both intrinsic steps of T cell proliferation. 
Altogether, the demonstration of endogenous expression of Hepc by 
lymphocytes and its vital role for lymphocyte proliferation upon activation gain 
particular interest in the context of inflammation/infection 74.  
In inflammatory conditions, M1 polarized macrophages also secrete 
autocrine Hepc as well as TNFα, thereby contributing to local Hepc levels as 
well as promoting Hepc expression by lymphocytes and subsequent iron 
retention and storage in both cell types along with lymphocyte proliferation. In 
fact, H-Ft was shown to be upregulated by TNFα, which suggest that in addition 
to macrophages, lymphocytes could also uptake and store iron by synthesizing 
H-Ft 193. Finally, recent data by the same research group show that, like 
hepatocytes, T lymphocytes can uptake and accumulate NTBI (in particular iron 
citrate), giving further support to this hypothesis 194. The finding of an “iron-
donor” profile in lymphocytes as well as macrophages present in cancerous 
mastectomy samples also support the role of lymphocytes as a mobile iron 
storage compartment that could provide iron to the surrounding cells/tissues 188. 
Overall, although in vivo studies are necessary to further understand the 
relevance of lymphocyte-derived Hepc, these findings give further support to the 
possible role of lymphocytes in the surveillance of iron toxicity as postulated in 
1978 by De Sousa. 
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3. Atherosclerosis: an inflammatory disease with 
infiltration of immune cells, lipids and iron 
accumulation  
 
3.1.  Atherosclerosis and cardiovascular disease 
A study conducted by the World Health Organization reported that 
vascular diseases (VD) are the main cause of death worldwide from 2000-2012, 
particularly in industrialized countries 195. VD refer to the clinical manifestations 
of coronary heart disease, cerebrovascular disease and peripheral artery 
disease, all of which frequently have atherosclerosis (ATH) as the underlying 
pathology 196. Today, ATH is considered a chronic inflammatory condition 
resulting from interaction between modified lipoproteins, infiltrated immune cells 
and the components of the arterial wall, all leading to the development of 
complex lesions that protrude into the arterial lumen. These lesions or 
atherosclerotic plaques constitute the hallmark of ATH and, although advanced 
complex plaques may compromise or block the blood flow, it is often the rupture 
of such plaques and subsequent formation of thrombus or cloths that are 
responsible for the occurrence of acute vascular events such as myocardial 
infarction and stroke. 
Among the several identified genetic and environmental risk factors 
associated with ATH, elevated levels of serum cholesterol are unique in being 
sufficient to drive the development of ATH in the absence of other risk factors. 
Indeed, the animal models commonly used to study ATH have defects on key 
proteins of lipid metabolism leading to hypercholesterolemia phenotype and 
accelerated ATH development 197. However, ATH is no longer considered a 
simple lipid-laden disorder and the role of inflammation in this pathology has 
been widely acknowledged by the scientific community 198. Interestingly, many 
individuals suffering from cardiovascular acute events present regular 
cholesterol levels, clearly pointing to other mechanisms in atherogenesis that 
are unrelated to cholesterol plasma level 199. The discovery of statins as a 
pharmacological tool to decrease the circulating cholesterol levels created the 
false expectation that ATH would soon be a treatable pathology. Nonetheless, 
VD continue to be the main cause of death worldwide 195 despite the efficacy of 
statins on lowering cholesterol levels. Understanding other key factors involved 
in atherogenesis is therefore essential for discovering alternative and efficient 
therapeutic targets to control this pathology.  
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3.2.  Atherogenesis 
The artery wall is composed of three organized layers: tunica intima, 
tunica media and tunica adventitia. The intima layer corresponds to a single 
layer of endothelial cells (EC) on top of the internal elastic lamina. The media 
layer is delimited by the internal elastic lamina and the external elastic lamina, 
being composed of vascular smooth muscle cells (SMC) embedded in 
interstitial extracellular matrix. The adventitia is the most external layer of the 
blood vessel and is composed of connective tissue, fibroblasts and perivascular 
nerves. In large vessels, the adventitia layer is characterized by a dynamic 
microvasculature (vasa vasorum) that maintains the media layer and presents 
an additional source for leukocyte infiltration. 
Atherosclerotic lesions can present different degrees of complexity, but in 
general they are composed of cells (immune cells, ECs and SMCs), 
extracellular matrix, lipids and debris. In 1977, Ross et al proposed the 
“response-to-injury” model of atherogenesis that has been refined and 
developed ever since 200. Today, the current model proposes that 
atherosclerotic lesions arise from the inflammatory response to focal endothelial 
injury.  
3.2.1. Endothelial dysfunction 
Several VD risk factors such as high blood pressure, smoking, elevated 
cholesterol and glucose levels favor the occurrence of endothelial dysfunction 
often associated with sites of turbulent blood flow where shear stress is 
increased. The endothelial dysfunction leads to ROS production and increased 
permeability, promoting the retention of lipoproteins such as low density 
lipoprotein (LDL) between the intima and the media layer. Once in the sub-
endothelial region, LDL undergoes enzymatic and non-enzymatic modifications 
such as oxidation, lipolysis, proteolysis and aggregation, giving origin to the so-
called modified LDL 201.  
 
3.2.2. Immune cells recruitment and formation of fatty streaks 
Accumulation of modified LDL is a key event in ECs activation, inducing 
the expression of adhesion molecules and chemokines that recruit immune cells 
to the site of lesion, in particular monocytes and T lymphocytes 202. Once in the 
lesion, the release of cytokines (TNFα, IFNγ) and growth factors (macrophage- 
colony stimulating factor, M-CSF) cause monocytes to differentiate into 
macrophages and to mature into active macrophages, which release pro-
inflammatory cytokines and ROS species. Such event will amplify the 
inflammatory and oxidative microenvironment at the lesion in a vicious cycle of 
lipoprotein oxidation and local inflammation. During the maturation process, the 
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expression of scavenger receptors is upregulated, promoting the uptake of 
modified LDL by the macrophage. Accumulation of cholesteryl esters in the 
cytoplasm of macrophages will lead to the differentiation of lipid-laden cells 
denominated foam cells 203. In addition to macrophages, SMC were also 
reported to uptake and accumulate lipids, contributing to the total amount of 
foam cells within the atherosclerotic plaque 204,205. Subendothelial accumulation 
of foam cells results in the formation of lesions denominated as “fatty streaks” 
that are considered the onset of ATH. These lesions are small and may or not 
progress into larger and complex atheromatous plaques.  
3.2.3. Formation of atheromathous plaques 
During the progression into a more complex lesion, fatty streaks develop a 
necrotic core and a fibrous cap. The excessive lipid uptake by foam cells 
ultimately leads to cell death and release of their cytoplasmic content to the 
extracellular medium, promoting the formation of a necrotic core rich in lipids 
and cell debris at the center of the lesion, whereas the infiltration of monocytes 
and T lymphocytes continues to take place mostly at the shoulder region. As the 
lesion grows larger and more complex, the increased production of 
inflammatory cytokines such as IFNγ induces apoptosis of macrophages, 
contributing to the necrotic core development 206,207. At this point, the 
atheromathous plaque is denominated as “atheroma”.  
 
Production of growth factors and cytokines by degranulated platelets, ECs, 
macrophages, SMCs, and foam cells promotes the de-differentiation and 
proliferation of SMCs. In addition, the release of matrix metalloproteinases and 
IFNγ by macrophages and foam cells induces the downregulation of matrix 
production by SMCs, which further contributes to the degradation of the 
extracellular matrix while facilitates the migration of the SMCs from the media to 
the intima layers and subsequent formation of the fibrous cap 208. The lesions 
presenting a defined fibrous cap overlaying the necrotic core are denominated 
as “fibroatheroma”.  
As the lesions become more advanced and complex, some typical 
features may be observed, including development of intraplaque microvessels 
and calcifications. Indeed, the development of microvessels and intraplaque 
hemorrhage has been associated with accelerated atherogenesis as it allows 
for infiltration of leukocytes and erythrocytes, promoting the pro-inflammatory 
environment in the plaque. Occurrence of fissures or rupture, hematoma and 
thrombosis in fibroatheroma plaques give origin to the so-called “complicated 
lesions” 205.  
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Figure I.9 - The development of an atherosclerotic plaque. The subendothelial accumulation 
of LDL and its modification (step 1 and 2) trigger the activation of ECs, which results in the 
release of cytokines and growth factors as well as induction of adhesion molecules (step 3), 
favoring the infiltration of monocytes to the site of lesion (step 4). Intralesional monocytes 
differentiate into macrophages (step 5) which, along with SMCs, will uptake and accumulate the 
modified LDL, forming the so-called foam cells (step 6). Foam cell accumulation and death by 
necrosis along with SMC proliferation result in a lesion with a necrotic core and fibrous cap, 
leading to the formation of the fibroatheroma (steps 7 and 8). Image originally published in 
Faxon et al (2004) 
209
. 
3.2.4. Stable and unstable atheromathous plaques 
According to its composition, the atherosclerotic lesion can be classified 
as a stable or unstable plaque, this latter one being more prone to rupture. A 
plaque with a small necrotic core, reduced number of inflammatory cells and 
thick fibrous cap is considered to be a stable plaque. On the other hand, a 
plaque with a large necrotic core, high number of inflammatory cells and a thin 
fibrous cap is considered to be unstable and likely to rupture, particularly at the 
shoulder regions where the inflammation is concentrated. Rupture of a plaque 
leads to the formation of a thrombus, which may occlude the artery lumen and 
cause acute cardiovascular events such as myocardial infarction or stroke 
206,210. Nonetheless, the rupture of a plaque does not necessarily lead to the 
occlusion of the artery and the plaque may heal by regeneration or scarring. 
However, the cost of the rupture is the enlargement of the plaque due to the 
thrombus formation, narrowing the blood vessel (stenosis). Indeed, the growth 
of atherosclerotic plaques appears to occur in bursts, probably associated with 
repeated events of plaque rupture and healing that are often associated with a 
greater incidence of fatal acute vascular events 211 (Figure I.10).  
The rupture of the plaque is associated with increased apoptosis of SMCs, 
reduced production and increased degradation of extracellular matrix leading to 
the thinning of the fibrous cap. Also, the apoptosis of macrophages in addition 
to the apoptosis of foam cells increase the size of the necrotic core, inducing 
pressure on the fibrous cap as it becomes thinner 206. Another cause for plaque 
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rupture is the formation of microvessels within the plaque and subsequent 
intraplaque hemorrhage, which can potentiate its instability through the 
infiltration of more leukocytes as well as erythrocytes 212. 
 
Figure I.10 - Atheroma plaque progression and stability. During atherogenesis, the sub-
intimal accumulation of modified LDL triggers the infiltration of immune cells and differentiation 
of foam cells. The progressive accumulation of these cells and their subsequent death by 
necrosis leads to the formation of a necrotic core and a fibrous cap in the lesion (atheroma). 
The atheroma may evolve into a stable lesion with a small necrotic core and thick fibrous cap, 
or into a vulnerable plaque prone to rupture due to the large necrotic core and thin fibrous cap. 
The rupture of a vulnerable plaque leads to the formation of a thrombus, which may occlude the 
artery and trigger a cardiovascular event such as an acute myocardial infarction. However, if the 
occlusion is only partial, the plaque may heal at the additional cost of its enlargement, narrowing 
the lumen of the vessel (stenosis). Image originally published in P. Libby (2002) 
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3.3. Iron as a potential risk factor in Atherosclerosis 
 
3.3.1. The iron hypothesis  
In 1981, Sullivan presented the “iron hypothesis” in which it was proposed 
that iron could constitute a modifiable risk factor in ATH 214. This hypothesis 
suggested an alternative or additional explanation for the gender-associated 
difference of ischemic heart disease incidence, in which pre-menopausal 
women presented a significantly lower risk than age-matched men. This same 
risk of cardiovascular acute events would double in post-menopausal women 
when compared with pre-menopausal women. Possible explanations 
associated with the increased cholesterol levels after menopause or associated 
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with estrogen production as a protective factor were proposed. However, the 
rise in cholesterol levels in post-menopausal women was not sufficient to 
explain the doubling of ischemic heart disease incidence observed 214,215. Also, 
regarding estrogen as a protective factor, the fact that the women’s protection 
against VD was not observed in surgery-induced post-menopausal woman that 
preserved their ovaries, argues against this hypothesis. In addition, the 
hormonal replacement therapy has been associated with increased risk of VD 
complications, which is contrary to what was expected 216.  
As a fundament of his hypothesis, Sullivan noticed that VD corresponded 
to the main cause of death in industrialized countries, an observation that 
remains valid to this day. Accordingly, in undeveloped countries where the 
majority of the population lives in poor conditions, VD associated with ATH were 
not at the top of the list of death causes. Interestingly, Sullivan pointed out that 
a condition often associated with the population of such countries is iron 
deficiency 214. Pre-menopausal women often present iron deficiency or low 
levels of body iron stores as a consequence of the blood losses associated with 
menstruation. On the other hand, men progressively accumulate iron at a higher 
rate than pre-menopausal women, presenting mean Ft levels of 108-120 µg/L at 
age of 25 to 44 years old, while women present mean Ft levels of 38 µg/L at the 
same age. While men present a Ft blood concentration of 139-143 µg/L at age 
45-64 years old, this value increases to 60-74 µg/L in women reflecting the 
increase of body iron stores in women after menopause 217. Sullivan proposed 
that higher iron stores would be translated in higher availability of redox-active 
iron at site of oxidative and/or inflammatory injury, in which iron could play a role 
at site of atherosclerotic lesions promoting its progression. Accordingly, a state 
of sustained iron depletion or mild iron deficiency induced by regular 
phlebotomy could have a protective effect against ATH progression 214,218.  
3.3.2. Presence of iron in atherosclerotic lesions 
Since its proposal in 1981, the iron hypothesis has been the focus of many 
studies, supporting a still ongoing controversy. Evidence of the existence of 
catalytic iron in human atherosclerotic lesions was previously shown by Smith et 
al, who reported lipid peroxidation induced by the iron-rich content of the plaque 
219. Pang et al reported that both H-Ft and L-Ft (iron storage) are highly 
expressed in human atherosclerotic plaques, being induced on both ECs and 
macrophages at the early onset of the lesion and previous to the occurrence of 
intralesional hemorrhage often observed in advanced lesions. The same group 
showed that Ft was also induced in SMC in advanced lesions, where it could be 
involved in the promotion of cell proliferation. In this study, rabbits fed with high 
fat diet expressed high Ft levels in early and advanced lesions, but detection of 
iron deposits by Prussian blue was only observed in advanced lesions 220. The 
use of more sensitive techniques such as nuclear microscopy by another group 
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revealed a significant increase of iron content observed in early atherosclerotic 
lesions of rabbits placed on a high fat diet 221. 
 
3.3.3. Iron depletion and atherosclerosis 
A previous report showed that repeated bleeding of rabbits placed on a 
high fat diet decreased the iron level accumulated in the lesions and delayed 
the onset of the disease 221. In a similar study using high cholesterol-fed rabbits, 
treatment with an iron chelator induced a decrease in both lesion area and iron 
content, supporting a role for iron in early stages of ATH 222. A different strategy 
was adopted by other researchers, using a murine model presenting a defect in 
apolipoprotein E (ApoE) which develops hypercholesterolemia independently of 
a cholesterol-rich diet. Lee et al observed a progressive accumulation of iron in 
lesions on apoE-deficient mice placed on a standard diet. After an iron-
restricted diet for three months, a decrease of approximately 30% on circulating 
Ft was confirmed along with lower level of circulating auto-antibodies against 
oxidized LDL (oxLDL, the most common form of modified LDL) and increased 
resistance of isolated lipoproteins towards copper-induced oxidation. 
Accordingly, a decrease in the area of atheromatous plaques was observed in 
this iron-restricted group 223. Altogether, these studies support a protective role 
of the depletion of body iron stores on the progression of ATH as suggested by 
Sullivan.  
Indeed, Sullivan initially proposed that a possible test to his “iron 
hypothesis” in ATH would be a randomized prospective study evaluating the 
risk for developing VD in frequent blood donors in comparison with appropriate 
controls. Ensuring depletion of body iron stores without causing anemia would 
be an important condition in such study. Over the last decades, some trials 
attempted to test the effect of blood donation on the susceptibility to VD, but 
different study designs lead to opposite conclusions 224-227. Interestingly, the 
results from the study which presented the closest experimental design to the 
one proposed by Sullivan indicated that high-frequency blood donors showed 
decreased body iron stores, decreased oxidative stress and enhanced vascular 
function when compared with low-frequency donors. These observations 
suggest that sustained iron depletion may have a protective effect towards the 
development of VD 228. 
3.3.4. Iron overload and atherosclerosis 
Although Sullivan emphasized the importance of testing the effect of 
sustained iron depletion state on ATH, many other studies focused their 
investigation on the role of iron overload on ATH progression generating 
confusing results.  
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Chronic administration of iron-dextran (which is specifically cleared from 
circulation by macrophages in the liver, spleen and bone marrow) followed by 
photochemical carotid artery injury in mice lead to accelerated arterial 
thrombosis, increased vascular oxidative stress, and impaired vaso-relaxation 
229. Araujo et al reported augmented formation of atherosclerotic lesions in 
rabbits placed on a cholesterol-rich diet combined with iron overload condition 
through iron-dextran administration 230. In contrast, a similar study (iron dextran 
overload) using the same rabbit model by Dabbagh et al reported a decrease in 
the lesion area associated with iron overload rabbits while iron-deficient ones 
presented a slight increase in the area of lesions 231. Noteworthy, the different 
iron status in this study influenced the circulating cholesterol levels, and iron-
dextran was proposed to have a hypocholesteromic effect, decreasing the 
cholesterol levels and likely leading to the observed decrease in the lesions 
formation 231. The conflicting results of the multiple studies sustained the 
controversy around the “iron hypothesis” to this day.  
3.3.5. Hepcidin, iron macrophage and atherosclerosis 
A common argument often pointed out against the “iron hypothesis” relied 
on the lack of association between HH and increased susceptibility to ATH 
development 232,233. In response to the controversy around HH, a refinement of 
the “iron hypothesis” was later on presented by Sullivan 234,235. Inspired by the 
recent knowledge about Hepc as the master regulator on systemic iron 
homeostasis, downregulating the iron exporter Fpn1 and blocking both iron 
absorption and mobilization from hepatocytes and macrophages, Sullivan 
proposed a possible mechanism in which Hepc could play a role in the 
progression of ATH. HH is characterized by systemic iron overload as result of 
disrupted Hepc-Fpn1 axis, causing continuous iron absorption and mobilization 
from stores. Interestingly, a curious fact about HH patients is that despite the 
iron overload, these patients present iron-depleted macrophages as a result of 
inappropriately low level of Hepc (in face of the body iron overload) or Fpn1 
gain-of-function mutations. Given the key role of macrophages in ATH and the 
multiple observations of iron accumulation in macrophages and foam cells at 
the atherosclerotic plaque, Sullivan proposed that macrophage iron retention 
could be an essential feature for the progression of lesions in ATH. Indeed, 
Hepc is upregulated by inflammatory conditions in lymphocytes, monocytes and 
macrophages, which could promote macrophage iron retention. Noteworthy, 
iron loading in macrophages was reported to favor cholesterol uptake and 
accumulation by upregulating scavenger receptor 1 236. Hepc-dependent iron 
retention in intraplaque macrophages could therefore contribute to the formation 
of foam cells and subsequent progression of the lesion. Accordingly, iron-
depleted macrophages typically observed in HH patients could therefore 
constitute a mechanism of protection against foam cell formation. Additionally, 
milder inflammatory response and decreased cholesterol levels also associated 
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with HH condition could contribute to protect against ATH despite systemic iron 
overload 234. Interestingly, recent studies by Valenti et al showed Hepc levels 
correlated with the release of IL-6 and MCP-1 as well as with vascular damage 
in high-risk individuals with metabolic alterations, with exception for those with 
HH which presented low Hepc levels 237.  
Unlike HH, pathologies characterized by chronic macrophage iron 
retention could show increased susceptibility to ATH. For instance, anemia of 
inflammation is a condition that presents iron-loaded macrophages as a 
consequence of Hepc upregulation by inflammatory conditions. Interestingly, 
Hepc was considered a direct link between anemia of inflammation and the 
increased risk for ATH development in patients suffering from rheumatoid 
arthritis 238. In addition, Saeed et al recently reported that pharmacological 
suppression of Hepc in apoE-deficient mice using a BMP inhibitor decreased 
macrophage iron content and increased cholesterol efflux. This resulted in 
reduced foam cell formation and decreased lipid burden and area of 
atherosclerotic lesions, pointing to an eventual protection against ATH 
progression by inducing Hepc inhibition 239. Accordingly, another study suggests 
that Hepc may constitute a positive regulator of atherosclerotic plaque 
destabilization by regulating macrophage iron homeostasis. In particular, 
overexpressed Hepc production at the carotid artery affected the plaque 
composition, increasing the number of intraplaque macrophages while 
decreasing SMCs and collagen content. In addition, Hepc overexpression 
induced iron retention in macrophages, increasing oxidative stress and 
production of pro-inflammatory cytokines concomitantly to the increase in 
oxLDL levels in intraplaque macrophages 240.  
Altogether, these findings support the “iron hypothesis” and indicate that 
interaction between Hepc, cellular iron retention (particularly in macrophages) 
and lipid accumulation are critical for development of foam cells, leading to 
plaque destabilization. However, a recent study conducted by Kautz et al to test 
the effect of Hepc and iron-loaded macrophages in ATH progression in ApoE 
knockout mice found no association between macrophage iron loading and ATH 
progression, adding again new controversy to the “old” iron hypothesis.  
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Figure I.11 - Schematic overview of the iron hypothesis. Macrophages can accumulate iron 
from different sources, including heme (free or associated with Hb) as a result of heme intestinal 
absorption, hemolysis or erythrophagocytosis. Once stored in the cell, iron can be mobilized to 
the bloodstream via Fpn1-mediated export according to the body iron demand through a 
mechanism regulated by Hepc. The “iron hypothesis” proposes that high hepcidin levels may 
constitute a risk factor for plaque progression and destabilization. The inflammatory conditions 
associated with atherogenesis may upregulate Hepc levels, leading to Fpn1 internalization and 
subsequent macrophage iron retention. The iron accumulation in macrophages would increase 
intracellular ROS levels and ultimately lead to decreased cholesterol efflux, promoting 
cholesterol accumulation and foam cell formation, inflammation and eventual plaque instability. 
Image adapted from Vinchi et al (2014) 
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3.3.6. Macrophage polarization, iron and Atherosclerosis 
 
3.3.6.1. M1, M2 and M4 phenotypes  
Macrophages can be polarized into different phenotypes according to the 
surrounding microenvironment (see section 2.3). Indeed, macrophage 
polarization represents a continuum of functional states that encompasses a 
broad range of macrophage phenotypes with interchangeable characteristics, in 
which fully polarized M1 and M2 phenotypes represent two opposite extremes.  
During the progression of atherosclerotic lesions, the complex 
microenvironment within the plaque is reflected in the heterogeneity of 
macrophages phenotypes. Indeed, M1 and M2 polarized macrophages were 
reported to co-exist in the atherosclerotic plaque and, although M1 is portrayed 
as pro-atherogenic due to its pro-inflammatory characteristics and M2 is 
considered to be anti-atherogenic, both M1 and M2 were shown to uptake lipids 
and subsequent transformation into foam cells in vivo 242,243. However, besides 
M1 and M2, a mixed M1/M2 phenotype was also observed along with other 
polarized macrophage phenotypes in atherosclerotic lesions.  
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For instance, Gleissner et al reported that platelet chemokine CXCL4 
polarizes macrophages into a M4 phenotype with some common genes to both 
M1 (e.g.: IL-6 and TNFα) and M2 (e.g.:CCL18 and CCL22). However, some 
other genes showed that M4 macrophages constitute a different phenotype. 
Among those distinct markers are: low expression oxLDL scavenger receptors 
such as scavenger receptor 1 and CD36, low MR and complete absence of Hb-
Hp receptor CD163, low HO-1 and IL-10 expression, and increased levels of 
cholesterol exporters. Moreover, this newly characterized phenotype was 
shown to be present in the atherosclerotic plaques and experiments with double 
knockout mice ApoE and CXCL4-deficiency (ApoE-/-Pft4-/-) presented reduced 
ATH, which indicates that M4 macrophages could have a pro-atherogenic 
role244.  
3.3.6.2. Hemorrhage-associated macrophages 
Boyle et al reported a new polarized phenotype distinct from M1 and M2 
macrophages. These polarized macrophages were denominated as 
hemorrhage associated-macrophages (HA-mac) and were first identified in 
human plaques with fatal coronary thrombosis, where they would localize 
around the hematoma, being mostly absent in the stable and hemorrhage-free 
plaques analyzed. HA-mac are distinct from the lipid-laden macrophages, 
presenting low lipid content, suppressed oxidative stress and decreased 
expression of myeloperoxidase (MPO) and human leukocyte antigen (HLA-DR), 
as well as increased expression of CD163, MR, HO-1 and IL-10. This polarized 
phenotype was differentiated in vitro by exposure to oxidized erythrocytes, Hb 
or heme during seven days, in which HO-1 upregulation was found to be Nrf2-
dependent and essential for the polarization of HA-mac 245,246. Later on, Boyle 
renamed HA-mac as Mhem macrophages and clarified the underlying 
regulatory mechanism in which heme triggered the activation of both Nrf2 and 
ATF-1 and their translocation to the nucleus. HO-1 upregulation was mediated 
by both activating transcription factor 1 (ATF-1) and Nrf2, while ATF1 alone 
mediated liver X receptor (LXR) induction (likely LXR-β) and subsequent 
upregulation of ApoE as well as cholesterol exporter, promoting cholesterol 
mobilization out of the Mhem macrophage 247.  
In a parallel study, Finn et al reported a polarized macrophage phenotype 
denominated as M(Hb) and driven by Hb-Hp during macrophage differentiation, 
resembling the Mhem phenotype reported above 248. When comparing M(Hb) 
with M2 macrophages, similar levels of MR were observed along with higher 
levels of CD163 and IL-10 in M(Hb) macrophages as observed in Mhem. Finn 
observed that M(Hb) were localized in the area surrounding intraplaque 
hemorrhage as previously observed for Mhem macrophages described by 
Boyle, presenting also upregulated HO-1. A mechanism was reported in which 
increased Fpn1 levels and subsequent increased iron export in M(Hb) 
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macrophages resulted in low intracellular iron and ROS. The low oxidative 
stress activated LXR-α, leading to increased levels of the cholesterol exporters 
ATP-binding cassette A1 and G1 (ABCA1 and ABCG1), protecting M(Hb) from 
transformation into foam cells 248. In another study by the same research group, 
the atheroprotective effect of M(Hb) was proposed to be dependent on low 
Hepc production by these cells and subsequent high levels of Fpn1 and low 
intracellular iron, pointing pharmacological suppression of Hepc as a possible 
strategy against ATH progression 239.  
3.3.6.3. The Mox phenotype 
Another polarized macrophage phenotype entitled as Mox was recently 
reported by Kadl et al, differentiated upon exposure to oxidized phospholipids 
(particularly oxPAPC) 249. Mox macrophages presented decreased phagocytic 
capacity of beads and apoptotic thymocytes as well as decreased capacity of 
promoting monocyte migration when compared with M1 and M2 macrophages. 
Also, both M1 and M2 macrophages were polarized into Mox phenotype in vitro 
upon exposure to oxPAPC, suggesting that Mox macrophages could constitute 
a major population in the atherosclerotic plaque. Mox macrophages also 
presented a distinct pattern of gene expression, in which M1 and M2 markers 
such as iNOS, TNFα, IL-12, MCP-1 and Arg-1 are not upregulated. Instead, a 
total of 119 genes analyzed were exclusively upregulated in Mox macrophages, 
including the ones coding for HO-1, glutathione reductase 1, sulforedoxin-1, 
thioredoxin reductase, glutathione reductase 1, glutamate-cysteine ligase 
modifier subunit, thrombospondin, and vascular endothelial growth factor 
(VEGF). Apart from VEGF, the other genes mentioned above present anti-
oxidant or anti-angiogenesis activities. The upregulation of some of these anti-
oxidant genes was found to be Nrf2-dependent, including the gene coding for 
HO-1 among others. Additionally, Kadl et al reported that Mox macrophages 
presented decreased protection against cell death in the absence of Nrf2 or 
HO-1, revealing the importance of this pathway in the survival of macrophages 
in such oxidative environment as the one found in atherosclerotic lesions.  
Finally, analysis of macrophages isolated from atherosclerotic lesions of 
LdlR-/- mice placed on high-fat diet using flow cytometry technique revealed the 
presence of 39.2% M1 (CD86+, HO-1-, MR-), 34.4% Mox (CD86-, HO-1+, MR-), 
21.8% M2 (CD86-, HO-1-, MR+) and 9.6% Mox/M1 (CD86+, HO-1+, MR-) and 
2.3% Mox/M2 (CD86-, HO-1+, MR+) polarized macrophages, proving the 
existence of Mox macrophages in atherosclerotic lesions 249. The observation of 
the mixed populations Mox/M1 and Mox/M2 suggests that the different 
populations of M1, M2 and Mox may co-exist within the plaque in spatially 
distinct microenvironments, in which the mixed populations could be located in 
the transition of the different microenvironments. Interestingly, the mixed 
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phenotype Mox/M2 (CD86-, HO-1+, MR+) could also correspond to Mhem/M(Hb) 
phenotype described before.  
Interestingly, in a different study, Seneviratne et al reported that Mox 
macrophages constitute the main macrophage population in the aortic root 
lesions (36% Mox vs. 5,6% M1 and 0,2% M2). Additionally, the same author 
used a murine model to test low shear stress into the development of vulnerable 
plaques, and oscillatory shear stress to induce a stable plaque phenotype in the 
carotid artery 250. The results showed that Mox and M2 populations were not 
significantly different between lesions triggered by either low or oscillatory shear 
stress, while M1 macrophages were significantly increased in advanced LSS-
induced lesions (unstable plaque) 250, which suggests that Mox macrophages 
constitute a major population during the progression of atherosclerotic plaques, 
independently from their stability. 
 
Figure I.12 - Macrophage polarized phenotypes in Atherosclerosis. Macrophages (Mø) 
present a high plasticity in response to the surrounding microenvironment, in which M1 and M2 
macrophages constitute the two extreme phenotypes. M1 macrophages show strong pro-
inflammatory properties and are involved in the development and progression of the lesion (+) 
while M2 macrophages are considered anti-inflammatory and have been reported as anti-
atherogenic (-). In addition, several other macrophage phenotypes are observed in the 
atherosclerotic plaque: Mhem macrophages which are characterized by high levels of HO-1, 
CD163 and MR (CD206) as well as ABCA1 and ABCG1 (cholesterol exporters), promoting the 
reverse cholesterol export and considered to be anti-atherogenic; Mox macrophages which 
present anti-oxidant properties, expressing high levels of anti-oxidant genes such as HO-1, 
Txnrd1, and Srxn1. However, the potentially athero-protective effect of Mox macrophages 
needs to be demonstrated; M4 macrophages which differentiate in response to the chemo-
attractant CXCL4, showing pro-inflammatory and pro-atherogenic effects and presenting low 
levels of CD163 and high levels of MHCII and CD86. Illustration adapted from Vinchi et al 
(2014) 
241
. 
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3.3.7. Ferroportin-1 and its partners in atherogenesis 
Several studies show iron and lipid accumulation co-exist in foam cell 
macrophages, with exception to Mhem/M(Hb) polarized phenotype in which 
cells present low intracellular iron and low intracellular lipid content. Both M1 
and M2 macrophages have already been characterized concerning the main 
proteins involved in iron metabolism (section 2.3.1). However, apart from HO-1, 
expression of iron metabolism proteins in Mox macrophages is poorly 
described. Concerning the significant proportion of Mox macrophages in 
atherosclerotic lesions and how iron and lipid metabolisms are interconnected, 
the characterization of the expression of iron metabolism proteins in this 
polarized phenotype is highly relevant, with particular interest for the proteins 
involved in iron export: Fpn1 and its ferroxidase partner(s). 
Fpn1 is so far the only iron exporter identified in mammals 24,95,96. Recent 
publications point to an important role of macrophage iron retention in the 
progression of atherosclerotic lesions 184,240,248,251. Moreover, increased 
macrophage iron export by Fpn1 was shown to be essential for resistance to 
foam cell formation 248. Indeed, Fpn1 expression is downregulated at both 
mRNA and protein level by pro-inflammatory conditions (M1 phenotype), 
leading to impaired iron export and progressive iron accumulation in M1 
macrophage 28,110,111,252. In Mox macrophages, the transcription factor Nrf2 is 
activated in response to oxidized phospholipids 249. Interestingly, Nrf2 is 
involved in Fpn1 upregulation in response to heme 109, suggesting that Fpn1 
could be upregulated in Mox macrophages. However, oxLDL was also reported 
to induce the release of pro-inflammatory cytokines 253, which could promote 
Fpn1 downregulation. Understanding how Fpn1 expression is modulated in 
response to oxLDL (Mox) is fundamental considering the relevant role of iron 
retention in the progression of atherosclerotic lesions.  
Besides Fpn1 expression, the iron export is also modulated by the 
expression of the ferroxidase partner interacting with Fpn1. Indeed, lack or 
impaired ferroxidase activity, in particular Cp, was associated with decreased 
levels of Fpn1 at cell surface, which suggested that ferroxidase activity could 
promote Fpn1 stabilization at cell surface 121,122. Macrophage iron retention in 
pathological conditions (aceruloplasminemia) or animal models (Cp-/- mice), in 
which Cp expression is impaired or nonexistent, indicates that Cp plays an 
important role in macrophages iron export 51,63. Indeed, Sarkar et al reported 
extracellular Cp activity was essential for iron export from macrophage under 
hypoxic conditions 254. Interestingly, Cp is an acute phase protein and, as such, 
its levels are highly upregulated in pro-inflammatory conditions (IFNγ, IL-1β, IL-
6, LPS) 136, while Fpn1 is downregulated. However, in addition to its role in 
cellular iron export, Cp can also oxidize other substracts, including lipoproteins 
such as LDL 255,256. Increased levels of circulating Cp have been associated 
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with increased cardiovascular risk 255,257-259, which could be attributed to its 
capacity to oxidize circulating LDL. In addition to increased circulating Cp levels, 
the pro-inflammatory conditions as well as hypoxia found in atherosclerotic 
plaques could promote Cp expression and subsequently LDL oxidation. 
Accordingly, co-localization of Cp and oxLDL in the enlarged intima of pro-
atherosclerotic areas was previously reported, supporting the hypothesis that 
Cp local production by immune cells at the site of lesion could be associated 
with increased LDL oxidation, and thus to increased susceptibility to VD 260. 
Noteworthy, in addition to Cp-mediated LDL oxidation, Cp was also reported to 
enhance SMC- and EC-mediated LDL oxidation by a superoxide-dependent 
mechanism 261. Therefore, considering both its role in cellular iron export as well 
as LDL oxidation, characterization of Cp isoforms expression in lymphocytes, 
monocytes, and macrophages is necessary to get insight on the role of Cp in 
atherogenesis.  
Another possible partner of Fpn1 is APP, which was reported by Duce et 
al to act as a ferroxidase in neurons 139. Although its putative ferroxidase activity 
is currently under discussion 140,141, APP interaction with Fpn1 was 
demonstrated by McCarthy et al which showed that sAPP stabilized Fpn1 at cell 
surface of brain microvasculature ECs, thereby influencing the iron export in 
these cells 142. APP expression in monocytes and macrophages was previously 
reported 262, which suggests that APP could be one additional partner of Fpn1 
in macrophages. Moreover, like Fpn1, APP translation is regulated by the 
IRE/IRP system and its expression was shown to be upregulated by iron in 
neural cell lines 263,264. Increased iron accumulation in the liver (hepatocytes), 
kidney and brain (neurons) of App-/- mice point to an important role of APP in 
iron metabolism 263. Interestingly, an association was found between ATH and 
Alzheimer’s disease 265, a pathology in which APP is directly involved. In fact, 
double knockout mice for ApoE and APP (ApoE-/-App-/-) showed increased 
susceptibility to ATH, developing larger lesions than ApoE-/- mice 266. In this 
same study, ApoE-/-App-/- mice presented upregulated levels of chemokines, 
adhesion molecules and pro-inflammatory cytokine IL-6, showing that APP 
plays a role in protection against ATH 266. As some of these features have also 
been associated with increased macrophage iron retention 184,240,251, it is thus 
possible that APP involvement in Fpn1 stabilization and iron export could be at 
the origin of the increased ATH susceptibility in ApoE-/-App-/-. 
Overall, Fpn1, Cp and APP have been individually associated with ATH 
and are likely involved in iron efflux in macrophages. In addition, Cp capacity of 
directly oxidizing LDL points to a role of Cp in atherogenesis that goes beyond 
the iron export. Therefore, understanding the effect of pro-inflammatory and 
atherogenic conditions on these proteins in immune cells and, in particular, in 
macrophages is important to bring insight on their role in ATH and to clarify the 
relationship between iron and ATH. 
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4. Rationale of the study and objectives 
The iron hypothesis on ATH etiology is based on the principle that high stored 
iron levels could constitute a risk factor in the development and progression of 
ATH. Characterization of the mechanisms underlying the regulation of iron 
metabolism in the main immune cells involved in the progression of 
atherosclerotic lesions is thus necessary to understand the role of iron in 
atherogenesis. 
Figure I.13 - Schematic illustration of the interconnection between iron metabolism, 
immune cells and inflammation on the “iron hypothesis” of atherosclerosis etiology. 
 
In this broad perspective to understand how iron metabolism, immune 
cells and atherogenesis are interconnected (Figure I.13), we designed three 
major objectives: 
1) Characterize the expression of Cp isoforms (sCp and GPI-Cp) in 
lymphocytes, monocytes and macrophages.  
In chapter 1 and 2, we studied the expression of iron metabolism proteins 
in immune cells that infiltrate the plaque and actively contribute to its 
progression In this context, we focused of the expression of Cp in immune cells 
given its potential role as a ferrroxidase partner of Fpn1 in these cells as well as 
its potential pro-oxidant role in atherogenesis. 
2) Investigate the potential ferroxidase(s) interacting with Fpn1 in 
macrophages. 
In chapter 2, we clarified some aspects of iron metabolism concerning the 
ferroxidase partners of Fpn1 in macrophages. 
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3) Study the effect of pro-inflammatory (M1) and/or atherogenic (Mox) 
context on macrophages iron metabolism, particularly on the 
regulation of the proteins involved in iron efflux.  
In chapter 3, we characterized the effect of pro-atherogenic conditions on 
the expression of key iron metabolism proteins in macrophages. In particular, 
we studied the expression of iron metabolism proteins in the new polarized 
phenotype Mox. We also investigated the effect of simultaneous challenge with 
M1 and Mox activators on macrophage polarization as well as on the 
expression of some iron metabolism proteins. 
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II. Material and Methods 
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1. Reagents 
 
1.1.  Source of reagents 
All chemical reagents and human AB serum were purchased from Sigma-
Aldrich, unless stated otherwise. All cell culture media, bovine serum and 
antibiotics were purchased from Invitrogen (GIBCO BRL). All cytokines were 
purchased from BD Biosciences. All reagents for Western blot were purchased 
from Bio-RAD unless stated otherwise. Reagents for In-Cell Western blot were 
purchased from Li-COR unless stated otherwise. Plasmid containing human 
GPI-Cp full-length cDNA was a kind gift from Doctor Jonathan Gitlin (Marine 
Biological Laboratory, Massachusetts, USA). Plasmid containing human Fpn1 
full-length cDNA was purchased from ORIGENE. Construction of plasmids 
containing the sequence of the different epitopes of human Fpn1 for antibody 
production was carried out as a service by IMAGIF (ICNS, Gir-sur-Yvette, 
France). All primers used for quantitative transcriptional analysis are indicated 
in Table 1 while all antibodies used in the different proteomic techniques are 
indicated in Tables 2, 3 and 4. Native LDL solution was a kind gift from Doctor 
Anne Negre-Salvayre (Inserm/UPS UMR 1048-I2MC, Toulouse, France). The 
antibody anti-Hepc was a gift from Doctor Sophie Vaulont (Institut Cochin, 
Paris, France) 267. 
 
1.2.  Preparation of native, oxidized and acetylated LDL 
Native LDL (nLDL) solution was extensively dialyzed 20 h at 4ºC against 
NaCl2 (9 g/L) with several changes of buffer in order to remove the traces of 
ethylenediaminetetraacetic acid (EDTA). The nLDL solution was then filtered 
with 0,2 µm filter for sterilization and then quantified and diluted to 1 mg/ml, 
before being incubated for 24 h at 37ºC in the presence of 10 µM of CuSO4 for 
preparation of oxLDL. For each experiment, fresh oxLDL solution was prepared 
and used immediately after completing the 24 h incubation since oxidation is a 
continuous process that would only be stopped by EDTA addition. Untreated 
“control” cells were incubated in parallel in the presence of the same 
concentration of NaCl2 and CuSO4 in culture medium as in oxLDL-treated cells. 
For preparation of acetylated LDL (acLDL), non-dialyzed nLDL was quantified 
and diluted to 2 mg/ml and then diluted 1:1 with saturated acetate solution to a 
final concentration of 1 mg/ml. Then, under mild agitation, anhydrous acetic acid 
was added (2 µL acid/mg LDL) every 15 min for 1 h at 4ºC. The resulting acLDL 
was then extensively dialyzed against overnight (O/N) a 4ºC against NaCl2 (9 
g/L) with several changes of buffer to remove all traces of acid and EDTA. The 
solution of acLDL was then filtered for sterility and dosed using BCA, being 
stored at 4ºC or used directly on cells. Efficiency of both oxLDL and acLDL 
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treatment was monitored by lipid staining using a specific dye. Oxidation level of 
oxLDL and nLDL solutions was verified by TBARS determination in 
collaboration with Doctor Anne Negre-Salvayr’s Lab. 
1.3.  Preparation of plasmids 
Large-scale production of recombinant plasmids containing full-length 
cDNA of human GPI-Cp and human Fpn1 were performed by transformation of 
competent DH5α E.coli (Invitrogen) through thermal shock, followed by plasmid 
DNA extraction using the PureLink HiPure Plasmid Filter Maxiprep Kit 
(Invitrogen). Plasmids were then precipitated with absolute ethanol O/N at -
20ºC, washed with 70% ethanol, and then resuspended in sterile TE (pH 8.0). 
Quantitative and qualitative analysis were performed using Nanodrop 1000 
(Thermo Scientific) and electrophoretic agarose gel (0,8%) analysis. Presence 
of GPI-Cp or Fpn1 cDNA cassettes was confirmed by conventional polymerase 
chain reaction (PCR) using specific primers. 
2. Cell culture 
 
2.1. Human peripheral blood cells 
Human peripheral blood mononuclear cells (huPBMC) were isolated from 
either buffy coats or whole blood of healthy blood donors collected at Hospital 
Reynaldo dos Santos using either Ficoll-Paque (GE Healthcare) or BD 
vacutainer CPT tubes (BD Biosciences), respectively. Remaining erythrocytes 
were lysed by incubating the cells in erythrocyte lysis solution (10 mM Tris, 16 
mM NH4Cl, pH 7.4) for 10 min at 37ºC and followed by centrifugation at 400 g 
for 10 min. huPBMC were resuspended in warm RPMI 1640 culture medium 
and centrifuged at 300 g for 15 min to remove most platelets from suspension. 
huPBMC were then washed in Hank’s balanced Salt solution (HBSS) and 
resuspended in RPMI 1640 culture medium supplemented with GlutaMAXTM I, 
25 mM HEPES buffer, 10% fetal bovine serum (FBS) and 1% penicillin-
streptomycin (P/S). 
For lymphocyte enrichment (huPBL), huPBMC were seeded in T75 culture 
flasks pre-coated with FBS, followed by 1 h incubation at 37ºC with 5% CO2 
atmosphere. Cells in suspension were collected and washed in phosphate-
buffered saline (PBS) solution. For monocyte enrichment (huPBMn), cells 
adherent to the flask after 1h incubation were washed several times with HBSS 
(Mg+Ca+) and scrapped in PBS-EDTA (2 mM). Cells were then collected by 
centrifugation and washed in PBS before undergoing cell fixation or lysis 
according to different protocols. Purity of cell suspension (huPBL > 95%; 
huPBMn > 87%) was confirmed by flow cytometry using Simultest LeucoGATE 
(CD45-FITC/CD14-PE) reagent (BD Biosciences). 
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For human macrophage culture, the adherent huPBMn were washed with 
warm HBSS (with calcium and magnesium) followed by incubation with RPMI 
1640 medium supplemented with 10% FBS, 10% human AB serum, 1% P/S 
and 50 ng/ml recombinant human M-CSF (R&D Systems). At day 5, medium 
was removed and adherent cells were washed with warm HBSS to remove any 
dead cells, followed by addition of new complete medium. Cells remained in 
culture with medium renewal every 2 days until treatment at day 7/8.  
2.2. Murine bone Marrow Derived Macrophages 
Murine bone marrow derived macrophages (BMDM) were cultured as 
described previously 170. Briefly, bone marrow cells were isolated from femurs of 
SWISS or C56BL/J6 mice, washed in HBSS and seeded in complete medium 
(RPMI 1640 supplemented with 10% FBS, 10% L929-condicioned culture 
medium (LCCM) and 1% P/S) at a concentration of 3x105 cells/ml and 
incubated at 37ºC with 5% CO2 atmosphere. Cells were seeded in 100 mm 
diameter plates for protein extraction (subcellular fractionation and iodixanol 
gradient), 35 mm diameter plates for RNA extraction, 96-well or 48-well cell 
culture plates for In-Cell Western blot analysis (LI-COR) or onto circle glass 
coverslips placed in 24-well cell culture plates for immunofluorescence and Oil 
Red O staining. At day 4, the medium was removed and adherent cells were 
washed twice with warm HBSS to remove non-adherent dead cells, followed by 
addition of new complete medium. Cells remained in culture with daily medium 
renewal until treatment at day 7/8. 
2.3. Cell lines 
Human hepatocarcinoma cell lines HepG2 and HuH7 as well as monocytic 
cell line THP-1 were cultured in RPMI 1640 medium supplemented with 10% 
FBS and 1% P/S. For THP-1 derived macrophages, cells were treated with 
phorbol myristate acetate (PMA) at 20 nM for 48h. CHO cells were cultured in 
advanced DMEM F12 medium supplemented with 10% FBS and 1% P/S. 
J774A1 were cultured in DMEM medium supplemented with 10% FBS and 1% 
P/S. All cultures were performed at 37ºC with 5% CO2 atmosphere. Cells were 
seeded in 100 mm diameter plates for protein extraction, on 35 mm diameter 
plates for RNA extraction or onto glass coverslips in 6-well plates for 
immunofluorescence studies. 
2.4. Treatment of cells 
HepG2 and J774A1 were treated at 80% confluence (48 h culture), murine 
BMDM and human macrophages were treated at days 7/8 of culture, human 
PBL were seeded at 2x106 cells/ml before treatment, THP-1 macrophages were 
seeded at 8x105 cells/ml and differentiated with 20 nM PMA for 48 h at 37ºC 
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before treatment. All treatments were performed at 37ºC with 5% CO2 
atmosphere and the specific conditions are described below: 
 Iron: cells were treated with Fe-nitrilotriacetate solution (FeNTA, 50-200 
µM), apo-Tf (3 mg/ml) or holo-Tf (3 mg/ml) for 18 h in complete medium.  
 Cytokines: huPBL cells were treated with recombinant human IFNγ, IL-6, 
and TNFα (20 ng/ml, 18 h, BD Biosciences) in complete medium. Murine 
BMDM were treated with LPS /IFNγ (10 ng/ml each, 18 h) for 
differentiation of M1 macrophages.  
 Hepcidin: In general, cells were treated with 700 nM of human hepcidin 
(Peptides International) for 3 h in complete medium. For two particular 
experiments, THP-1 cells were treated with 1 µM human Hepc for 4 h 
while HepG2 cells were treated with 700 nM human Hepc for 18 h in 
complete medium.  
 PIPLC: cells were incubated with 0,5 U/ml enzyme (Invitrogen) for 1 h at 
37ºC prior to Cp immunofluorescence staining. 
 Anti-Hepc: HepG2 cells were incubated with 0,6 µg/ml anti-Hepc 267 in 
complete culture medium for 18 h. 
 LDL: cells were treated with dialyzed nLDL, dialyzed acLDL or non-
dialyzed oxLDL at 50-100 µg/ml during different time points (3,5 h, 7 h, 
24 h) in complete medium. Cell viability after incubation with the different 
LDL solutions for the maximum time point (24 h) was evaluated through a 
colorimetric assay using methyl thiazolyl tetrazolium (MTT).  
In all treatments, control cells (untreated) were incubated with the vehicle 
solution (water in general, PBS for cytokines, NaCl2 for LDL solutions) used for 
each treatment. 
3. Transfection 
Transient transfection of CHO or HuH7 cells with a plasmid containing the 
human GPI-Cp or human Fpn1 full-length cDNA was performed using 
Lipofectamine 2000 (Invitrogen) according with the manufacturer’s instructions 
and in the absence of antibiotics. After 6h of incubation with cells at 37ºC, 
medium containing DNA-lipid complexes was removed and cells were washed 
with warm medium before addition of new complete medium without antibiotics. 
Transfected cells were incubated O/N before any protein or RNA extraction. 
Transfection success was confirmed by semi-quantitative reverse transcription-
PCR (RT-PCR) using cDNA of the transfected cells and specific primers against 
GPI-Cp, Fpn1 and β-actin cDNA. 
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4. RNA analysis 
 
4.1. RNA extraction 
For RNA analysis of adherent cells, TRIzol reagent (Invitrogen) was added 
directly to cell culture plates after discarding all culture medium, homogenized 
and stored at -80ºC until RNA extraction. Total RNA was extracted according to 
manufacturer’s instructions, followed by quantitative and qualitative analysis 
using Nanodrop 1000 (Thermo Scientific) or Nanophotometer P360 (Implen).  
4.2. Two step reverse transcription-quantitative PCR 
 
4.2.1. Reverse transcription 
Synthesis of cDNA was carried out through a reverse transcription (RT) 
reaction using 1 µg of total RNA, oligo(dT) primers and MMLV Reverse 
Transcriptase (Invitrogen) according to the manufacturer’s instructions. All 
cDNA’s were diluted 1/8 with water in a total volume of 160 µL. A pool of cDNA 
was prepared for each experiment mixing equal amount of each diluted cDNA 
sample and used for preparation of serial dilutions (1/2, 1/4, 1/8, 1/16, 1/32 and 
1/64) for calculation of qPCR reaction efficiency. 
4.2.2. Quantitative PCR 
Quantitative PCR (qPCR) was performed on a LightCycler 480 instrument 
(Roche Diagnostics) using a mix with 2 µL of diluted cDNA sample or cDNA 
pool dilutions, 5 µL of LightCycler 480 DNA SYBR Green I Master reaction mix 
(Roche Diagnostics), specific primers (600 nM) and water up to 10 µL per 
reaction. The following cycling parameters used were: 5 min at 95°C, followed 
by 40 cycles of denaturation for 15 sec at 95°C, annealing for 10 sec at 60°C, 
and extension for 10 sec at 72ºC. Melting curve analysis of amplified products 
was performed for confirmation of primers specificity. The sequence of all the 
primers used in qPCR is indicated in Table 1.  
Hprt gene coding for hypoxanthine guanine phosphoribosyltransferase 
was used as reference gene and relative quantification was performed using the 
ΔΔCt method. 268. The relative expression ratios were calculated using the 
formula 2-ΔΔCt, in which ΔΔCtA-B = (Ctgene- CtHprt)B -(Ctgene- CtHprt)A and A=control 
group and B = experimental group. All samples were run in duplicate (technical 
duplicate) and, for each experiment, all conditions were tested in biological 
duplicates. A set of 3 independent experiments were used for statistical 
analysis, using paired Student’s t test on ΔCt values (α=0,05). Comparison of 
specific gene expression between BMDM Nrf2+/+ and Nrf2-/- was performed 
using two-way repeated measure ANOVA (α=0,05), which allowed also to 
analyse the interaction between Nrf2 genotype and each in vitro treatment on 
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gene expression. The significant results are presented as: *p-value (p)<0.05, 
**p<0.01, ***p<0,001 and ****p<0.0001. GraphPad Prism 6 software was used 
for statistical analysis. 
5. Protein analysis 
 
5.1. Preparation of crude membrane and cytosolic extracts 
Suspension cells such as huPBL were collected by centrifugation at 400 g 
for 10 min at 4ºC while adherent cells were collected by scrapping in PBS-
EDTA (2 mM) on ice and followed by centrifugation in the same conditions. 
Exceptionally for human macrophages, to avoid cell adherence to tube walls, 
cells were incubated with PBS-EDTA (5 mM) for 30 min at 4ºC before scrapping 
and collection by centrifugation at 400 g for 10 min at 4ºC. Cell pellets were 
homogenized in lysis buffer (10 mM Tris-HCl, pH 7; 1 mM MgCl2) supplemented 
with protease inhibitor cocktail (PI’s; Sigma-Aldrich) and 
phenylmethanesulfonylfluoride (PMSF; Sigma Aldrich). The lysates were 
centrifuged at 1,200 g for 10 min at 4ºC to eliminate nuclei and unbroken cells. 
The protein extracts (post-nuclear supernatant, PNS) were then ultracentrifuged 
at 260,000 g at 4ºC for 1 h in TLA100.3, TLA 100.4, or TLS55 rotor (Beckman) 
to separate the crude membrane fractions from the cytosolic proteins. 
Supernatants corresponding to cytosolic extracts were then collected and 
membrane pellets were resuspended in TNE buffer (10 mM Tris-HCl, pH 7.0; 
100 mM NaCl; 10 mM EDTA) containing PI’s and PMSF. All protein extracts 
(PNS, membrane or cytosolic fractions) were quantified by BCA assay 
(Piercenet) or Bradford assay (Bio-RAD) and stored at -80°C until use. 
5.2. Preparation of protein extracts from culture medium 
Culture medium of huPBL suspension was separated from cells by 
centrifugation at 400 g for 10 min at 4ºC, collected in new tubes and then stored 
at -80ºC until use. For each experimental condition, 4 ml of culture medium was 
concentrated using Amicon ultra-4 centrifugal filter tubes (Merck Millipore) 
according to manufactor’s instructions. The concentrated sample was then 
precipitated by addition of 10 volumes of ice-cold 10% trichloroacetic acid in 
acetone (w/v), followed agitation and precipitation O/N at -20ºC. The 
precipitated protein was then collected by centrifugation at 15,000 g for 15 min 
at 4ºC, washed once in 100% acetone, and then air-dried after discarding 
supernatant. The dried protein pellets were then rehydrated using TNE buffer 
(see section 6.2) supplemented in PI’s and PMSF. Culture medium-derived 
protein extract was quantified by BCA assay (Piercenet) and stored at -80ºC 
until use. 
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5.3. Preparation of lipid raft/detergent resistant membrane 
fractions 
Lipid rafts from BMDM and HepG2 cells were isolated as detergent (Triton 
X-100) resistant membranes (DRM) as described previously 118. Briefly, cells 
were washed with cold PBS, scrapped into PBS-EDTA (2 mM), collected by 
centrifugation 400 g for 10 min at 4ºC and incubated for 1 h at 4°C in 600 μL of 
lysis buffer (150 mM NaCl, 25 mM MES, 5 mM EDTA, pH 6.5, 1% Triton X-100) 
supplemented with PI’s and PMSF. Samples were then homogenized by 20 
passages through a 25-gauge needle (5/8-inch). For HepG2, cell lysates were 
centrifuged at 1,200 g for 10 min at 4ºC and the supernatant was recovered. 
Crude cell lysate (BMDM) or post-nuclear supernatant (HepG2) were adjusted 
to a final concentration of 40% (w/v) iodixanol (OptiPrep®, Sigma-Aldrich) and 
the mixture was then layered under a 20-40% discontinuous iodixanol gradient 
and centrifuged at 260,000 g for 16 h at 4°C using an SW 41 Ti Rotor (Beckman 
Coulter) and no break. After spinning, fractions of 1 ml were collected from the 
top to the bottom of the gradient tube. Aliquots of each gradient fraction were 
immediately prepared in Laemmli buffer (equal volume independently of the 
protein concentration of each gradient fraction) and stored at -20ºC, while the 
original fractions were stored at -80ºC. Quantification of protein content for all 
fractions was determinated using Bradford assay. Western blot analysis of 
these fractions for the known raft proteins caveolin-1 (Cav-1) or Flotillin-1 (Flot-
1) and non-raft proteins (TfR1) was performed to identify the fractions enriched 
in DRM and non-DRM (NDRM) proteins. 
5.4. SDS-PAGE and Western blot 
All samples were prepared in Laemmli buffer (50 mM Tris, 55 mM SDS, 1 
M glycerol, 570 mM β-mercaptoethanol and bromophenol blue) and 
denaturated for 30 min at room temperature (R/T) or for 5 min at 95ºC 
depending on the target protein. For Cp detection, serum purified human Cp 
(Sigma-Aldrich) and extracts of transfected CHO expressing human GPI-Cp 
cDNA (CHO-GPICp) were used as positive controls. Samples were resolved in 
7-12% acrylamide gels according to standard protocols and transferred onto 
PVDF membrane (Amersham). To control protein loading and transfer, 
membranes were stained with 0,1% Red Ponceau S for 5 min an R/T. 
Membranes were then unstained in 0,1% Tween-PBS and blocked O/N at 4ºC 
or for 1 h at R/T with 5% skim milk in 0,1% Tween-PBS. Each membrane was 
probed with adequate dilution of primary antibody in blocking solution for 2 h at 
R/T or O/N at 4ºC. After washing in 0,1% Tween-PBS, blots were incubated in 
blocking solution for 1 h at R/T containing the respective diluted secondary 
antibody conjugated with horse radish peroxidase (HRP). Membranes were 
then washed in 0,1% Tween-PBS and followed by development with either 
Immobilon Western (Millipore) or ECL Prime (Amersham) Chemiluminescent 
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HRP substrate reagents. Primary and secondary antibodies used and the 
respective dilutions are indicated in Tables 2, 3 and 4. 
5.5. Quantitative immunofluorescence assay (In-Cell Western 
blot) 
After treatments, BMDM cultured in 48-well or 96-well cell culture plates 
were fixed with 100% methanol for 15 min at -20°C, washed with PBS, and then 
permeabilized with Triton X-100 (0.1% in PBS) for 10 min at R/T. Cells were 
washed in PBS, blocked with Odyssey blocking buffer (LI-COR Bioscience) for 
1h at R/T and then incubated O/N at 4°C with specific primary antibody (table 2 
and 3) diluted in Odyssey blocking buffer. After 5 washes with 0.5% Tween- 
PBS, cells were incubated for 1 h at R/T with LI-COR IRDye 800 labeled 
secondary antibodies (1/800, LI-COR Bioscience) and with Sapphire700 
(1/1000, LI-COR Bioscience) and DRAQ5 (1/2000, LI-COR Bioscience) for cell 
number normalization. Sapphire700 is a non-specific cell stain that accumulates 
in both nucleus and cytoplasm of fixed cells whereas DRAQ5 is a cell 
permeable DNA-interactive agent. Finally, cells were washed 5 times with 0.5% 
Tween-PBS, twice with PBS and dried before the scan of the plate by Odyssey 
Infrared Imaging System (LI-COR Bioscience). Scans were analyzed and raw 
data extracted using Odyssey 2.1 software (LI-COR Bioscience). Primary and 
secondary antibodies used and the respective dilutions are indicated in Tables 
2, 3 and 4. 
5.6. Immunofluorescence 
In general, cells were fixed with 100% methanol for 20 min at -20ºC or with 
2-4% formaldehyde in PBS for 20 min at R/T. Fixed cells were stored in PBS at 
4ºC until immunostaining. When required, permeabilization of cells was 
performed by incubation for 10 min at R/T with 0.1% Triton X-100 in PBS. Apart 
from Cp/Fpn1 co-labeling in BMDM, all cells were blocked for 30 min at R/T with 
1% bovine serum albumin (BSA) in PBS (exclusively for Cp single labeling) or 
with 1% BSA and 10% goat serum in PBS (for all other proteins labeling). 
Primary antibodies incubations were performed O/N at 4ºC or for 45 min at R/T 
while incubation with fluorochrome-conjugated antibodies (primary or secondary 
antibody) was performed for 45 min at R/T in the dark. All washes during the 
labeling protocol were carried out with 0,5% BSA in PBS. After the final washes, 
labeled cells were mounted in Vectashield (VectorLab) or Prolong Gold (DAKO) 
mounting medium with DAPI. Image acquisition were performed either with a 
confocal microscope (Leica TCS, SPE model) using a 63x oil objective or with a 
fluorescent microscope (Nikon TE2000E equipped with a Nikon DXM1200F 
digital camera or Leica DM4000 B) using a 40x or 60x oil objective. Mean 
fluorescence intensity (MFI) of Cp in huPBL and HepG2 was quantified using 
the software package Image J (Rasband, W.S., ImageJ, U.S. National Institutes 
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of Health, Bethesda, Maryland, USA, http://rsb.info.nih.gov/ij/, 1997-2010) and 
Image-Pro Plus 4.0 (Media Cybernetics). Statistical analysis was performed 
using paired t student test for comparison of Cp expression levels at cell surface 
on untreated and PIPLC-treated cells. Primary and secondary antibodies used 
and the respective dilutions are indicated in Tables 2, 3 and 4. 
5.6.1. Human peripheral blood cells 
All huPBMC, huPBL and huPBMn were fixed in formaldehyde and set to 
adhere onto sylane coated-slides (Sigma-Aldrich) using Shandon cytospin III 
(Thermo) before blocking and labeling steps. Cells were blocked for with 1% 
BSA in PBS, incubated in the dark with sheep anti-human Cp FITC-conjugated 
(BIOTREND GmbH), followed by washes and mounting. Labeling of the 
monocyte marker CD14 was performed by blocking in1% BSA and 10% goat 
serum in PBS solution, followed by incubation with mouse anti-CD14 (Abcam). 
Cells were then washed, incubated with anti-mouse IgG Cy3-conjugated 
antibody (Jackson Immunoresearch Laboratories) in the dark, washed and 
mounted. 
5.6.2. HepG2 cells 
Cells were grown onto glass coverslips in 6-well plates at 37ºC with 5% 
CO2 atmosphere. To observe membrane Cp, cells were blocked with 1% BSA 
in PBS, probed with sheep anti-human Cp FITC-conjugated (BIOTREND 
GmbH) for 45 min at R/T in the dark and then fixed with 100% methanol, 
washed and mounted. For cytosolic Cp labeling, cells were firstly fixed in 100% 
methanol as described before, permeabilized, blocked and finally probed with 
sheep anti-human Cp FITC-conjugated (BIOTREND GmbH) for 45 min at R/T in 
the dark, washed and mounted. 
5.6.3. Murine Bone Marrow Derived Macrophages 
For single labeling, BMDM were fixed with 100% methanol (for Fpn1/HO-1 
staining) or with formaldehyde (for Cp, CD11b and APP staining). Cells were 
then permeabilized if required, blocked and incubated with primary antibody for 
45 min at R/T or O/N at 4ºC. After washes in 0,5% BSA in PBS, cells were 
incubated with secondary antibody for 45 min at R/T and in the dark, followed 
by washes and mounting. The following primary and secondary antibodies used 
for single labeling were: commercial rabbit anti-mouse Fpn1 (Alpha 
Diagnostics), non-commercial rabbit anti-mouse Fpn1 (antibody developed by 
Doctor François Canonne-Hergaux 269), mouse anti-mouse Cp (BD 
Biosciences), rat anti-CD11b (AbD Serotec), rabbit anti-human HO-1 
(Stressgene), mouse APP (Millipore), Alexa488 goat anti-rabbit IgG, Alexa568 
goat anti-mouse IgG, Alexa568 goat anti-rat IgG or the Alexa488 goat anti-mouse 
IgG antibodies (Invitrogen).  
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For Fpn1 and Cp co-labeling, living cells were blocked with 1% BSA in 
PBS for 5 min at 4ºC and then incubated with mouse anti-mouse Cp (BD 
Biosciences) for 30 min at 4ºC prior to 100% methanol fixation and 
permeabilization. After PBS washes, cells were incubated in blocking solution 
(BSA 1% and 10% heat-inactivated goat serum in PBS) for 30 min at R/T. 
Incubation with rabbit anti-mouse Fpn1 (Alpha Diagnostics) was then performed 
for 45 min at R/T, followed by washes with 0,5% BSA in PBS and incubation 
with mix of secondary antibodies (goat anti-mouse IgG Alexa568 and goat anti-
rabbit IgG Alexa488) diluted in blocking solution for 45 min at R/T and in the 
dark. Finally, cells were washed with 0,5% BSA in PBS and mounted.  
5.7. Immunophenotyping and flow cytometry analysis 
After incubation with and without PIPLC (0,5 U/mL, 1 h, 37ºC), huPBMC 
(treated and untreated) were collected, washed and then resuspended in 
staining buffer (0,2% fetal calf serum, 0,09% NaN3 in PBS, pH 7,4). Cells were 
then plated in 96-well round-bottomed microtiter plates (Nunclon) at 5×105 
cells/well and incubated for 15 min at 4ºC with AB-human serum solution (1/10 
in staining buffer), blocking the Fc-receptor binding sites for reduction of non-
specific reactions. Afterwards, cells were stained for Cp using the rabbit anti-
human Cp (KOMA Biotech) diluted in staining buffer for 45 min at 4ºC, washed 
once with staining buffer and centrifuged at 250 g for 5 min at 4ºC. 
Subsequently the cells were incubated for 45 min at 4ºC with the secondary 
antibody: goat F(ab′)2 anti-rabbit FITC-conjugated (Rockland) diluted in staining 
buffer. For huPBMn gating, in addition to the secondary antibody referred 
above, the following antibodies were added: monoclonal anti-CD45 PerCP-
conjugated (BD Pharmigen) and anti-CD14 APC-conjugated (Miltenyi Biotec). 
Unstained cells of each condition were used as negative control in order to 
determine autofluorescence of cells. After staining, cells were washed, 
centrifuged at 250 g for 5 min at 4ºC and resuspended in the staining buffer, 
transferred to cytometer tubes and immediately analyzed in a FACSCalibur 
Flow Cytometer (BD Biosciences). CellQuest (BD Biosciences) was used for 
data acquisition, and measurement of Cp expression was performed using 
Weasel v.2.7.4 software. Statistical analysis was performed using paired t 
student test for comparison of Cp expression level at cell surface of untreated 
and PIPLC-treated huPBMn. Primary and secondary antibodies used and the 
respective dilutions are indicated in Tables 2, 3 and 4. 
6. Oil Red O staining 
Cells were fixed in paraformaldehyde 4% for 20 min at R/T, washed and 
stored in PBS until staining. Cells were quickly rinsed in 60% isopropanol, 
stained in Oil Red O (ORO) solution (0,25% ORO in 60% isopropanol, filtered) 
for 10 min at R/T, rinsed quickly in 60% isopropanol and then in water. After 
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counterstaining with hematoxylin (Mayer’s solution, Sigma-Aldrich) for 4 min at 
R/T, cells were rinsed several times with water, incubated for 1 min at R/T in 
saturated sodium bicarbonate solution, and again rinsed several times in water. 
Coverslips were air-dried and mounted in glycerol mounting medium (Sigma-
Aldrich). Slides were observed at Leica DM4000 B microscope with 20x and 
40x objective. 
7. Production of polyclonal antibodies against human 
ferroportin-1 
For the production of the rabbit polyclonal anti-human Fpn1 antibody, 
three different epitopes were selected: Fpn1’ (intracellular loop), Fpn2’ 
(extracellular epitope) and Fpn3’ (C-terminus). The nucleotidic sequence of the 
different epitopes was cloned in-frame with glutathione-S-transferase (GST) in 
pGEX vectors. The respective fusion proteins GST-Fpn1’, 2’ and 3’ were 
expressed in large scale and affinity purified as described (see section 12.1). 
New Zealand White rabbits were injected with purified GST-Fpn1’/2’/3’ fusion 
proteins (800 µg/injection) in different time points (day 0, 14, 28, 42 and 56). 
Blood collection was performed before and during the immunization process 
(days 28, 49 and 63) before sacrifice and final blood collection. Two rabbits 
were immunized for each epitope, but one of the GST-Fpn3’ immunized hosts 
died during manipulation. For affinity purification of the anti-serum, the same 
nucleotidic sequence of the Fpn1 epitopes (Fpn1’, 2’ or 3’) was fused to 
dihydrofolate reductase (DHFR) with a histidine tag. The respective fusion 
proteins ((6xHis)-DHFR-Fpn1’, 2’ or 3’) were used for the affinity purification of 
the different anti-sera using a preparative immunoblot protocol (see section 
12.2).  
7.1. Expression and purification of ferroportin-1 fusion proteins 
The nucleotidic sequence of the three different epitopes (Fpn1’, 2’ and 3’) 
of human Fpn1 was cloned in pGEX and pQ40 vectors (IMAGIF, Gif-sur-Yvette, 
France), creating a total of 6 different plasmids (pGEX-Fpn1’/2’/3’ and pQ40-
Fpn1’/2’/3’). Bacteria were transformed with the different plasmids and 
recombinant cells were seeded in 50 ml of Terrific Broth (TB) medium 
supplemented with ampicillin and incubated O/N at 37ºC with agitation. The 
culture was then diluted to OD600 = 0,6 with TB medium supplemented with 
ampicillin, and synthesis of fusion protein was induced by IPTG (0,5 mM) for 4 h 
at 37ºC with agitation. Cells were then centrifuged at 5500 g for 10 min at 4ºC 
(SLA-3000 rotor, Sorvall) and the cell pellet medium was stored at -20ºC until 
purification procedure.  
For purification of GST-Fpn1’/2’/3’ fusion proteins, glutathione sepharose 
4B beads (Amersham, GE Healthcare) were used according with the 
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manufactory’s instructions. Briefly, each cell pellet was resuspended in ice-cold 
PBS solution supplemented with PI’s and PMSF (pH 7,3), followed by 
sonication for complete cell lysis. Triton-X100 was then added to the lysate at 
final concentration of 1%, followed by incubation for 30 min at 4ºC with gentle 
agitation. The lysate was centrifuged, followed by supernatant recovery (cleared 
lysate). Glutathione sepharose 4B beads (pre-washed according to instructions) 
were then added to each cleared lysate and incubated for binding of beads to 
GST-Fpn1’/2’/3’ fusion proteins. Purification of GST-Fpn1’/2’/3’ fusion proteins 
was performed according to the gravity flow column purification method, using a 
solution of 50 mM Tris-HCl, 10 mM reduced glutathione (pH 8.0) as elution 
buffer. A total of eight elution fractions were collected per lysate and stored at -
80ºC.  
For purification of (6xHis)-DHFR-Fpn1’/2’/3’ fusion proteins, Ni-NTA 
agarose beads (QIAGEN) were used according with the manufactory’s 
instructions. Briefly, each cell pellet was lysed in denaturating conditions using 
guanidine hydrochloride 6 M buffer. The lysate was then centrifuged, followed 
by supernatant recovery (cleared lysate). Imidazole solution was added to the 
cleared lysate to a final concentration of 20 mM, followed by incubation with Ni-
NTA agarose beads (pre-washed according to instructions). Purification of 
(His)-DHFR-Fpn1’/2’/3’ fusion proteins was performed according to the gravity 
flow column purification method, using a solution of 250 mM Imidazole as 
elution buffer (native conditions). A total of six elution fractions were collected 
per lysate and stored at -80ºC. All elution fractions of GST-Fpn1’/2’/3’ and 
(6xHis)-DHFR-Fpn1’/2’/3’ fusion proteins were dosed using Bradford Reagent 
and analyzed by SDS-PAGE. 
7.2. Antibody purification from crude serum 
One aliquot of 250 µg of purified fusion protein was prepared in Laemmli buffer 
for each (6xHis)-DHFR-Fpn1 (1’, 2’ and 3’), followed by denaturation for 5 min 
at 99ºC. Each aliquot was loaded on a 12% acrylamide gel with a single well 
and separated by regular SDS-PAGE electrophoresis. Electrotransfer to a 
PVDF membrane was performed at 30 V for 18 h at 4ºC. Each membrane was 
stained in Red Ponceau solution and the band identified as the 6xHis-DHFR-
Fpn1’/2’/3’ was then excised and cut in pieces into a tube. The membrane 
pieces were unstained by washes in 0,1% Tween-PBS (5 min, R/T) and blocked 
in 0,1% Tween-PBS with 7% skim milk for 2 h at R/T with agitation. After 
blocking, the membrane pieces were washed twice in 0,1% Tween-PBS and 
then incubated with 3 ml of anti-serum diluted in PBS (1:1) O/N at 4ºC with 
agitation. After incubation, the supernatant was removed and the membrane 
pieces underwent 4 washes in PBS, 1 wash in 0,1% Tween-PBS and 3 washes 
in PBS (5 min, R/T). The purified antibody bound to the respective fusion 
protein was eluted from the PVDF pieces by addition of 0,5-0,75 ml of 0,2 M 
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glycine elution buffer (pH 2,2) and incubation for 3 min at R/T with agitation. The 
supernatant containing the eluted purified antibody was then recovered to a 
new tube, immediately followed by pH neutralization with 1 M Tris solution (pH 
8,0) and addition of glycerol and BSA to a final concentration of 50% (v/v) and 
0,1% (w/v), respectively. The affinity-purified antibodies (anti-huFpn1’/2’/3’) 
were stored at -20ºC. 
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Table 1 - Sequence of primers used in quantitative PCR. 
  
Specie Protein Gene Sequence Primer sense 
Mouse 
HPRT Hprt 
CTGGTTAAGCAGTACAGCCCCAA forward 
CAGGAGGTCCTTTTCACCAGC reverse 
Fpn1 
Fpn1, also 
known as 
Scl40a1 
CATTGCTGCTAGAATCGGTCTT forward 
GCAATCGTGTCACCGTCAAAT reverse 
H-Ft Fth1 
GAGGTGGCCGAATCTTCCTG forward 
GCTCTCCCAGTCATCACGGTC reverse 
Cp Cp 
ACACTGTACACTTCCACGGCC forward 
AGAACTGTATACTCCCCTGTGCTTG reverse 
sCp Cp 
ACAGATGGACAGAGCAACAGACTG forward 
CCCAGCGAACAAATGCATG reverse 
GPI-Cp Cp 
AGGACCACAGACGCCAAATC forward 
AACTATGGCAGAGAGCGTTGC reverse 
HO-1 Hmox1 
GGTGACAGAAGAGGCTAAGAC forward 
GCTCCTCAAACAGCTCAATG reverse 
APP App 
TGTGCCAGCCAATACCGAA forward 
CAGAACCTGGTCGAGTGGTCA reverse 
Hepc Hamp1 
AAGCAGGGCAGACATTGCGAT forward 
CAGGATGTGGCTCTAGGCTATGT reverse 
VEGF Vegf 
CCTGGTGGACATCTTCCAGGAGTACC forward 
GAAGCTCATCTCTCCTATGTGCTGGC reverse 
Human 
HPRT HPRT 
AAGCTTGCGACCTTGACCAT forward 
TGCTTTCCTTGGTCAGGCAG reverse 
Fpn1 
FPN1, also 
known as 
SLC40A1 
GCTGCTAGAATCGGTCTTTGGT forward 
TCTTGCAGCAACTGTGTCACAG reverse 
H-Ft FTH1 
AAATGACCCCCATTTGTGTGAC forward 
AGAGATATTCCGCCAAGCCAG reverse 
Cp CP 
ATGGGTAATGAAGTTGATGTGCAC forward 
CAGGGTAGCAGGAAAGAGGTTG reverse 
HO-1 HMOX1 
GCCAGCAACAAAGTGCAAGATT forward 
TGAGTGTAAGGACCCATCGGAG reverse 
APP APP 
ACACCGTCGCCAAAGAGACAT forward 
CACACAAACTCTACCCCTCGGA reverse 
Hepc HAMP 
CTCTGTTTTCCCACAACAGAC forward 
TAGGGGAAGTGGGTGTCTC reverse 
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Table 2 - List of unconjugated primary antibodies and respective use dilutions. WB: 
Western blot; IF: imunofluorescense; ICW: In-Cell Western blot; FC: flow cytometry. 
Antibody Source IF WB ICW FC 
Polyclonal Goat anti-
human Cp 
Koma BioTECH - 
1:100 to 
1/1000 
- 1/50 
Monoclonal mouse 
anti-mouse Cp 
BD Bioscience 
1/25 (double 
labeling w/ 
Fpn1); 1/50 
(single labeling) 
1/100 to 
1/250 
1/50 - 
Monoclonal mouse 
anti-human APP 
(22C11) 
Chemicon, Millipore - 
1/500 to 
1/1000 
1/50 to 
1/100 
- 
Polyclonal rabbit 
anti-human HO-1 
Stressgen 1/500 to 1/1000 - 
1/500 to 
1/1000 
- 
Monoclonal rat anti-
mouse CD11b IgG 
Developmental Studies 
Hybridoma Bank 
(DHSB), University of 
Iowa 
1/50 - - - 
Polyclonal mouse 
anti-TfR1 
Zymed Laboratories - 
1/1000 
to 
1/10000 
- - 
Monoclonal mouse 
anti-mouse Flot-1 
BD Bioscience - 
1/1000 
to 
1/5000 
- - 
Polyclonal rabbit 
anti-human Cav-1 
Tebu-Bio - 1/200 - - 
Polyclonal rabbit 
anti-human Cav-1 
Santa Cruz 
Biotecnology 
- 1/1000 - - 
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Table 3 - List of unconjugated primary antibodies against ferroportin-1 and respective use 
dilutions. WB: Western blot; IF: immunofluorescense; ICW: In-Cell Western blot. 
 
Antibody Source IF WB ICW 
Polyclonal rabbit 
anti-mouse Fpn1 
Alpha Diagnostics Ab#3 - 
1/1000 to 
1/2000 
- 
Polyclonal rabbit 
anti-mouse Fpn1 
Non-commercial, 
produced by F Canonne-
Hergaux et al 
269
 
Ab#6 1/100 
1/200 to 
1/1000 
1/100 
to 
1/200 
Polyclonal rabbit 
anti-human Fpn1 
Non-commercial, gift from 
another laboratory 
Ab#1 - 1/400 - 
Polyclonal rabbit 
anti-human Fpn1 
Non-commercial, gift from 
another laboratory 
Ab#4 - 1/1000 - 
Polyclonal mouse 
anti-human Fpn1 
Novus Biologicals 
(H00030061-B01) 
Ab#2 - 1/200 - 
Polyclonal rabbit 
anti-human Fpn1 
Novus Biologicals (NBP1-
21502SS) 
Ab#5 - 1/1500 - 
Polyclonal rabbit 
anti-human Fpn1 
Lifespan Biosciences Ab#7 - 1/100 - 
Polyclonal rabbit 
anti-human Fpn1 
Non-commercial, developed by 
our laboratory 
- 1/500 - 
Polyclonal rabbit 
anti-human Fpn2 
Non-commercial, developed by 
our laboratory 
- 1/500 - 
Polyclonal rabbit 
anti-human Fpn3 
Non-commercial, developed by 
our laboratory 
- 
1/500 to 
1/100 
- 
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Table 4 - List of conjugated primary and secondary antibodies and respective use dilutions. 
WB: Western blot; IF: immunofluorescense; ICW: In-Cell Western blot; FC: flow cytometry. 
 
Conjugated antibody Source IF WB ICW FC 
Polyclonal sheep anti-
human Cp FITC 
BioTREND 
GmbH 
1/50 (single 
labeling); 1/800 
(double labeling 
w/ CD14) 
- - - 
Polyclonal anti-mouse 
IgG Cy3-conjugated 
Jackson 
Immunoresearch 
Laboratories 
1/200 - - - 
Alexa
488
 goat anti-
rabbit IgG 
Invitrogen 1/200 - - - 
Alexa
568 
goat anti-
mouse IgG 
Invitrogen 1/200 - - - 
Alexa
568
 goat anti-rat 
IgG 
Invitrogen 1/200 - - - 
 Alexa
488
 goat anti-
mouse IgG 
Invitrogen 1/200 - - - 
Polyclonal Goat Anti-
Mouse IgG, HRP-
conjugated 
Dako - 1/20000 - - 
Polyclonal Goat Anti-
Rabbit IgG, HRP-
conjugated 
Dako - 1/20000 - - 
Polyclonal Rabbit 
Anti-Goat IgG, HRP-
conjugated 
Dako - 1/20000 - - 
IRDye 800CW Goat 
anti-Rabbit Secondary 
Antibody 
Li-COR 
Biosciences 
- - 1/800 - 
Polyclonal rabbit anti-
IgG Goat, F(ab)’2, 
FITC-conjugated 
Rockland - - - 1/50 
Monoclonal mouse 
anti-human CD45 
PerCP-conjugated  
BD Biosciences - - - 1/10 
Monoclonal mouse 
anti- human CD14 
APC-conjugated 
Miltenyi Biotec - - - 1/10 
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1. Introduction 
Cp is a multicopper oxidase able to oxidize Fe2+ to Fe3+, a reaction that 
has been shown to participate in cellular iron export by Fpn1 and subsequent 
iron distribution associated with Tf 51,133,270. This ferroxidase activity has also 
been associated with an anti-oxidant effect, by preventing Fe2+ participation in 
Fenton reactions and subsequent formation of ROS 132,133. However, Cp 
capacity to oxidize other substracts such as lipids has been associated with a 
pro-oxidant activity and has been associated to the physiopathology of some 
diseases, including ATH 271,272. Despite previous studies of Cp expression in 
immune cells, the characterization of the specific Cp isoforms expressed by 
human peripheral blood mononuclear cells (huPBMC) is poorly documented 
and only sCp isoform was previously reported in lymphocytes, monocytes and 
macrophages 273-275. Our previous results showed that human peripheral blood 
lymphocytes (huPBL) constitutively express the transcripts for the two distinct 
Cp isoforms, confirming Cp detection at huPBL cell surface by flow cytometry 
and immunofluorescence 276.  
2. Aims 
The goal of this study was to characterize the expression of both Cp 
isoforms in distinct human immune cells (lymphocytes and monocytes). For this, 
the human hepatocarcinoma cell line HepG2 was used as a positive control for 
Cp expression and as a hepatocyte model. 
3. Results 
 
3.1. Membrane and soluble ceruloplasmin isoforms are 
expressed in human peripheral blood lymphocytes and 
hepatocytes 
Cp expression was investigated by immunofluorescence on permeabilized 
and non-permeabilized HepG2 cells and huPBL, showing that Cp is detected at 
cell surface (non-permeabilized cells) as well as intracellularly (permeabilized 
cells), which suggests the existence of a membrane Cp isoform in addition to 
the soluble isoform already reported in these cells (Figure III.1A). Noteworthy, 
Cp detection in permeabilized cells was stronger than in non-permeabilized 
cells. In contrast with huPBL, Cp detection at the surface of HepG2 cells is 
characterized by a distinct dotted pattern suggestive of Cp accumulation in 
specific membrane domains at cell surface (Figure III.1A). Immunoblotting of 
subcellular fractions isolated from both huPBL and HepG2 showed that Cp is 
detected in both cytosolic and crude membrane fractions (Figure III.1B), 
confirming the existence of a soluble isoform as well as a membrane-associated 
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isoform of Cp in these cells. The specificity of the anti-Cp antibody was 
controlled using a human serum-purified Cp and protein extracts from 
transfected CHO expressing the membrane-associated human GPI-Cp (Figure 
III.1B). The pattern of detection of the human serum-purified Cp suggests that 
the lowest molecular weight specie of Cp in huPBL likely corresponds to a 
proteolytical cleavage fragment frequently observed in Cp detection 271,277.  
 
Figure III.1 - Ceruloplasmin expression in human peripheral blood lymphocytes and 
HepG2 cell line. (A) Immunostaining of Cp in permeabilized (right; +) and non-permeabilized 
(left; -) huPBL and HepG2 cells. Insets at the left bottom corners correspond to high 
magnification of individual cells. Cp staining is shown in green, while nuclei (N) are stained in 
blue (DAPI). The white bars represent 25 µm. (B) Immunoblotting detection of Cp in post-
nuclear supernatants (P), cytosolic fractions (C) and crude membrane fractions (M) isolated 
from huPBL and HepG2. Purified human Cp (hCp) was used as a positive control as well as 
transfected CHO expressing GPI-Cp. The position and size in kilodaltons (kDa) of the molecular 
weight markers are indicated on the right. Vertical dashed lines indicate repositioned gel lanes. 
* Cp proteolitic cleavage product.  
 
To test the hypothesis that Cp detected in membrane extracts from huPBL 
and HepG2 corresponds to the GPI-Cp isoform, cells were treated with the 
enzyme PIPLC – which specifically cleaves GPI-anchored proteins from cell 
surface to the extracellular medium – prior to Cp immunostaining. The results 
obtained (Figure III.2A and III.2B) showed a significant decrease of 34% and 
50% on Cp staining in PIPLC-treated huPBL and HepG2 cells compared with 
untreated cells (p<0.001, T-student test, Figure III.2B), which demonstrate that 
the membrane-associated Cp detected at cell surface of these cells 
corresponds, at least in part, to the GPI-Cp isoform. 
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Figure III.2 - Effect of PIPLC on ceruloplasmin expression in human peripheral blood 
lymphocytes and HepG2 cell line. (A) Confocal analysis of PIPLC enzyme effect on Cp 
membrane expression in non-permeabilized huPBL and HepG2 cells. Insets at the left bottom 
corners correspond to high magnification of individual cells. Cp staining is shown in green, while 
nuclei (N) are stained in blue (DAPI). The white bars represent 25 µm. (B) Graphics of Cp mean 
fluorescence intensity (MFI) in untreated (control) and PIPLC-treated huPBL and HepG2 cells. 
MFI analysis is indicated in arbitrary units (A.U.). ** Statistically significant differences on Cp 
surface expression between untreated and PIPLC-treated cells (p<0,01), Student’s t test.  
 
To evaluate the efficiency of PIPLC activity, the expression of CD14 (a 
known GPI-protein) in human peripheral blood monocytes (huPBMn) treated or 
untreated with PIPLC was analyzed by flow cytometry. The results obtained 
revealed a significant (p<0,01), but also partial decrease of 64% of CD14 
staining in PIPLC-treated cells compared with control. Analysis of CD45 
expression, a non-GPI-protein, remained unchanged by PIPLC treatment, 
confirming the enzyme specificity (Figure III.3).  
 
Figure III.3 - Effect of PIPLC on 
CD14 and CD45 expression in 
human peripheral blood 
monocytes. Graphics of CD14 (GPI-
protein) and CD45 (non-GPI-protein) 
mean fluorescence intensity (MFI) in 
untreated (control) and PIPLC-treated 
huPBMn analyzed by flow cytometry. 
MFI is indicated in arbitrary units 
(A.U.). **Statistically significant 
differences on CD14 or CD45 surface 
expression between untreated and 
PIPLC-treated cells (p<0,01), using 
paired Student’s t test. 
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As a ferroxidase reported to promote iron export through interaction with 
Fpn1, the effect of iron on the expression of both Cp isoforms was investigated 
in huPBL. However, no effect was observed in huPBL treated with iron complex 
(FeNTA) or Tf-bound iron (apo/holo-Tf) in the conditions tested (Figure III.4A,D). 
In addition, no effect was observed upon Hepc stimulation (Figure III.4B,D), 
known to downregulate Fpn1 levels at cell surface. Considering that Cp is an 
acute phase protein, the modulation of Cp isoforms expression in huPBL by 
cytokines was also tested. However, no significant modulation of Cp was 
observed as result of the pro-inflammatory cytokines tested in total huPBL 
(Figure III.4C,D), with exception of IFNγ which upregulated sCp detected in 
concentrated extracellular culture medium (Figure III.4D), but only slightly in the 
cytosolic fraction (Figure III.4C). 
 
Figure III.4 - Effect of different stimuli on ceruloplasmin expression in human peripheral 
blood lymphocytes. (A-C) Immunoblotting detection of Cp in cytosolic (Cyt) and crude 
membrane (Memb) fractions isolated from huPBL untreated (ctrl) and treated with different 
stimuli: (A) free iron (FeNTA, 100 μM, 18 h) and apo-Tf/holo-Tf (3 mg/ml, 18 h); (B) Hepc (700 
nM, 3 h); (C) cytokines IL-6, IFNγ, and TNFα (20 ng/ml, 18 h). (D) Immunoblotting of 
concentrated extracellular culture medium (CM) of the huPBL cultures analyzed in (A-C). 
Purified human Cp (hCp) was used as a positive control. Red Ponceau staining was used for 
control of equal protein loading of samples. The position and size in kilodaltons (kDa) of the 
molecular weight markers are indicated on the left. Vertical dashed lines indicate repositioned 
gel lanes. *Cp proteolitic cleavage product. 
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3.2. Human Peripheral Blood Monocytes express both soluble 
and membrane-associated ceruloplasmin isoforms  
Cp expression was studied by immunofluorescence in non-permeabilized 
huPBMC, including both lymphocytes and monocytes. Two distinct patterns of 
Cp staining were observed, with cells expressing low Cp levels (arrowhead, 
Figure III.5A) or high Cp levels (arrow, Figure III.5A). Considering the cell size, 
the nucleus shape and the frequency of these cells in huPBMC, the cells 
expressing high levels of Cp at cell surface were likely to be huPBMn whereas 
the cells expressing low levels of Cp could correspond to huPBL.  
To test this hypothesis, double labeling of Cp and CD14 (surface 
monocyte marker) was performed in non-permeabilized huPBMC. The cells 
expressing high level of Cp (acquired at low laser intensity; Figure III.5B) were 
all positive for CD14, which confirmed that these cells correspond to huPBMn 
(Figure III.5B). In addition, co-localization of Cp/CD14 (arrows in Figure III.5B) 
also confirmed that Cp is expressed at the cell surface of huPBMn. Such 
observation was reinforced by immunofluorescence studies realized with non-
permeabilized huPBMn isolated by cell adherence (Figure III.5C), which 
showed Cp accumulation at specific areas of the cell membrane (Figure III.5C, 
arrows), suggesting that this form of Cp could be concentrated in particular cell 
membrane domains. 
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Figure III.5 - Ceruloplasmin expression in human peripheral blood mononuclear cells. (A) 
Confocal analysis of Cp staining in non-permeabilized huPBMC. Depending of the intensity of 
the laser lamp of the confocal microscope, two different staining patterns were observed, one 
intense (arrows) and one faint (arrowheads). (B) Confocal analysis of Cp (low laser intensity) 
and CD14 (monocyte marker) staining in huPBMC. Morphological features and co-localization 
of Cp and CD14 identified the Cp positive (bright cells) as human monocytes. (C) Cp staining in 
human monocytes (huPBMn) by immunofluorescence indicates accumulation of Cp in specific 
membrane domains (arrows) at the cell surface. Insets in (A-C) correspond to high 
magnification of individual cells. Cp staining is shown in green, CD14 in red and nuclei (N) are 
in blue (DAPI). The white bars represent 25 µm. 
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In addition, immunoblotting analysis of Cp expression in cytosolic and 
crude membrane extracts of huPBMn confirmed that, besides sCp, these cells 
also express a membrane form of Cp, which may correspond to GPI-Cp (Figure 
III.6A). Treatment of huPBMn cells with the enzyme PIPLC lead to a decrease 
of approximately 30% of Cp staining at their cell surface (Figure III.6B), which 
suggests that at least part of the membrane-associated Cp in huPBMn 
corresponds to GPI-Cp isoform.  
 
Figure III.6 - Ceruloplasmin expression in human peripheral blood monocytes. (A) 
Immunoblotting detection of Cp in cytosolic (C) and crude membrane (M) protein extracts of 
huPBMn, using purified human sCp as a positive control. The position and size in kilodaltons 
(kDa) of the molecular weight markers are indicated on the left. Vertical dashed lines indicate 
repositioned gel lanes. *Cp proteolitic cleavage product. (B) Graphic of Cp mean fluorescence 
intensity (MFI) in untreated and PIPLC-treated huPBMn analyzed by flow cytometry, with a 
decrease of 30% not statistically significant by paired Student’s t test (p=0,1191). MFI analysis 
is indicated in arbitrary units (A.U.).  
 
3.3. Study of ferroportin-1 expression in human cells 
The endogenous expression of fpn1 in huPBL was investigated 
considering it is a key protein in iron metabolism and that it was previously 
reported to interact with Cp in other cells. As a positive control for Fpn1 
detection, different cell lines were tested in order to determine the specificity of 
the different antibodies tested (Table 3). 
3.3.1. THP-1 cell line as a macrophage model 
The human monocytic cell line THP-1 was cultured in the presence of the 
activator phorbol myristate acetate (PMA) for differentiation into macrophages 
(20nM PMA, 48h), followed by Hepc addition to culture medium (1µM, 4h) as 
described elsewhere 85,278. According to these authors, Hepc induced Fpn1 
downregulation in THP-1 macrophages in such conditions. Four different 
antibodies raised against human Fpn1 (Ab#1, Ab#2, Ab#4 and Ab#5) as well as 
one antibody raised against murine Fpn1 (Ab#3, same antibody used by the 
authors in 85,278) were tested by Western blot using membrane extracts of THP-
1 macrophages treated or not with Hepc. Multiples bands were detected in each 
antibody with no common band within all the antibodies tested. In addition, none 
of the bands detected with a molecular weight compatible with Fpn1 was 
84 
decreased in Hepc-treated THP-1 macrophages (Figure III.7). Therefore, none 
of the antibodies tested was validated for human Fpn1 detection in this THP-1 
macrophage model. 
Figure III.7 - Immunoblotting 
analysis of ferroportin-1 detection 
in THP-1 macrophages. Human 
THP-1 derived macrophages were 
differentiated in the presence of the 
activator PMA (20ng/ml, 48h), followed 
by Hepc stimulation (1µM, 4h). Crude 
membrane extracts (M) were analyzed 
using four different antibodies raised 
against human Fpn1 (Ab#1, 2, 4, 5) 
and murine Fpn1 (Ab#3). The position 
and size in kilodaltons (kDa) of the 
molecular weight markers are 
indicated on the left. Vertical dashed 
lines indicate repositioned gel lanes. 
 
3.3.2. HepG2 cell line as an hepatocyte model 
Recently, Fpn1 was reported to be expressed in murine hepatocytes, 
being upregulated by serum starvation and downregulated by Hepc 55. HepG2 
was chosen as a cellular model for human hepatocyte Fpn1 detection. A 
commercial antibody raised against murine Fpn1 (Ab#3) detected a band with 
the expected molecular weight (Figure III.8A-C), exclusive of membrane protein 
extract (Figure III.8A). This potential human Fpn1 band was detected at the 
same level as murine Fpn1 in iron-treated murine macrophage cell line J774 
(Figure III.8A-C) and was also detected in huPBL membrane extracts (Figure 
III.8D). However, unlike murine Fpn1 in J774 macrophages, this band was not 
modulated by increasing concentrations of iron, Hepc or serum starvation in 
HepG2 cells (Figure III.8B-C), indicating that this band may not correspond to 
human Fpn1. Moreover, TNFα, inorganic iron (FeNTA) and holo-Tf, which were 
reported to induce Hepc expression and subsequent internalization of the 
overexpressed human GFP-Fpn1 in huPBL 74, had no effect on the intensity of 
the putative Fpn1 band detected by Ab#3 in huPBL (Figure III.8D).  
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Figure III.8 - Immunoblotting analysis of ferroportin-1 detection in HepG2 cell line and 
human lymphocytes. (A-D) Immunoblotting analysis of Fpn1 on cytosolic (C) and crude 
membrane extracts (M) of HepG2 cell line, murine macrophagic cell line J774 (positive control 
for mFpn1) and human lymphocytes (huPBL) using a commercial anti-murine Fpn1 antibody 
(Ab#3). Red Ponceau staining was used as control of equal protein loading of samples. The 
position and size in kilodaltons (kDa) of the molecular weight markers are indicated on the left. 
Vertical dashed lines indicate repositioned gel lanes. The potential human Fpn1 band in HepG2 
membrane extract is indicated by the arrowhead while “*” indicates unspecific bands. (A-B) 
Comparison of the Ab#3 detection between HepG2 and J774 subcellular extracts. J774 cells 
were pre-treated with iron (200 µM FeNTA, 18h), followed or not by Hepc treatment stimulation 
(700nM, 3h). HepG2 were untreated or treated with different concentrations of iron (FeNTA 50-
200µM, 18h) or Hepc (700nM, 3h). (C) Membrane extracts of HepG2 cells treated with 0% (-, 
lane 2), 10% serum (+, lane 3) for 36h, or treated with 10% serum for 24 h followed by 
treatment with Hepc (700nM, 18h) in the presence of 10% serum (lane 4). Membrane extract of 
iron-treated J774 macrohages was used as Fpn1 detection positive control. (D) Membrane 
extracts isolated from huPBL untreated (ctrl) and treated with different stimuli: free iron (100μM 
FeNTA, 18h); apo-Tf/holo-Tf (3mg/ml, 18h); cytokines IL-6, IFNγ, TNFα (20ng/ml, 18h). HepG2 
extracts were used as a potential positive control for human Fpn1 (arrowhead).  
 
Nonetheless, the lack of Hepc effect on the potential Fpn1 band  detected 
by Ab#3 in both huPBL and HepG2 could also be explained by a “Hepc 
resistance” due to the Hepc autocrine production by these cells. As Hepc main 
producers, hepatocytes could be expected not to present significant levels of 
Fpn1 at cell surface. In such conditions, despite the putative low level of Fpn1 
expression at cell surface, Fpn1 could still be detected in crude membrane 
extracts as these extracts contain the plasma membrane as well as intracellular 
endomembranes. To test this hypothesis, HepG2 were cultured in the absence 
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or presence of a non-commercial antibody against Hepc, in order to sequester 
any Hepc that could exist in culture medium as a result of endogenous 
production and secretion by HepG2 cells. Crude membrane extracts were then 
analyzed by immunoblotting using Ab#3, but no effect was observed on the 
potential human Fpn1 band detected on HepG2 treated with anti-Hepc antibody 
(Figure III.9A). However, although the antibody against Hepc was used in the 
conditions indicated by its producer, we cannot conclude about the antibody 
efficiency in the sequestration of external Hepc.  
At last, a highly specific antibody raised against murine Fpn1 (Ab#6, 119) 
as well as a recently reported commercial antibody raised against human Fpn1 
(Ab#7, 139) were tested in crude membrane extracts of HepG2 treated or not 
with Hepc. Again, multiple bands were detected but none of the potential Fpn1 
bands with compatible molecular weight was modulated by incubation with 
Hepc (Figure III.9B).  
Altogether, no conclusive and consistent detection of human Fpn1 was 
obtained using the different models, conditions and antibodies tested. As a 
result, Fpn1 detection in human cells was not validated and the study of Fpn1 in 
human cells, and in particular huPBL, was not further investigated in this 
chapter. 
 
Figure III.9 - Immunoblotting analysis of Fpn1 detection in HepG2 cell line using different 
antibodies. (A) Immunoblotting analysis of membrane extracts of HepG2 cell line, cultured in 
the absence or presence of an antibody raised against Hepc (0,6µg/ml, 18h), was performed 
using Ab#3. Membrane extract of iron pre-treated J774 was using as a positive control for Fpn1 
detection. The potential human Fpn1 band is indicated by the arrowhead while “*” indicates 
unspecific bands. (B) Immunoblotting analysis of crude membrane extracts of HepG2 cells 
untreated and treated with Hepc (700nM, 3h) using one antibody raised against human Fpn1 
(Ab#7) and two antibodies raised against murine Fpn1 (Ab#3 and 6). Iron treated J774 
membrane extract was used as positive control for Fpn1 detection. Red Ponceau staining was 
used for control of equal protein loading of samples. The position and size in kilodaltons (kDa) 
of the molecular weight markers are indicated on the left. Vertical dashed lines indicate 
repositioned gel lanes. 
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4. Discussion 
The current concept about Cp expression in mammals describes that Cp is 
mainly synthesized as a soluble protein secreted by hepatocytes into plasma, 
whereas the membrane GPI-Cp isoform is predominantly expressed in cells of 
the brain and of the testis 134,279,280. The results presented in this work revealed 
a more ubiquitous expression of the GPI-Cp isoform than the one described 
previously in the literature and gives further support for a recent study showing 
GPI-Cp detection in purified membranes of multiple organs of rats and mice 281. 
 Herein, we demonstrated that immune cells as well as hepatocytes 
express the GPI-Cp isoform in addition to the secreted form of Cp. Indeed, 
expression of both Cp isoforms was demonstrated by immunofluorescence and 
Western blot analysis in human lymphocytes, monocytes, and in HepG2 cells. 
Treatment with PIPLC induced a partial decrease of Cp staining at cell surface 
in all the cells studied, indicating that at least part of membrane-Cp corresponds 
to the GPI-Cp isoform. The partial decrease could be due to incomplete 
efficiency of the enzyme as observed on CD14 (Figure III.3). In addition, a Cp 
receptor was reported previously in immune cells, including lymphocytes and 
monocytes 282. It is therefore possible that part of Cp staining detected by 
immunofluorescence and FACS could be due to sCp bound to its receptor. 
Furthermore, immunofluorescence analysis of Cp staining showed that Cp 
levels at cell surface of huPBL is significantly lower compared with huPBMn 
(Figure III.5). Interestingly, contrasting with the diffuse and homogenous Cp 
staining at huPBL membrane, the dotted pattern of Cp expression exhibited in 
huPBMn and HepG2 membranes was highly suggestive of Cp localization in 
specific cell membrane domains such as lipids rafts. Noteworthy, results 
presented in Supplemental Data (section V), confirmed that GPI-Cp expressed 
in HepG2 is indeed localized in lipid raft microdomains. 
The expression of sCp and GPI-Cp in immune cells, namely lymphocytes 
and monocytes, suggests a close functional relationship among immune 
system, oxidative stress and iron metabolism. In fact, Cp is an acute-phase 
protein with its plasma concentration increasing in many diseases such as 
hepatitis, ATH, polyarthritis, cancer and many other inflammatory and infectious 
diseases 271,283,284. Inflammatory processes that occur in these diseases are 
associated with strong local recruitment of immune cells, including lymphocytes 
and monocytes. In such context, lymphocytes and monocytes-derived Cp could 
play an important local role in host protective function against the potential 
toxicity of iron and its deposition in tissues. For instance, Cp secretion or 
shedding of membrane Cp by immune cells would rapidly promote iron loading 
onto Tf and Lf molecules, thus contributing for iron withhold from pathogens. 
Simultaneously, iron loading on Tf and Lf molecules would prevent dissociated 
iron from participating in Fenton reactions and thus contribute to decrease ROS 
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generation and protection of host cells. Accordingly, it was recently reported 
that Cp forms a complex with Lf and MPO enzyme 285, which supports the 
hypothesis that Cp plays an important role in host immune response that is 
closely associated with free iron availability.  
Alternatively, expression of GPI-Cp by immune cells, and in particular 
higher expression at cell surface of innate immune system cells like monocytes 
(Figure III.5A-B) and NK cells 276, could be regarded as a self-protection 
mechanism against oxidative stress. These cells produce and secrete high 
amounts of toxic compounds during their killing activity that could harm its own 
cellular integrity. Expressing high levels of Cp at cell surface could therefore 
constitute a defense mechanism against oxidative stress by immune cells.  
In striking contrast, several reports have shown that Cp possess pro-
oxidant activity depending on the microenvironment 271. For instance, the 
oxidation of other substracts (e.g. lipoproteins) by Cp in conditions of chronic 
inflammation would have a harmful effect at both local and systemic level and 
could be involved in the etiology of inflammatory pathologies involving oxidative 
stress such as ATH. 
 In addition to the delivery of high amounts of Cp at site of inflammation, 
leukocytes could also participate into the systemic acute-phase response, an 
observation that is so far only attributed to hepatocytes in regard to their ability 
to secret high amounts of sCp. The dramatic increase of circulating leukocytes, 
in particular lymphocytes, observed during inflammatory and/or infectious status 
286 could contribute to the raise in plasma Cp, either through the synthesis of 
sCp and/or through cell surface shedding of the GPI-Cp as previously observed 
for other GPI-proteins expressed in immune cells 287. Supporting this 
hypothesis, it was previously proposed that the serum concentration of Cp 
during inflammation reflects not only hepatic but also extra-hepatic synthesis 
283. Indeed, IFNγ was reported to induce sCp expression in human monocytes 
274. Herein, our immunoblotting analysis detected IFNγ-induced mild 
upregulation of sCp at the cytosolic fraction and culture medium (Figure III.4C-
D) of human PBL, giving further support to this hypothesis.  
Effect of different stimuli on GPI-Cp in human monocytes and lymphocytes 
was investigated in our lab using flow cytometry 288. GPI-Cp higher expression 
in monocytes vs. total lymphocytes and in non-T cells (B and NK cells) vs. T 
cells was confirmed. Interestingly, both naturally activated monocytes and 
lymphocytes presented higher levels of GPI-Cp compared with non-activated 
cells. However, PMA-induced activation of these cells significantly upregulated 
GPI-Cp in human monocytes, while significantly downregulating GPI-Cp in total 
and activated human lymphocytes. Similar results were obtained by LPS-
induced activation of human monocytes and lymphocytes 288. Such opposite 
effects of activation on human monocytes and lymphocytes activation suggest a 
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cell-specific regulation of GPI-Cp expression. Cp upregulation in human 
activated monocytes is in agreement with the general immune response 
strategy of sequestration of free iron by promoting its oxidation and loading in 
iron-binding proteins such Tf, Lf, and Ft 289.  
On the other hand, regarding GPI-Cp downregulation in activated 
lymphocytes, it was recently reported that either activated or iron-stimulated 
lymphocytes expressed increased levels of Hepc, downregulating GFP-Fpn1 at 
lymphocyte cell surface and promoting intracellular iron retention. This 
mechanism was demonstrated to be essential for proliferation of human 
activated lymphocytes 74. Considering that both Cp isoforms have been 
reported to promote iron export by Fpn1 in other cells 51,254,270, GPI-Cp 
downregulation in activated lymphocytes could be regarded as a strategy to 
promote intracellular iron retention and subsequent cell proliferation. Supporting 
this hypothesis, stimulation of human lymphocytes with IL-2, a cytokine known 
to activate and induce lymphocyte proliferation, downregulated GPI-Cp in total 
and activated lymphocytes 288. 
Lymphocyte Cp expression gives further support to the original postulate 
from de Sousa et al addressing an important role for lymphocytes circulation in 
the regulation of iron metabolism 147,190. Herein, no iron effect on Cp expression 
was observed when immunoblotting membrane and cytosolic fractions of 
human lymphocytes in the conditions tested (Figure III.2A). However, it is 
possible that a mild effect in total lymphocytes or a strong effect in only a 
fraction of total lymphocytes could fail to be detected by such technique. 
Interestingly, unpublished data by our group showed that the number of huPBL 
expressing Cp at cell surface (GPI-Cp) was increased in iron deficiency anemia 
patients in agreement with increased circulating levels of Cp compared with 
appropriate controls. Accordingly, in HH patients with systemic iron overload, 
the number of huPBL expressing Cp at cell surface as well as the level of 
circulating Cp was downregulated. These results suggest that hypoxia/iron 
deficiency conditions might be more relevant for the putative role of Cp in 
promoting huPBL iron export than the iron overload conditions investigated in 
this study. 
Ultimately, GPI-Cp expressed in human monocytes and lymphocytes 
could be playing a role in iron export along with Fpn1. However, as observed in 
Figure III.7-9, despite our effort to demonstrate the endogenous expression of 
human Fpn1, we could not anticipate any conclusion regarding the specific 
detection of endogenous Fpn1 in the models and conditions tested using 
different antibodies. The contribution of GPI-Cp and sCp as well as its possible 
interaction with Fpn1 on iron export from human lymphocytes, monocytes and 
hepatocytes remains thus to be further clarified. Noteworthy, while writing the 
manuscript of this thesis, recent work by Pinto et al characterizes the 
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expression of endogenous Fpn1 and iron export in human lymphocytes using a 
commercial antibody 290.  
Nonetheless, during the course of the work presented in this manuscript, 
our limitation in detecting endogenous human Fpn1 in immune cells lead us to 
change the initial plan of studying the key proteins involved in iron export in 
human macrophages. Given the features and specificity of antibodies available 
for murine Fpn1, including one developed by one of the co-supervisors of this 
work (Doctor François Canonne-Hergaux), murine macrophages were the 
selected model for the subsequent studies presented in Chapters 2 and 3. In 
addition, aiming to overcome the antibody limitation, a project to produce a 
specific antibody against human Fpn1 was initiated during the course of this 
work. The design, production, validation and current status of this project are 
presented in Chapter 4.  
5. Conclusion 
In summary, we demonstrated that both Cp isoforms are expressed in all 
the cell types analyzed. The cell surface Cp was identified as a membrane GPI-
anchored isoform. Due to the importance of lymphocytes and monocytes in the 
immune response, the role of both secreted and GPI-Cp isoforms in these cells 
is likely cell-specific and needs to be further explored. Therefore, further 
research in the different cell types is needed in order to clarify the specific 
function of each Cp isoform on the molecular mechanisms underlying the iron 
transport as well as the cellular protection against iron-mediated oxidative 
stress and the cellular damage mediated through oxidative reactions. 
Deciphering the role of sCp and GPI-Cp isoforms in immune cells and 
hepatocytes may likely contribute to clarify the importance of this ferroxidase in 
many diseases related to iron metabolism, inflammation and oxidative biology, 
including ATH.  
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1. Introduction 
The macrophage is the cell responsible for erythrophagocytosis and 
erythrocytes iron recycling, a key event for daily iron supply for erythropoiesis. 
The iron recycled by this cell can be either stored or exported by Fpn1 to 
extracellular medium coupled with the activity of a ferroxidase partner 35,122,270. 
Cp has been proposed as the ferroxidase interacting with Fpn1 in macrophages 
254. Indeed, Cp-/- mice show significant iron accumulation in the liver, particularly 
in Kupffer cells (tissue macrophages) 51. However, the only isoform of Cp 
previously reported in macrophages was sCp, being upregulated and secreted 
in macrophages upon stimulation with pro-inflammatory and infectious 
conditions 274,275. We showed in chapter 1 that human monocytes express high 
levels of Cp at cell surface, likely to correspond to the GPI-Cp isoform, which 
suggest that this isoform may also be detected in macrophages. In addition to 
Cp, other ferroxidases were shown to interact with Fpn1 in other cells, namely 
Heph and APP 25,139. Noteworthy, APP was previously shown to be expressed 
in human monocytes and macrophages 262.  
2. Aims 
In this study, we investigated if GPI-Cp is expressed in murine 
macrophages and if GPI-Cp, APP or both co-localize with Fpn1 in these cells. 
Murine bone marrow-derived macrophages (BMDM) were the model selected to 
the study due to the lack of specific antibody against human Fpn1 at the time of 
investigation.  
3. Results 
 
3.1. Murine macrophages express both ceruloplasmin isoforms 
The results obtained through immunofluorescence in non-permeabilized 
and permeabilized BMDM showed that these cells express Cp at their cell 
surface as well as in the cytosol (Figure III.10A). Moreover, immunoblotting of 
Cp in cytosolic and crude membrane extracts confirmed the existence of a 
soluble and a membrane-anchored isoform of Cp (Figure III.10C). Interestingly, 
the pattern of Cp staining in non-permeabilized BMDM (Figure III.10B) showed 
Cp accumulation in plasma membrane domains, resembling GPI-Cp staining in 
HepG2 cell line (chapter 1) and suggesting that this membrane-associated Cp 
could be localized in lipid rafts.  
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Figure III.10 - Subcellular localization of ceruloplasmin in murine macrophages. (A) Cp 
immunostaining in non-permeabilized (left; -) and permeabilized (right; +) bone marrow-derived 
macrophages (BMDM), showing Cp positive staining at both cell surface and intracellular level. 
(B) High magnifications of Cp immunostaining in non-permeabilized BMDM show Cp 
concentration in discrete membrane microdomains at the cell surface. Cp staining is shown in 
red and nuclei (N) are stained in blue (DAPI). The white bars in panels represent 20 µm. Insets 
in (B) show enlargement of individual cells staining. (C) Immunoblotting detection of Cp in 
untreated BMDM subcellular fractions: cytosol (C) and crude membrane extracts (M). Human 
serum-purified Cp (hCp) was used as a positive control. The position and size in kilodaltons 
(kDa) of the molecular weight markers are indicated on the left. Vertical dashed lines indicate 
repositioned gel lanes. *Cp proteolitic cleavage product.  
  
Cp immunostaining in non-permeabilized BMDM untreated or treated with 
PIPLC (0,5 U/ml, 1h at 37ºC) showed a significant decrease of Cp signal at cell 
surface, showing that this membrane-associated Cp likely correspond to the 
GPI-cp isoform (Figure III.11).  
Figure III.11 - GPI-anchored 
ceruloplasmin at the cell 
surface of in murine 
macrophages. The effect of 
the enzyme PIPLC on Cp 
expression was analyzed in 
non-permeabilized BMDM and 
a significant decrease of Cp 
staining is observed in PIPLC-
treated BMDM (right, +). Insets 
show enlargement of individual 
cells staining. The white bars 
in panels represent 20 µm.  
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3.2. Ceruloplasmin and ferroportin-1 partially co-localize in lipid 
rafts in iron-treated murine macrophages 
The pattern of GPI-Cp staining at cell surface of iron-treated BMDM 
(Figure III.10B) was suggestive of its accumulation in membrane domains. To 
test if this ferroxidase could be localized in lipid rafts, GPI-Cp immunostaining 
was investigated in iron-treated BMDM. The results obtained showed a partial 
co-localization with CD11b, a cell surface marker and a lipid raft-associated 
antigen (Figure III.12A) 291. Noteworthy, co-localization of Fpn1 and CD11b at 
cell surface was previously reported to be significantly enhanced upon iron 
stimulation in BMDM 119. Also, in order to test if GPI-Cp and Fpn1 could co-
localize in the same lipid rafts at the plasma membrane of murine BMDM upon 
iron stimulation, co-staining of both Cp and Fpn1 was investigated in iron-
treated BMDM (Figure III.12B). As observed, both proteins were localized at the 
cell surface with some overlay of the Fpn1 and GPI-Cp staining (see arrows in 
Fig III.12B). However, only a partial co-localization of GPI-Cp and Fpn1 was 
observed.  
 
Figure III.12 - GPI-anchored 
ceruloplasmin is partially co-
localized with CD11b and 
ferroportin-1 in lipid rafts on iron-
treated murine macrophages. (A) 
Co-staining of GPI-Cp (green) with 
CD11b (red, cell surface marker and 
raft-associated antigen) in iron-
treated BMDM. (B) Co-staining of 
GPI-Cp (red) and Fpn1 (green) in 
iron-treated BMDM. The white bars 
represent 20 µm. Arrows indicate the 
co-localization sites of the two 
labeled proteins (yellow) in some 
areas at cell surface.  
 
 
 
 
 
 
 
 
96 
For further confirmation, lipid rafts from untreated and iron-treated BMDM 
were isolated as detergent (Triton X-100) resistant membranes (DRM) as 
previously described 118, followed by immunoblotting analysis (Fig III.13). 
According to the principle of this technique, proteins localized in lipid rafts are 
expected not to be solubilized by detergent and to float associated with 
phospholipids to the lighter fractions of the density gradient (DRM). Caveolin 
forms oligomers and associates with cholesterol and sphingolipids in lipid rafts, 
leading to the formation of caveolae, a specific subset of lipid rafts 292. 
Therefore, caveolin-1 (Cav-1) was used as a lipid raft marker and its distribution 
in the gradient was used as a guide to define the DRM fractions. Accordingly, 
the top six lower density fractions were defined as DRM, whereas the non-DRM 
(NDRM) was defined as the denser material in fractions 7 to 11(Figure III.13). 
Interestingly, Fpn1 was only detected in DRM fractions, with its expression 
being significantly enhanced by iron treatment and its distribution mostly 
enriched in fractions 1 to 3. On the other hand, Cp was mostly detected in 
fractions 8 to 10 in untreated cells. Upon iron treatment, Cp expression was 
increased and distributed in fractions 5 to 11. Moreover, in both untreated and 
iron-treated BMDM, Cp was strongly detected in NDRM fractions (9 to 11), and 
likely correspond to sCp isoform in these cells (Figure III.13). Indeed, NDRM 
fractions typically correspond to solubilized membrane proteins as well as 
cytosolic proteins and broken membrane/cells. Nonetheless, an overlap 
between Fpn1 and Cp distribution in the iodixanol gradient was observed in 
fractions 5 and 6, supporting immunofluorescence studies in which only a partial 
co-localization of Fpn1 and GPI-Cp was observed in iron-treated BMDM.  
 
Figure III.13 - Ceruloplasmin 
partially co-localizes with 
ferroportin-1 in lipid rafts 
fractions in iron-treated murine 
macrophages. Immunoblotting 
detection of Fpn1, Cp and cav-1 
(raft marker) in detergent 
resistant membrane (DRM) and 
non-detergent resistant 
membrane (NDRM) fractions of 
BMDM untreated and iron-treated 
(FeNTA, 100 µM ). The positions 
and sizes in kilodaltons (kDa) of 
the molecular weight markers are 
indicated on the left. Vertical 
dashed lines indicate 
repositioned gel lanes. *Cp 
proteolitic cleavage product.  
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3.3. Effect of iron on ceruloplasmin expression in murine 
macrophages  
Our previous results with the iodixanol gradient showed an upregulation of Cp in 
iron-treated BMDM (Figure III.13). To confirm this result, we investigated the 
effect of iron on Cp protein levels using different technical approaches. The 
results obtained by immunofluorescence (Figure III.14A), In-Cell Western blot 
(Figure III.14B), and conventional Western blot of BMDM subcellular fractions 
(Figure III.14C) confirmed the upregulation of Cp in response to iron treatment. 
Moreover, analysis of Cp labeling in permeabilized and non-permeabilized 
BMDM showed that iron loading in these cells increased both membrane-
associated Cp and intracellular Cp (Figure III.14A). The increased Cp detection 
in both cytosolic and crude membrane fractions of iron-treated BMDM further 
confirmed these results. In addition to Cp upregulation, Fpn1 was also strongly 
induced by iron (Figure III.14A and III.14C) as previously reported 119  
Figure III.14 – Regulation of 
ceruloplasmin by iron in 
murine macrophages. (A) 
Immunofluorescence staining of 
Fpn1 (green) and Cp (red) in 
non-permeabilized and 
permeabilized BMDM untreated 
or treated with iron (FeNTA). (B) 
In-Cell Western blot detection 
(left panel) and quantification 
(histogram, right panel) of Cp 
expression in iron treated (+) 
and untreated (-) BMDM. For 
correction of variation in cell 
numbers from well to well, Cp 
intensity signals in histogram 
were normalized to cell density 
(left panel). (C) Immunoblotting 
of Cp and Fpn1 in crude 
membrane (M) and cytosolic (C) 
extracts isolated from untreated 
or iron-treated BMDM (FeNTA, 
100 µM). Red Ponceau staining 
was used for total protein 
loading control. Vertical dashed 
lines indicate repositioned gel 
lanes. The positions and sizes in 
kilodaltons (kDa) of the 
molecular weight markers are 
indicated on the left. Vertical 
dashed lines indicate 
repositioned gel lanes. *Cp 
proteolitic cleavage product.  
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The effect of iron on total Cp mRNA levels was also investigated and no 
difference was observed between untreated and iron-treated BMDM for short 
time point (Figure III.15A), suggesting a post-transcriptional regulation of Cp by 
iron. However, posterior qPCR experiments in which iron-treated BMDM were 
used as a positive control, revealed a progressive decrease of Cp mRNA levels 
(total Cp and both isoforms: GPI-Cp and sCp) directly proportional to time of 
culture in the presence of iron (Figure III.15B).  
 
Figure III.15 - Iron effect on ceruloplasmin transcriptional expression in murine 
macrophages. (A) qPCR analysis of total Cp mRNA levels in untreated (control) and iron-
treated BMDM (FeNTA, 100 μM) for 3,5 h. Graphic representative of one experiment with 
biological and technical duplicates, with fold change data presented as mean ± confidence 
interval (95%). (B) Kinetics of total Cp and its isoforms GPI-Cp and sCp mRNA levels in BMDM 
untreated (control) and iron-treated BMDM (FeNTA, 100 μM) at different time points. Graphic 
represents data obtained in three independent experiments, each with biological and technical 
duplicates. Data in (A-B) are shown in mean fold change calculated as 2
-ΔΔCt
 using Hprt as the 
reference gene and then normalized against the respective experimental control condition at 
each time point.  
 
3.4. β-amyloid precursor protein is upregulated by iron and co-
localizes with ferroportin-1 in lipid rafts microdomains in 
murine macrophages 
Considering the partial co-localization of GPI-Cp and Fpn1, we 
investigated if another ferroxidase could be also interacting with Fpn1 in iron-
treated BMDM. Besides Cp, of the three other proteins reported to interact with 
Fpn1 in different cells and tissues, only APP was previously described to be 
expressed in human monocytes and macrophages 262. In order to test this 
hypothesis, we first analyzed APP expression in crude membrane extracts of 
untreated and iron-treated BMDM. We observed a significant upregulation of 
both immature (≈110 kDa, N-glycosylated form) and mature APP (≈130 kDa, N- 
and O-glycosylated form) along with Fpn1 upregulation in iron-treated cells 
(Figure III.16A). A higher molecular weight band (*) was also observed in iron-
treated BMDM membrane extract, but its identification was uncertain. 
Noteworthy, other authors have reported a spectrum of bands of mature APP 
corresponding to both fully glycosylated and phosphorilated mature APP 293. 
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Analysis of App mRNA levels revealed that, unlike Fpn1, APP upregulation was 
not observed at the mRNA level (Figure III.16B), indicating that APP 
upregulation occurs exclusively through a post-transcriptional mechanism. 
 
Figure III.16 - β-amyloid precursor protein is upregulated by iron in murine macrophages. 
(A) Immunoblotting detection of Fpn1 and APP on crude membrane extracts (M) of untreated 
and iron-treated BMDM. The position and size in kilodaltons (kDa) of the molecular weight 
marker are indicated on the left. The black arrowhead indicates mature APP protein (mAPP) 
while the gray arrowhead indicates immature APP protein (imAPP). *Unknown protein positively 
detected by antibody raised against APP. Red Ponceau staining was used for control of total 
protein loading. (B) Quantification of App and Fpn1 mRNA levels by qPCR in untreated and 
iron-treated BMDM (FeNTA, 100 µM). Fold change data are represented as mean ± confidence 
interval (95%), in which fold change data were calculated as 2
-ΔΔCt
 using Hprt as the reference 
gene and then normalized against the respective experimental control condition at 3,5 h. 
Statistical analysis was performed on the ΔCt values obtained during three independent 
experiments, using Student’s t test. Statistically significant differences on Fpn1 and App mRNA 
mean expression between untreated and iron-treated (FeNTA) BMDM at 3,5 h time point are 
indicated as **(p<0,01).   
 
Fpn1 was previously reported to localize in lipid rafts at cell surface of iron-
treated BMDM 118. In order to test if APP would co-localize with Fpn1, lipid rafts 
of untreated and iron-treated BMDM were isolated as described before and 
analyzed by immunoblotting (Figure III.17A). Distribution of the raft marker Cav-
1 through the gradient fractions showed that DRM proteins were mostly 
enriched in fractions 1 to 6. Analysis of Fpn1 and APP detection confirmed that 
iron stimulation upregulates both APP and Fpn1, with Fpn1 being distributed in 
DRM fractions, but mainly enriched in fractions 1 to 5. On the other hand, in 
untreated BMDM, APP was detected in fractions 5 to 11 being enriched in 
fractions 10 and 11. Upon iron stimulation, APP was significantly upregulated, 
being detected in almost all fractions of the gradient. Despite the significant 
detection of APP in fractions 5 to 11, its mature form (130 kDa) was detected in 
the top four DRM fractions where it overlaps with Fpn1 distribution, pointing to a 
co-localization of these two proteins in DRM fractions.  
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Figure III.17 - β-amyloid precursor 
protein co-localizes with 
ferroportin-1 in lipid rafts 
microdomains in iron-treated 
murine macrophages. (A) 
Immunoblotting detection of Fpn1, 
APP and caveolin-1 (cav-1; raft 
marker) in detergent resistant 
membrane (DRM) and non-detergent 
resistant membrane (NDRM) fractions 
isolated from untreated and iron-
treated BMDM (FeNTA, 100 µM). The 
position and size in kilodaltons (kDa) 
of the molecular weight marker are 
indicated on the left. Black 
arrowheads indicate mature APP 
protein (mAPP) while gray 
arrowheads indicate immature APP 
protein (imAPP). *Unknown protein 
positively detected by antibody raised 
against APP. (B) Typical protein 
distribution in BMDM iodixanol 
gradient. The low protein 
concentration in DRM fractions 1-4 
compared with NDRM-enriched 
fractions 9-12, show that fractions 1-4 
are highly enriched in DRM proteins 
despite the minimal protein content.  
Immunofluorescence studies were also attempted to demonstrate APP 
and Fpn1 co-localization in the same lipid rafts. However, the detection of APP 
by immunofluorescence was not validated (Figure III.18). The staining of APP 
observed was not typical of a membrane protein as expected and its detection 
was not modulated by iron (a known inducer of APP expression 263,264) and as 
previously observed in Western blot (Figure III.16A. and III.17A). One possibility 
is that the antibody used for APP detection (22C11, Millipore) may have higher 
affinity for the denaturated APP protein in Western blot conditions than for the 
native form of APP, failing to detect APP in immunofluorescence experiments. 
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Figure III.18 - Immunofluorescence study of β-amyloid precursor protein in murine 
macrophages. Staining of BMDM untreated and treated with iron (FeNTA, 100 μM) overnight 
using an antibody against APP protein. The white bars represent 25 µm.  
Co-immunoprecipitation (Co-IP) studies were also attempted as an 
alternative approach, but the results obtained were inconclusive. The antibody 
used for APP precipitation (22C11, Millipore) often contaminated the 
immunoprecipitated protein extracts, being detected when probed with 
secondary antibody during Western blot. As the IgG heavy chain dimers of the 
anti-APP antibody used for the immunoprecipitation possess a molecular weight 
close to APP, the strong detection of the antibody in the eluted protein extracts 
chains masked the results. As an alternative to overcome this technical 
limitation, a biotinilated conjugate of the antibody against APP was tested for 
the Western blot detection. In such conditions, the antibody used for 
precipitation would not be detected in the Western blot. However, the 
biotinilated antibody failed to detect APP in total extracts as well as eluted 
extracts of iron-treated BMDM (data not shown).  
4. Discussion 
In the present study, we showed that murine macrophages (BMDM) 
express a membrane-associated Cp in addition to the soluble form already 
reported in macrophages 274,275. Decrease of Cp membrane staining upon 
incubation with PIPLC, an enzyme that specifically cleaves GPI-anchored 
proteins, demonstrated that this form of Cp corresponds, at least in part, to GPI-
Cp as we have reported in human lymphocytes, monocytes and hepatocytes. In 
addition, we confirmed previous observations describing increased Fpn1 
expression at BMDM cell membrane in response to iron overload conditions, 
being enriched in lipid raft microdomains 118,119.  
In this study, we also demonstrated an upregulation of Cp protein in iron-
treated BMDM using different technical approaches. However, the upregulation 
was observed exclusively at protein level, which suggested a post-
transcriptional mechanism mediated by iron regulating Cp levels in BMDM. 
Surprisingly, posterior studies consistently revealed a progressive decrease of 
Cp mRNA level directly proportional to time in culture in the presence of free 
iron. For such reason, the upregulation of Cp protein induced by iron in BMDM 
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is currently under investigation in our group in order to clarify the opposite 
effects of iron observed on Cp expression (mRNA and protein). Noteworthy, a 
study in the C6 glioma cells reported Cp upregulation by iron deficiency and 
downregulation by iron overload conditions 294. Accordingly, circulating Cp was 
reported to be downregulated in HH patients 295, hepcidin-deficient murine 
models presenting systemic iron overload 84, and further confirmed in HH 
patients by our group (unpublished results). On the contrary, increased 
circulating Cp was reported in iron deficient rats 296 and iron deficiency anemia 
patients 297, which is in agreement with unpublished results by our group in 
these patients. Nonetheless, regulation of Cp expression by iron in a specific 
cell such as the macrophage could differ from circulating Cp or glial cells and, 
for that reason, our previous results concerning iron regulation of macrophagic 
Cp need to be further investigated and clarified. 
Considering the reported localization of Fpn1 in lipid raft microdomains in 
iron-treated BMDM, the expression and distribution of Cp in DRM and NDRM 
fractions of iron-treated BMDM was also investigated. Indeed, a partial co-
localization of GPI-Cp with Fpn1 was found in lipid raft fractions of iron-treated 
BMDM. As previously proposed, GPI-Cp ferroxidase activity could promote iron 
efflux by Fpn1 in a situation whenever iron recycling is more demanding in order 
to maintain iron homeostasis 254,270. Accordingly, iron efflux assays after 
challenging the reticuloendothelial system, revealed that both hepatocytes and 
tissue macrophages had impaired iron release in Cp-/- mice compared with 
Cp+/+ mice. Such impairment was not observed when Cp-/- mice were injected 
with holo-Cp, showing that Cp indeed plays a role on iron export in both 
hepatocytes and tissue macrophages 51.  
However, in our study, only a partial co-localization of Fpn1 and GPI-Cp 
was observed in iron-treated BMDM. Indeed, Fpn1 was strongly enriched in 
lipid rafts fractions that did not express any GPI-Cp, showing that a significant 
amount of Fpn1 located at cell surface is not co-localized with GPI-Cp in the 
conditions tested. This suggests that iron export by Fpn1 may not be exclusively 
dependent on GPI-Cp activity in iron-treated BMDM. In fact, the participation of 
the soluble Cp isoform also expressed and secreted by macrophages may also 
contribute to Fpn1 transport activity. Additionally, it is possible that another 
ferroxidase besides Cp could be also expressed in our murine macrophage 
model. Interestingly, despite the progressive iron accumulation in different 
tissues, Cp-/- mice and aceruloplasminemia patients only develop anemia at 
early adult life 51. This fact suggests that despite the lack of Cp, recycling 
macrophages are still exporting enough iron to sustain the erythropoietic 
demand during the first years of life. Although non-enzymatic iron oxidation was 
proposed to be responsible for the Tf iron loading in this condition 51, the 
existence of another ferroxidase in recycling macrophages should not be 
disregarded. Indeed, the expression of different ferroxidases in the same tissue 
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has been previously reported. For instance, in rats, Heph and Cp were reported 
to be co-expressed with Fpn1 in the heart, being differently regulated by iron 
and indicating that both could interact with Fpn1 under different conditions 125. 
On the other hand, APP and Cp were reported to be co-expressed in liver of 
mice, more specifically in hepatocytes, both contributing equally to the 
ferroxidase activity presented by this organ 139.  
Our results showed that APP is expressed in murine BMDM, being 
upregulated by iron through a post-transcriptional mechanism likely associated 
with the IRE on the 5´-UTR sequence of its mRNA reported elsewhere 263. 
Additionally, we demonstrated that, in response to iron, both mature APP and 
Fpn1 detection overlapped in DRM/lipid rafts fractions indicating that these two 
proteins could co-localize in such microdomains under iron overload conditions. 
Previous studies reported that APP is present in two different pools in neurons, 
following different processing destinations according to its localization in or out 
of lipid raft microdomains 298,299. It is therefore not surprising to find APP not 
exclusively enriched in DRM fractions where Fpn1 is also enriched in iron-
stimulated BMDM. However, only the mature form of APP was detected in such 
fractions, suggesting that APP localization in lipid rafts could be essential to its 
function. The fact that both APP and Fpn1 are upregulated by iron likely through 
an IRE element, co-localizing in the lightest DRM fractions suggests that these 
two proteins could be interacting in order to promote iron release from 
macrophage in conditions of cellular iron overload.  
Interestingly, the expression of both Cp and APP in BMDM could indicate 
overlapping, but also complementary roles as potential ferroxidase partners of 
Fpn1 in macrophages. For instance, as APP and Fpn1 are upregulated by iron 
overload conditions likely through an IRE element in their mRNA, also Fpn1 and 
Cp were reported to be transcriptionally upregulated by hypoxia (condition often 
associated with anemia) through the HRE element in their mRNA 65,108,254,300. 
One may propose that APP could be the main ferroxidase partner of Fpn1 
under normoxic and iron overload conditions, while Cp could be the main 
partner under hypoxic conditions in which the stored iron would be mobilized 
from Ft and exported to respond to the increased erythropoietic demand. Under 
such conditions, despite the increased intracellular iron levels derived from Ft 
degradation, the observed progressive Cp mRNA decay mechanism triggered 
by intracellular iron could be counteracted by the transcriptional upregulation of 
Cp induced by hypoxia. Accordingly, extracellular Cp activity was shown to 
promote macrophage iron export in a hypoxia-dependent mechanism. However, 
our results in this chapter did not investigate the Cp/Fpn1/APP interaction nor 
its modulation in hypoxia, demonstrating only partial co-localization of GPI-
Cp/Fpn1 and Fpn1/APP in normoxic conditions combined with iron overload. 
Noteworthy, it is possible that co-localization of GPI-Cp and Fpn1 could be 
differently modulated by hypoxia and thus further research on this topic is 
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necessary in order to clarify the ferroxidase partner(s) of Fpn1 and their 
regulation by iron in murine macrophages. 
Additionally, the ferroxidase activity of domain E2 in APP reported by 
Duce et al 139 was recently challenged by another group that pointed technical 
limitations in the ferroxidase experiments in Duce et al and concluded that APP 
has no ferroxidase activity 140,141. Nonetheless, APP-/- mice present increased 
iron accumulation in the cells where APP is endogenously expressed (neurons, 
hepatocytes and others) 139 and a very recent publication by a third group 
showed that sAPP modulates iron export in brain microvascular endothelial 
cells by stabilizing Fpn1 at cell surface, despite no iron oxidation promoted by 
sAPP was observed 142. Thus, even if APP ferroxidase activity is currently 
discussed, different publications support that APP or its soluble form sAPP 
interact with Fpn1 and influence iron export. In such scenario, the ferroxidase 
activity of sCp secreted by macrophages could play a major role promoting iron 
export through Fpn1. 
Ultimately, one should not neglect the important anti-oxidant role played 
by Cp not only at systemic level, but also at site of inflammation/infection 
275,283,284. The significant upregulation of Cp under inflammatory and infectious 
conditions, that simultaneously downregulate Fpn1, emphasize how Cp function 
in immune cells is not limited to the partnership with Fpn1 on iron export. In fact, 
it was recently reported that macrophage-derived Cp contributes significantly 
towards protection against inflammation and tissue injury in acute and chronic 
experimental colitis 179, supporting the relevance of Cp anti-oxidant function. 
However, the significant upregulation of Cp in conditions of chronic 
inflammation might lead to a deleterious effect due to its pro-oxidant activity and 
subsequent oxidative modification of other substracts besides iron. An example 
of such role of Cp is the high values of plasma Cp associated with increased 
risk of developing VD events in ATH 258,259,271, most likely associated with Cp 
capacity to oxidize LDL particles in circulation and at the site of lesion. 
5. Conclusion  
In this study, we focused on the expression and subcellular localization of 
two possible ferroxidase partners of Fpn1 in murine macrophages. Herein, we 
reported the expression of GPI-Cp in addition to the soluble isoform of Cp in 
BMDM, demonstrating a partial co-localization between GPI-Cp and Fpn1 in 
lipid raft microdomains after iron challenge. Given the partial co-localization, we 
proposed that another protein besides GPI-Cp and sCp could be also 
interacting with Fpn1 in these cells. APP, which was recently reported as a 
ferroxidase interacting with Fpn1 in neurons, was as a likely candidate. Our 
results confirmed that APP is significantly upregulated by iron in BMDM, and 
demonstrated that part of mature APP is co-localized with Fpn1 in lipid raft 
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fractions and could therefore correspond to an additional ferroxidase partner for 
Fpn1 in iron-treated macrophages. Alternatively, given the recent controversy 
on APP ferroxidase activity, it is possible that APP would interact with Fpn1 
promoting Fpn1 stabilization while a ferroxidase, possibly sCp, could promote 
iron oxidation in addition to iron non-enzymatic oxidation (Figure III.19).  
 
Figure III.19 - Scheme of possible interactions between ferroportin-1, ceruloplasmin and 
β-amyloid precursor protein in lipid rafts microdomains in murine macrophages. At 
macrophage cell surface, lipid rafts constitute microdomains enriched in sphingolipids and 
cholesterol as well as GPI-anchored proteins. In BMDM, Fpn1, GPI-Cp and APP are localized in 
lipid rafts microdomains. Iron export by Fpn1 is dependent on interaction with a ferroxidase that 
oxidizes Fe
2+
 to Fe
3+
, maintaining an iron gradient while facilitating iron load onto Tf (holo-Tf). In 
(A), one possible model of macrophage iron export proposes that Fpn1 interacts with GPI-Cp, 
sCp and APP in lipid rafts, which oxidize the exported Fe
2+
 to Fe
3+
. This interaction with different 
membrane ferroxidases (GPI-Cp and APP) is likely to occur in different lipid rafts microdomains 
given the partial co-localization of GPI-Cp/Fpn1. Alternatively, in (B) APP presents no 
ferroxidase activity, but enhances Fpn1 levels at cell surface through physical interaction with 
the iron exporter. In this model, iron oxidation associated with Fpn1 iron export would be 
dependent on a multicopper oxidase, herein represented by sCp.  
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1. Introduction 
ATH is characterized by the formation of plaques in the vessel wall 
triggered by the accumulation and modification of LDL and subsequent 
recruitment of immune cells, namely monocytes and lymphocytes. Once in the 
lesion, monocyte-derived macrophages uptake and accumulate modified LDL, 
differentiating into lipid-laden cells named foam cells 198. Iron accumulation in 
atherosclerotic plaques was previously reported, in particular associated with 
macrophage-derived foam cells 220,301-303, and was proposed to be a modifiable 
risk factor in atherogenesis 214,218. The iron accumulation in foam cells could be 
the consequence of iron export impairment in the intraplaque macrophages and 
we decided to test this hypothesis. Different macrophages phenotypes have 
been described in the atherosclerotic lesion 243, including the classically 
activated M1 macrophages in which the iron export is impaired 111. Recently, a 
new macrophage phenotype (Mox) was reported to result from exposure to 
oxidized phospholipids (oxPAPC, also a product of LDL oxidation) and the 
transcriptional factor Nrf2 was shown to be involved in their polarization 249. 
However, apart from HO-1, the expression of iron metabolism proteins is poorly 
described in Mox macrophages 249.  
2. Aims 
In this study, we proposed to investigate the modulation of some key iron 
metabolism proteins expression in the Mox phenotype, with particular interest 
on the iron exporter Fpn1 and its potential partners Cp and APP. Moreover, in 
order to mimick the complex intraplaque microenvironment, we investigated the 
effect of simultaneous stimulation with activators of M1 and Mox polarization on 
these proteins expression. 
Given the difficulties expressed in chapter 1 in studying human Fpn1 due 
to lack of a specific antibody at the time of investigation, murine BMDM were 
the main macrophage model selected to the study. 
3. Results 
 
3.1. Effect of modified LDL on the transcriptional expression of 
iron metabolism proteins in murine macrophages 
BMDM were incubated in the absence (control) or presence of native LDL 
(nLDL), oxidized LDL (oxLDL) or acetylated LDL (acLDL). Staining with Red Oil 
O revealed significant lipid accumulation in both oxLDL and acLDL-treated 
BMDM, but not with nLDL or untreated cells (Figure III.20), showing that both 
sources of modified LDL can be uptaken by BMDM and promote foam cell 
differentiation. Noteworthy, oxLDL-derived foam cells presented higher lipid 
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accumulation than acLDL-derived foam cells, while these latter ones showed 
larger lipid droplets.  
 
Figure III.20 - Effect of native and modified LDL on foam cell differentiation from murine 
macrophages. BMDM were incubated for 24 h in complete medium and in the absence 
(control) or presence of nLDL, oxLDL or acLDL, followed by fixation and Oil Red O staining 
(lipid specific dye, red) with hematoxylin counterstain. Images were acquired using a Leica 
DM4000 B microscope with a 40x objective. The black bars represent 20 μm. 
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As can be observed in table 5, no significant mortality was associated with 
nLDL, oxLDL or acLDL treated cells and assay with MTT indicated increased 
cell viability in all conditions studied compared with untreated BMDM (control). 
Other authors have reported a dual effect of oxLDL, protecting against 
apoptosis at low concentrations while promoting cellular death at high and toxic 
concentrations 304. In particular, one study in murine BMDM reported an anti-
apoptotic effect of oxLDL (concentrations up to with 50 g/mL) 305, which is in 
agreement with our own observations. 
Table 5 - Effect of native and modified LDL on murine macrophages viability. The results 
are expressed as percentage and were normalized against the viability of untreated BMDM 
(control).  
 
On the other side, the effect of oxLDL on the transcriptional expression of 
iron metabolism proteins in BMDM was analyzed by qPCR at different time 
points. A high and transient upregulation of Hmox1 (HO-1 gene) and Fpn1 
mRNA level was observed on BMDM in response to oxLDL. This upregulation 
occurred at early time point and in a dose dependent-manner, followed by a 
decrease to basal expression level after 24 h of culture with oxLDL (Figure 
III.21A).  
Both nLDL and acLDL had no significant effect on Hmox1 and Fpn1 
mRNA level when compared with oxLDL (Figure III.21B), which indicates that 
the oxidative modification of LDL is important for the mechanism underlying the 
transcriptional upregulation of these genes. Moreover, the upregulation induced 
by oxLDL was directly proportional to the degree of LDL oxidation (Figure 
III.21C).  
 
Control 
nLDL 
50 µg/ml 
nLDL 
100 µg/ml 
oxLDL 
50 µg/ml 
oxLDL 
100 µg/ml 
acLDL 
50 µg/ml 
acLDL 
100 µg/ml 
Viability 100% 151% 158% 189% 142% 171% 185% 
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Figure III.21 - Effect of modified LDL on heme oxygenase-1 and ferroportin-1 
transcriptional expression. (A-C) qPCR analysis of Hmox1 and Fpn1 expression levels, at 
different time points, in BMDM untreated (control) or treated with: (A) different concentrations of 
oxLDL; (B) different sources of LDL (nLDL, oxLDL, or acLDL); (C) different degree of LDL 
oxidation. Fold change data were calculated as 2
-ΔΔCt
 using Hprt as the reference gene and then 
normalized against the respective experimental control condition at each time point. Mean of Ct 
values in the experiments analyzed: Hmox1 (Ct=19,1), Fpn1 (Ct=21,1). 
 
An upregulation of Fth1 (H-Ft gene) mRNA level was also observed in 
response to oxLDL, while no significant effect was observed on App mRNA 
level (Figure III.22). Total Cp mRNA level were significantly downregulated by 
oxLDL, reaching a minimum at 24 h of culture. This transcriptional 
downregulation of Cp was also confirmed on both sCp and GPI-Cp isoforms 
(Figure III.22). An upregulation of Hamp1 (Hepc gene) mRNA level was also 
observed on BMDM in response to oxLDL (Figure III.22). However, Hamp1 
basal expression levels (Mean Ct=31) indicates that no significant effect of 
oxLDL is expected on Hepc protein level. Other iron metabolism proteins such 
as DMT1 and TfR1 were also analyzed, but no significant and consistent effect 
of oxLDL was observed in Mox macrophages (data not shown). 
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Figure III.22 - Effect of oxidized LDL on the expression of iron metabolism proteins. qPCR 
analysis of Fth1, App, Hamp1 and Cp mRNA level in BMDM untreated (control) or treated with 
different concentrations of oxLDL at different time points. Fold change data were calculated as 
2
-ΔΔCt 
using Hprt as the reference gene and then normalized against the respective experimental 
control condition at each time point. Mean of Ct values in the experiments analyzed: Fth1 
(Ct=13,3), Hamp1 (Ct=31,4), App (Ct=20,7), total Cp (Ct=23,2), GPI-Cp (Ct=27,3), sCp 
(Ct=24,6).  
 
3.2. Transcriptional upregulation of heme oxygenase-1 and 
ferroportin-1 by oxidized LDL is Nrf2-dependent in murine 
macrophages 
In order to test the hypothesis that Fpn1 upregulation in Mox macrophage 
model is Nrf2-mediated, BMDM were prepared from wild type (Nrf2+/+) and Nrf2 
null mice (Nrf2-/-), and treated or not with oxLDL or iron (FeNTA) for 3,5 h before 
RNA extraction and analysis by qPCR. As observed in Figure III.23, 
upregulation of Hmox1 mRNA by both oxLDL and FeNTA was significantly 
inhibited in Nrf2-/- BMDM compared with Nrf2+/+ BMDM (p<0,0001). However, 
while the upregulation of Hmox1 mRNA by FeNTA was almost abrogated in 
Nrf2-/- BMDM, Hmox1 mRNA was still significantly upregulated by oxLDL in 
these cells. A significant difference was also observed on Fpn1 mRNA level on 
Nrf2-/- BMDM and Nrf2+/+ BMDM in response to oxLDL or FeNTA challenge 
(Figure III.23, p<0,0001). Noteworthy, Fpn1 mRNA level in Nrf2-/- BMDM is 
114 
severely downregulated compared with Nrf2+/+ BMDM (Figure III.23). In fact, 
Fpn1 mRNA level in Nrf2-/- BMDM untreated and treated with oxLDL or iron is 
bellow the basal expression level of Fpn1 in untreated Nrf2+/+ cells.  
As a control for the experiment, Vegf expression was also analyzed as it 
was reported to be upregulated by oxPAPC in Mox macrophages in an Nrf2-
independent manner 249. Accordingly, the upregulation of Vegf mRNA in 
response to oxLDL was not inhibited in Nrf2-/- BMDM compared with Nrf2+/+ 
BMDM in our model of Mox macrophages (Figure III.23). In fact, Vegf mRNA 
level in Nrf2-/- BMDM was even upregulated when compared with Nrf2+/+ BMDM, 
as observed in Kadl et al 249. 
Figure III.23 - Effect of oxidized LDL and iron on heme oxygenase-1 and ferroportin-1 
expression is Nrf2-dependent in murine macrophages. qPCR analysis of Hmox1 and Fpn1 
mRNA level in BMDM of Nrf2
+/+
 (black) and Nrf2
-/-
 (white) mice, untreated (control) or treated 
with oxLDL or iron (FeNTA) for 3,5 h. Vegf mRNA expression was analyzed as a control. Fold 
change data were calculated as 2
-ΔΔCt
 using Hprt as the reference gene and then normalized 
against the respective Nrf2
+/+
 experimental control condition. Data are presented as mean ± 
confidence interval (95%), in which fold change (Nrf2
+/+
 control)=1. Statistical analysis was 
performed on the ΔCt values obtained during three independent experiments, using 2-way 
repeated measures-ANOVA followed by Bonferroni’s post-hoc test for multiple comparisons. 
Statistically significant differences on Hmox1, Fpn1 or Vegf mean expression between Nrf2
+/+
 
and Nrf2
-/-
 BMDM at a specific condition are indicated by: *(p<0,05); **(p<0,01); ***(p<0,001), 
and ****(p<0,0001). Interaction between Nrf2 genotype and in vitro treatment was also analyzed 
and was statistically significant for both Hmox1 (p<0,01) and Fpn1 (p<0,05). Mean of Ct values 
for each gene in the experiments analyzed: Nrf2
+/+
 Hmox1 (Ct=19,3) vs. Nrf2
-/- 
Hmox1 
(Ct=20,8), Nrf2
+/+
 Fpn1 (Ct=19,5) vs. Nrf2
-/- 
Fpn1 (Ct=22,9), Nrf2
+/+
 Vegf (Ct=22,4) vs. Nrf2
-/-
 
Vegf (Ct=22,0).  
 
3.3. Heme oxygenase-1, but not ferroportin-1, is highly 
upregulated by oxidized LDL at protein level 
The significant upregulation of Hmox1 and Fpn1 mRNA level by oxLDL 
was subsequently studied at protein level. Iron-treated BMDM were used as a 
positive control since both HO-1 and Fpn1 were reported to be significantly 
upregulated at transcriptional and protein level in response to iron 107. In 
addition, both Hmox1 and Fpn1 mRNA level presented a similar kinetics when 
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challenged by oxLDL or iron, showing a highly but transient upregulation at 
early time point (Figure III.24A).  
In-Cell Western blot was used for analysis and quantification of protein 
levels of HO-1 and Fpn1 in BMDM untreated and treated with oxLDL or iron 
during 24 h. The results obtained showed that HO-1 is significantly upregulated 
by both oxLDL (p<0,05) and iron (p<0,01) (Figure III.24B). Noteworthy, contrary 
to the effect in mRNA levels shown in Figure III.24A, the induction of HO-1 
protein was significantly higher in response to iron than to oxLDL (Figure 
III.24B). On the other hand, despite the oxLDL-induced significant upregulation 
at transcriptional level, Fpn1 upregulation was only slightly reflected at protein 
level in BMDM while iron induced a significant upregulation of Fpn1 at both 
transcriptional and protein level (p<0,01)(Figure III.24B).  
 
Figure III.24 - Effect of iron and oxidized LDL on heme oxygenase-1 and ferroportin-1 
expression in murine macrophages. (A) qPCR analysis of Hmox1 and Fpn1 mRNA 
expression in BMDM untreated (control) or treated with either iron (FeNTA, 100 µM) or oxLDL 
(75 µg/ml) in different time points (n=3). Fold change data were calculated as 2
-ΔΔCt
 using Hprt 
as the reference gene and then normalized against the respective experimental control 
condition at each time point. Mean of Ct values for each gene in the experiments analyzed: 
Hmox1 (Ct=19) and Fpn1 (Ct=21). (B) In-Cell Western blot analysis of HO-1 and Fpn1 protein 
expression in BMDM untreated or treated with iron or oxLDL for 24 h. In-Cell Western blot 
images correspond to one experiment representative of the three independent experiments 
analyzed. Cell density (red) was used for normalization of protein expression (green) between 
wells. Fold change data were normalized against control (arbitrary units) and are presented as 
mean ± standard deviation (n=3). Statistical analysis was performed by Student’s t test and 
statistically significant differences on HO-1 or Fpn1 expression levels between treated and 
untreated cells are indicated by *(p<0,05) and **(p<0,01). 
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Immunofluorescence analysis of both HO-1 and Fpn1 further confirmed 
the results obtained by In-Cell Western blot. BMDM showed an intracellular 
staining of HO-1 in response to oxLDL or iron (Figure III.25, top panel). Fpn1 
staining was detected at intracellular as well as at cell surface level in both 
untreated (control) and oxLDL-treated BMDM (Figure III.25, bottom panel). 
However, upon iron treatment, Fpn1 protein levels were highly upregulated and 
mostly detected at the cell surface as previously reported 119. In addition, these 
observations are further supported by its significant downregulation after Hepc 
treatment (data not shown).  
Figure III.25 - Immunofluorescence study of iron and oxidized LDL effect on heme 
oxygenase-1 and ferroportin-1 expression in murine macrophages. Immunofluorescence 
analysis of HO-1 and Fpn1 protein in BMDM untreated (control) and treated with oxLDL (75 
µg/ml) or iron (FeNTA, 100 µM) for 24 h. HO-1 and Fpn1 staining is indicated in green, nuclei in 
blue (DAPI staining) and intracellular lipid droplets in red or yellow (autofluorescence of oxLDL). 
Yellow staining indicates overlay between HO-1 or Fpn1 staining (green) and intracellular lipid 
droplets (red) in BMDM. Insets at the lower left corner of each image represent high 
magnification of cells. The white bars represent 25 µm. 
 
3.4. Transient upregulation of heme oxygenase-1 and 
ferroportin-1 mRNA triggered by oxidized LDL is inhibited 
by LPS/IFNγ 
Kadl et al reported that upon stimulation with oxPAPC, resting 
macrophages (M0) and polarized M1 or M2 macrophages would differentiate 
into Mox macrophages 249. However, in these assays, macrophages would be 
firstly polarized and then exposed only to oxPAPC for Mox polarization. Herein, 
we investigated the effect of simultaneous stimulation with M1 activator 
(LPS/IFNγ) and Mox activator (oxLDL) on macrophage polarization and 
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expression of some iron metabolism proteins. BMDM were untreated (control, 
M0) or treated with oxLDL (Mox), LPS/IFNγ (M1) or both oxLDL and LPS/IFNγ 
(Mox/M1) for different time points. Oil Red O confirmed the differentiation of 
foam cells in both conditions in which oxLDL was added to culture medium 
(Figure III.26).  
 
Figure III.26 - Effect of oxidized LDL and pro-inflammatory conditions on foam cell 
differentiation from murine macrophages. BMDM were incubated for 24 h in complete 
medium and in the absence (control) or presence of oxLDL (Mox), LPS/IFNγ (M1) or both 
(Mox/M1). After incubation, cells were fixed and stained with Oil Red O (lipid specific dye, red) 
with hematoxylin counterstain. Images were acquired using a Leica DM4000 B microscope with 
a 40x objective. The black bars represent 20 μm.  
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Mox and M1 phenotypes were confirmed by the early upregulation (3,5 h) 
of Vegf and Hmox1 mRNA in Mox and Il6 (IL-6 gene) mRNA in M1 
macrophages. Mox/M1 phenotype presented a combination of Mox and M1 
features, with early high upregulation of Il6 mRNA and late upregulation of Vegf 
mRNA as observed in M1 macrophages (Figure III.27).  
 
Figure III.27 - Gene expression analysis of specific markers in M1, Mox and Mox/M1 
macrophages. Graphic representation of Vegf and Il6 mRNA kinetics. Data are presented in 
fold change calculated as 2
-ΔΔCt
 using Hprt as the reference gene and then normalized against 
the respective experimental control condition at each time point. BMDM were untreated (control, 
M0) or treated with oxLDL (Mox), LPS/IFNγ (M1) or both stimuli in different time points 
(Mox/M1). The results presented are the mean of three independent experiments, each with 
biological and technical duplicates. 
HO-1 is a Mox phenotype marker, reported to be transcriptionally 
upregulated by Mox activator and downregulated by M1 activator after 3h 
stimulation 249. In our studies, Hmox1 mRNA is highly upregulated at 3,5 h, 
returning to basal levels at 24 h in Mox macrophages, whereas in M1 
macrophages, Hmox1 mRNA is firstly downregulated at 3,5 h, followed by an 
upregulation at late time point (24 h) (Figure III.28A-B). In Mox/M1, the early 
downregulation of Hmox1 mRNA level typically induced by LPS/IFNγ is 
counteracted by oxLDL. However, the induction of Hmox1 mRNA at 3,5 h in 
Mox/M1 macrophages is milder than in Mox macrophages (p<0,01). Moreover, 
while Hmox1 transcriptional upregulation in Mox macrophages is transient, in 
Mox/M1 macrophages the induction of Hmox1 mRNA level is stable at early and 
late time points (Figure III.28A-B).  
Fpn1 mRNA is highly upregulated by oxLDL in Mox macrophages, while 
LPS/IFNγ significantly downregulates Fpn1 mRNA at early and late time points 
in M1 macrophages (Figure III.28A-B). In Mox/M1, no induction or significant 
downregulation of Fpn1 mRNA was observed at early time point, but at 24 h, 
Fpn1 mRNA level was significantly downregulated compared with control (M0) 
and Mox (p<0,01), although to a less extent than in M1 macrophages (p<0,05) 
(Figure III.28A-B).  
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Figure III.28 - Effect of oxidized LDL and pro-inflammatory stimuli on heme oxygenase-1 
and ferroportin-1 expression in murine macrophages. BMDM were untreated (control, M0 
macrophages) or treated with oxLDL (Mox macrophages), LPS/IFNγ (M1 macrophages) or both 
stimuli (Mox/M1 macrophages) in different time points, followed by qPCR analysis. (A) Kinetics 
of Hmox1 and Fpn1 expression levels. Fold change data were calculated as 2
-ΔΔCt
 using Hprt as 
the reference gene and then normalized against the respective experimental control condition at 
each time point. Mean of Ct values in the experiments analyzed: Hmox1 (Ct=19,8) and Fpn1 
(Ct=21,9). (B) Statistical analysis of the Hmox1 and Fpn1 expression levels shown in (A) at 3,5 
h and 24 h. Data are presented in a logarithmic scale and as mean ± confidence interval (95%). 
Statistical analysis was performed on the ΔCt values obtained during three independent 
experiments using Student’s t test. Statistically significant differences on Hmox1 and Fpn1 
expression levels between oxLDL vs. oxLDL+LPS/IFNγ and LPS/IFNγ vs. oxLDL+LPS/IFNγ 
treated BMDM are indicated by * (p<0,05), ** (p<0,01), and *** (p<0,001). 
On the other hand, Fth1 mRNA level was transiently upregulated in Mox 
macrophages with a maximum of 5-fold induction at 3,5 h, while in M1 
macrophages Fth1 mRNA was upregulated at later time point (9-fold at 24 h). In 
Mox/M1, Fth1 mRNA was progressively upregulated through time, reaching the 
maximum of 11-fold at late time point (Figure III.29). Total Cp mRNA level was 
highly upregulated in M1 macrophages (18-fold at 3,5 h) while a progressive 
downregulation was observed in Mox macrophages (0,1-fold at 24 h). In 
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Mox/M1, total Cp mRNA level was upregulated, but to a less extent than in M1 
macrophages (7-fold) (Figure III.29). Interestingly, while the regulation of the 
sCp mRNA was fairly represented by the total Cp mRNA level, the GPI-Cp 
isoform was modulated differently in M1 and Mox/M1 macrophages. In such 
polarized phenotypes, inflammatory conditions did not significantly upregulate 
GPI-Cp mRNA level as observed for sCp mRNA in M1 and Mox/M1 
phenotypes. Finally, the other potential ferroxidase App mRNA was mildly 
upregulated in Mox/M1 in a similar way as observed in M1 macrophages, 
whereas no significant effect was induced in Mox macrophages (Figure III.29). 
 
Figure III.29 - Kinetics of ferritin, β-amyloid precursor protein and ceruloplasmin 
expression after oxLDL and inflammatory stimuli in murine macrophages. BMDM were 
untreated (control, M0 macrophages) or treated with oxLDL (Mox macrophages), LPS/IFNγ (M1 
macrophages) or both stimuli (Mox/M1 macrophages) in different time points, followed by qPCR 
analysis. Fold change data were calculated as 2
-ΔΔCt
 using Hprt as the reference gene and then 
normalized against the respective experimental control condition at each time point. Mean of Ct 
values in the experiments analyzed: App (Ct=24,0), Fth1 (Ct=13,7), total Cp (Ct=26,9), GPI-Cp 
(Ct=28,4), and sCp (Ct=27,0).  
3.5. Effect of oxidized LDL on transcriptional expression of iron 
metabolism proteins in human macrophages 
In order to test if oxLDL would also induce a similar Mox phenotype in 
human macrophages, a preliminary assay was performed. In this context, 
primary human macrophages were fully differentiated from peripheral blood 
monocytes in the presence of M-CSF and then untreated (control) or treated 
with nLDL, oxLDL or iron during different time points.  
Staining with Oil Red O confirmed the uptake of oxLDL and differentiation 
of foam cells with high lipid accumulation. Noteworthy, unlike murine 
macrophages (BMDM), human macrophages untreated or treated with nLDL 
already showed a significant lipid accumulation (Figure III.30). This effect of 
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nLDL was also previously reported to result from macropinocytosis in human 
macrophages differentiated with M-CSF 306. 
 
Figure III.30 – Effect of native and oxidized LDL on foam cell differentiation from human 
macrophages. Mature human macrophages were untreated (control) or treated with nLDL or 
oxLDL for 24 h, followed by fixation and Oil Red O staining (lipid specific dye, red) with 
hematoxylin counterstain. Images were acquired using a Leica DM4000 B microscope with a 
40x objective. The black bars represent 20 μm. 
Transcriptional expression of iron metabolism proteins in human 
macrophages was analyzed by qPCR. The Mox marker HMOX1 mRNA level 
was transiently upregulated at 3,5 h (8-fold) by oxLDL as observed in murine 
macrophages, while iron induced HMOX1 mRNA to a less extent and at a later 
time point (Figure III.31). In addition, both the iron exporter FPN1 and the iron 
storage FTH1 mRNA levels were also upregulated in a synchronized manner in 
response to iron and oxLDL at 24 h (2,5-fold, Figure III.31). No significant effect 
was observed on APP or CP mRNA level in response to nLDL, oxLDL or iron 
(Figure III.31). However, unlike BMDM, not only a downregulation was not 
observed in response to oxLDL, but a slight upregulation was noticed on CP 
mRNA level at 24 h, in a pattern similar to the one observed in FTH1 and FPN1. 
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An upregulation of HAMP mRNA mediated by oxLDL (3,5-fold) was observed in 
human Mox macrophages, similar to murine Mox macrophages. However, the 
mRNA basal level of HAMP was significantly higher in human macrophages 
than the homologous Hamp1 in murine macrophages (Mean Ct=24,3 in human 
macrophages vs. Mean Ct=31,4 in BMDM), thus suggesting that Hepc may be 
upregulated at protein level in human Mox macrophages. 
 
Figure III.31 - Effect of iron, native and oxidized LDL on iron metabolism proteins in 
human macrophages. Human macrophages were untreated (control) or treated with nLDL, 
oxLDL or iron (FeNTA) during different time points, followed by qPCR analysis of HMOX1, 
FPN1, APP, CP, FTH1 and HAMP. Fold change data were calculated as 2
-ΔΔCt
 using HPRT as 
the reference gene and then normalized against the respective experimental control condition at 
each time point. Mean of Ct values in the experiment analyzed: HMOX1 (Ct=20,2), FPN1 
(Ct=27,6), CP (Ct=29,2), APP (Ct=23,6), FTH1 (Ct=13,7), and HAMP (Ct=24,3).  
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4. Discussion 
 
4.1. Expression of iron metabolism proteins in Mox 
macrophages phenotype 
In atherogenesis, the macrophage plays a key role in which the uptake of 
modified LDL and differentiation of foam cells constitute early features in 
atherosclerotic lesions development and progression 307. Recently, a new 
macrophage phenotype named Mox was described as the result from exposure 
to oxidized phospholipids and to correspond to a significant part of the 
macrophage population in atherosclerotic lesions 249. Herein, we characterized 
the expression of some key iron metabolism proteins in murine and human Mox 
macrophages. As oxidized phospholipids are components of oxLDL, a model of 
oxLDL-derived Mox macrophage was used in this study. Upregulation of Vegf 
and Hmox1 at early time point in oxLDL-treated BMDM confirmed that our 
model corresponded to Mox phenotype.  
Gene expression analysis showed that, in addition to Hmox1, oxLDL also 
strongly upregulated Fpn1 mRNA level and, to a less extent, Fth1. The 
ferroxidase Cp mRNA was progressively downregulated while no significant 
effect was observed on App mRNA. The significant upregulation of Hmox1 and 
Fpn1 was shown to be specific of oxLDL, not being reproduced by nLDL or by 
another source of modified LDL (acLDL), which reinforces the concept that 
oxidative modification of LDL is important to trigger the differentiation of Mox 
phenotype. Accordingly, the upregulation of Hmox1 and Fpn1 was also directly 
proportional to the concentration and, most importantly, to the degree of 
oxidation of oxLDL. Interestingly, unlike nLDL, exposure of BMDM to acLDL 
lead to the differentiation of lipid-laden foam cells which confirmed the acLDL 
uptake. However, acLDL-derived foam cells presented minor lipid burden than 
in oxLDL-derived foam cells, which may indicate a differential uptake between 
acLDL and oxLDL that could also contribute in part to the different effect of 
acLDL and oxLDL on Hmox1 and Fpn1 expression.  
Moreover, Hmox1 and Fpn1 upregulation triggered by oxLDL was 
significantly decreased in Nrf2-/- BMDM compared with Nrf2+/+ BMDM, which 
indicates that this transcription factor is involved in the upregulation of both 
genes in response to oxLDL. Noteworthy, despite the significant decrease, 
Hmox1 mRNA level was still significantly upregulated in oxLDL-treated BMDM 
compared to Nrf2-/- and Nrf2+/+ untreated BMDM. This observation is indicative 
that other mechanisms Nrf2-independent must also be involved in the massive 
Hmox1 upregulation by oxLDL in BMDM. Indeed, Hmox1 expression was 
previously reported to be upregulated by multiple transcription factors including 
Nrf2, AP-1, Sp-1, Ets, CREB and NF-κB 308, of which some are also known to 
be triggered by oxLDL uptake in macrophages 309.  
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Remarkably, when comparing murine and human Mox macrophages, the 
kinetics of Hmox1/HMOX1 and Fpn1/FPN1 transcription in response to oxLDL 
and iron were not perfectly synchronized as previously observed in murine Mox 
macrophages. Indeed, in human Mox phenotype, HMOX1 was significant and 
transiently upregulated at early time point (3,5h) in response to oxLDL like 
observed in murine Mox macrophages. On the other hand, FPN1 seemed to be 
significantly upregulated only at late time point (24h) by oxLDL.  Iron treatment 
lead to a parallel increase at 24h of HMOX1, FPN1 and FTH, suggesting a 
common regulatory mechanism  in human macrophages in response to iron. 
Interestingly, Harada et al 318 showed a positive regulation of FPN1 in human 
macrophages in response to an Nrf2 activator, an upregulation which resembles 
the kinetics observed after iron or oxLDL treatment in our human macrophage 
model. One can hypothesize that Nrf2 could play a role in FPN1, FTH and 
HMOX1 upregulation by iron. Nrf2 could be also involved in the regulation of 
FPN1 and FTH  by oxLDL. On the other hand, the regulation of HMOX1 by 
oxLDL likely occurs through distinct molecular mechanisms. 
Analysis of protein expression by both In-Cell Western blot and 
immunofluorescence in murine macrophages showed that, unlike HO-1, Fpn1 
significant transcriptional upregulation triggered by oxLDL was only slightly 
reflected at protein level, which suggests that a post-transcriptional mechanism 
must be limitating Fpn1 translation in these cells. On the other hand, upon 
stimulation with iron, both Hmox1 and Fpn1 mRNA levels were significantly 
upregulated in Nrf2-dependent mechanism as observed for oxLDL. However, 
unlike Mox macrophages, HO-1 and Fpn1 were significantly upregulated at 
protein level in iron-treated macrophages. This result indicates that iron might 
be the limitating factor regulating the post-transcriptional mechanism involved in 
Fpn1 translation in Mox macrophages.  
In addition, contrary to the effect observed on mRNA, the induction of HO-
1 protein was significantly higher in response to iron than to oxLDL, which 
suggests that a post-transcriptional mechanism mediated by iron could also 
enhance HO-1 synthesis. Recently, several microRNA’s were reported to 
modulate HO-1 translation in a direct (miR-217, miR-377, and miR-378) 310,311 
or indirect manner (miR-155 and miR122) 312,313 and could constitute possible 
pathways for the iron-mediated enhancement of HO-1 translation.  
Concerning Fpn1 limitated translation in murine Mox macrophages, one 
post-transcriptional mechanism involved in the regulation of many iron 
metabolism proteins and which is sensitive to iron levels is the IRE/IRP system. 
Indeed, Fpn1 mRNA has an IRE element in its 5’-UTR sequence to which the 
IRP1 protein binds in conditions of low intracellular iron, blocking Fpn1 
translation 314. In iron-treated cells, the higher level of intracellular iron lead to a 
conformational change on IRP1 and subsequent dissociation from the IRE, 
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unblocking Fpn1 translation and leading to the upregulation of Fpn1 protein. In 
our study, exposure to oxLDL activated Fpn1 transcriptional upregulation as 
part of the response to oxidative stress in macrophages, but without an iron 
source, the intracellular iron level likely remains unchanged. In such case, the 
majority of IRP1 would not dissociate from the IRE, impairing Fpn1 translation 
and synthesis despite its significant transcriptional upregulation (Figure III.32). 
Additionally, Fpn1 mRNA level quickly returned to the basal level of expression 
which indicates a short time window for Fpn1 translation.  
 
Figure III.32 - Schematic illustration of heme oxygenase-1 and ferroportin-1 regulation in 
Mox macrophages and iron-treated macrophages. Uptake of oxLDL (but not acLDL) in Mox 
macrophages as well as uptake of iron by non-polarized macrophages activates the 
transcription factor Nrf2, which subsequently triggers a significant upregulation of both Hmox1 
and Fpn1 (also known as Slc40a1) mRNA. However, unlike Hmox1, Fpn1 transcriptional 
upregulation is only slightly reflected at protein level in Mox macrophages. On the other hand, in 
iron-treated macrophages, both HO-1 and Fpn1 are significantly upregulated at mRNA and 
protein level, indicating that the IRP/IRE system might be involved in the limited Fpn1 
translation in Mox macrophages. Iron transport in Mox macrophages is most likely unchanged 
whereas, in iron-treated macrophages, the high Fpn1 levels at cell surface indicate enhanced 
iron export in these cells. In addition, HO-1 translation is enhanced in iron-treated macrophages 
compared to Mox phenotype. 
 
 
Accordingly, considering the limited synthesis of Fpn1 in Mox 
macrophages, Fth1 transcriptional upregulation is also not expected to be 
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reflected at protein level as its translation is also controlled by the IRE/IRP 
system 70. The upregulation of Fpn1 and Fth1 together with Hmox1 and other 
genes associated to with anti-oxidant properties would constitute part of a 
complex cellular response against oxidative stress triggered by oxLDL in Mox 
macrophages, in which the iron storage and export could play an important role 
in reducing ROS formation. 
Another possible mechanism for cellular protection against oxidative 
stress triggered by oxLDL uptake could be the downregulation of both Cp 
isoforms in murine Mox macrophages. Indeed, a mechanism of Cp mRNA 
decay induced by extracellular and intracellular oxidative stress was recently 
reported, which supports this hypothesis 315. Despite its anti-oxidant “label” 
often associated with iron oxidation, Cp is a potent oxidase that acts on many 
substracts such as amines, lipids and lipoproteins 136. In fact, Cp has been 
associated with increased cardiovascular risk due to its pro-oxidant capacity, in 
which Cp promotes LDL oxidation 256. Nonetheless, downregulation of Cp 
induced by oxLDL could also have a potential deleterious effect on Fpn1 
expression and compromise on iron efflux. Indeed, Cp ferroxidase activity was 
reported to be essential for Fpn1 stabilization at cell surface 121,122. Although the 
co-localization of GPI-Cp and Fpn1 observed in our studies (chapter 2) was 
only partial in iron-treated macrophages, we could not dismiss the contribution 
of sCp on macrophage iron export nor evaluate the role of both Cp isoforms 
under other conditions such as hypoxia, often observed at the plaque. 
Therefore, lack of Cp ferroxidase activity in intraplaque macrophages triggered 
by oxLDL could contribute to higher Fpn1 degradation and possible impairment 
of iron export, which would lead to increased ROS formation and intracellular 
oxidative stress. However, this mechanism of Cp mRNA downregulation 
triggered by oxLDL was not observed in human Mox macrophages.  
In addition, our results showed that oxLDL also induced a mild but 
significant upregulation of Il6 (20-fold, Figure III.13) in BMDM, which may 
explain the observed upregulation of Hamp1 in response to oxLDL. An 
upregulation of IL-1β (20-fold) in Mox macrophages was reported by Kadl et al 
249 which, combined with our results, show that Mox macrophages express pro-
inflammatory cytokines, although to a lesser extent than M1 macrophages. 
Accordingly, we showed that oxLDL induced Hamp1/HAMP transcription in both 
murine and human Mox macrophages, which could be associated with the 
upregulation of Il6 induced by oxLDL. Although the low level of Hamp1 mRNA in 
murine BMDM indicates that this upregulation is likely to have no significant 
effect at protein level in these cells, the higher basal expression of HAMP in 
human Mox macrophages suggests that an upregulation of Hepc peptide 
should not be disregarded. In fact, Li et al reported that culture of J774 murine 
macrophages with oxLDL upregulated Hepc peptide along with increased 
production of pro-inflammatory cytokines and ROS, promoting cell apoptosis 240. 
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Induction of Hepc in response to oxLDL uptake could therefore constitute an 
atherogenic mechanism, promoting Fpn1 degradation and iron sequestration in 
macrophages.  
Overall, macrophage exposure to oxLDL triggers the polarization of a 
specific phenotype (Mox) characterized by enhanced transcriptional expression 
of genes associated with anti-oxidant properties in order to resolve the oxidative 
stress induced by oxLDL uptake, including Hmox1, Fpn1 and Fth1. However, 
Fpn1 was surprisingly not significantly upregulated at protein level despite the 
significant transcriptional induction by oxLDL, showing that iron export in Mox 
macrophages is not enhanced. In addition, the possible Cp downregulation in 
murine macrophages as well as Hepc upregulation in both murine and human 
macrophages in response to oxLDL could contribute to Fpn1 degradation and 
subsequent impairment of iron export in Mox macrophages.  
 
4.2. Expression of iron metabolism proteins in the combined 
Mox/M1 macrophages phenotype  
Another objective of this study was to investigate the effect of 
simultaneous exposure of macrophages to the activators of Mox (oxLDL) and 
M1 (LPS/IFNγ) phenotypes. M1 macrophages have been associated with 
plaque instability and are characterized by increased production of pro-
inflammatory cytokines and ROS as well as increased iron retention due to 
Fpn1 downregulation at both mRNA and protein level. 
 Previous authors reported that exposure of macrophages to oxLDL 
inhibited the inflammatory response driven by LPS 316,317. Moreover, Kadl et al 
reported that fully polarized M1 and M2 macrophages would switch to Mox 
phenotype once exposed to oxLDL 249. However, in none of these studies the 
macrophages were simultaneous stimulated with oxLDL and M1 activators. 
However, Harada et al reported that simultaneous stimulation with LPS and 
Nrf2 specific activators counteracted LPS-induced downregulation of Fpn1 in 
murine and human macrophages, supporting the previous data that Nrf2 
activation would inhibit the LPS-driven inflammatory response 318.  
In this study, we showed that oxLDL significantly upregulates Fpn1 at 
transcriptional level through an Nrf2-dependent mechanism. According to the 
literature, it was expected that co-stimulation of murine macrophages with both 
oxLDL and LPS/IFNγ would lead to a Mox-like phenotype with normal or 
enhanced Fpn1 expression. Surprisingly, a mixed Mox/M1 phenotype was 
observed with early upregulation of Hmox1 (Mox marker) along with massive Il6 
upregulation (M1 marker). Additionally, Hmox1 upregulation was significantly 
lower than in Mox macrophages, but stable remaining high up to 24 h. Unlike 
previous reports, NF-κB activation by LPS remained unaffected by oxLDL as 
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can be observed in App, Fth1 and Hmox1 expression, all NF-κB target genes 
that are significantly upregulated in Mox/M1 compared with murine Mox 
macrophages at 24 h.  
Moreover, the transcriptional upregulation of the iron exporter Fpn1 
triggered by oxLDL was inhibited in Mox/M1 macrophages and even 
downregulated at 24 h, showing that LPS/IFNγ counteracts the Nrf2-dependent 
upregulation of Fpn1 normally induced by oxLDL, which is contrary to previous 
studies 318. Nonetheless, in our model, we used oxLDL which activates Nrf2, but 
also other transcription factors, while Harada et al used electrophilic compounds 
(DEM and SFN) that are known to be specific Nrf2 activators 318. Indeed, the 
upregulation of Fpn1 mRNA by DEM in murine macrophages was stable and 
remained high at 24 h, while Fpn1 upregulation in our murine Mox macrophage 
model was transient, presenting basal mRNA levels at 24 h. Additionally, 
Harada et al used LPS in their experimental model while we used LPS 
combined with IFNγ, both stimuli reported to downregulate Fpn1 mRNA 
expression. However, in the context of atherogenesis, the complex intraplaque 
microenvironment is rich in oxidized lipids and lipoproteins as well as pro-
inflammatory cytokines such as IFNγ. It is therefore relevant to observe that 
Fpn1 downregulation induced by LPS/IFNγ is mostly unaffected by oxLDL 
uptake. Additionally, the known Hepc inducer Il6 was highly upregulated in 
Mox/M1 macrophages, which suggests that in addition to Fpn1 transcriptional 
downregulation, Fpn1 levels at cell surface could also be decreased in a Hepc-
dependent manner (Figure III.33).  
Cp mRNA was also significantly upregulated in Mox/M1, but to a less 
extent than in M1 macrophages. Considering the distinct regulation of Cp 
mRNA level in M1 and Mox macrophages, it is possible that the lower Cp 
mRNA level observed in Mox/M1 when compared with M1 macrophages could 
be due to simultaneous increased Cp transcription (LPS/IFNγ) and increased 
Cp mRNA degradation (oxLDL) through distinct molecular mechanisms. 
Surprisingly, Cp isoforms were differently modulated in both M1 and Mox/M1 
macrophages, with a significant upregulation of sCp mRNA triggered by 
inflammatory conditions, either combined or not with oxLDL, whereas GPI-Cp 
mRNA level remained mostly unaffected compared with untreated 
macrophages (M0). This differential modulation of Cp isoforms suggests a 
major role for sCp in inflammation compared with the membrane GPI-Cp.  
Altogether, macrophages stimulated with both oxLDL and LPS/IFNγ 
present a mixed expression profile of Mox and M1 phenotypes, in which the 
expression of the iron metabolism genes analyzed was closer to the expression 
profile in M1 phenotype than Mox. Noteworthy, Fpn1 expression was 
downregulated in Mox/M1, which indicates that iron export is likely impaired in 
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these cells leading to a progressive iron accumulation, which could be relevant 
to the pathogenesis of the atherogenic process (Figure III.33).  
 
Figure III.33 - Schematic illustration of heme oxygenase-1 and ferroportin-1 regulation in 
Mox macrophages and combined Mox/M1 macrophages. Uptake of oxLDL in Mox 
macrophages triggers a significant upregulation of Hmox1 and Fpn1 (also known as Slc40a1) 
mRNA dependent on Nrf2 activation. In Mox macrophages, unlike HO-1 which is highly 
upregulated at protein level, Fpn1 translation is limited by a post-transcriptional mechanism 
most likely involving the IRP/IRE system. Co-stimulation with both oxLDL (Mox) and LPS/IFNγ 
(M1) leads to a mixed phenotype Mox/M1 in which Hmox1 is stably upregulated at mRNA and 
protein level, while Fpn1 is transcriptionally downregulated, likely leading to impaired iron export 
and promoting iron retention in these cells.  
5. Conclusion 
The uptake of oxLDL by BMDM drives the differentiation of the Mox 
phenotype, in which oxLDL and not acLDL specifically upregulated Fpn1 and 
Hmox1 transcription through an Nrf2-dependent mechanism. The Mox 
phenotype is also associated with an upregulation of Fth1 and downregulation 
of Cp mRNA, while no significant changes on App expression were observed. 
However, unlike HO-1, Fpn1 upregulation by oxLDL was only slightly reflected 
at the protein level. On the other hand, iron induced a significant and Nrf2-
dependent upregulation of Fpn1 mRNA that was also observed at protein level, 
suggesting that basal intracellular iron level could be the factor restraining Fpn1 
translation in Mox macrophages, likely associated with the IRE/IRP system 
(Figure III.32).  
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Additionally, the co-stimulation of LPS/IFNγ (M1 activators) and oxLDL 
(Mox activator) that tends to mimic the Mox/M1 mixed phenotype observed in 
atherosclerotic lesions 249, promotes the upregulation of Hmox1 and Fth1 
mRNA combined with downregulation of Fpn1 mRNA at 24 h (Figure III.33). 
Thus, low expression of Fpn1 and subsequent decrease of iron export in 
response to both oxLDL and pro-inflammatory conditions could lead to 
increased macrophage intracellular iron and storage in Ft, a possible 
mechanism for iron accumulation in the atherosclerotic plaque and promotion of 
plaque progression and destabilization. 
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1. Introduction 
Fpn1 is a key protein in iron metabolism, being the only iron exporter in 
mammals. On chapter III, we investigated the expression of human Fpn1 in 
different cell types (PBL, THP-1 macrophages, and HepG2) using different 
commercial and non-commercial antibodies. The results obtained were 
inconclusive since none of the antibodies was considered specific in the cell 
models and conditions tested. Given the relevance of this protein in our study, 
we decided to produce our own antibody raised against human Fpn1. The 
project was designed and orchestrated by Doctor François Canonne-Hergaux, 
who has already developed a specific antibody against murine Fpn1 269.  
2. Aims 
In this study, we aimed to produce and characterize a specific antibody 
against human Fpn1. Herein, we present the specificity and validation results 
available at the moment. 
3. Results 
Based on the hypothetical structural model of human Fpn1 100, three 
different epitopes were selected for the production of the rabbit polyclonal 
antibody raised against this protein: Fpn1’ (intracellular loop), Fpn2’ 
(extracellular epitope) and Fpn3’ (C-terminus) (Figure III.34).  
 
Figure III.34 - Illustration of the epitopes selected for the antibody production against 
human Ferroportin-1. Scheme of human Fpn1 structure reported by Rice et al 
100
. The three 
different epitopes selected for antibody production are indicated in color: intracellular loop Fpn1’ 
(yellow), extracellular loop Fpn2’ (green) and intracellular C-terminus Fpn3’ (red).  
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The strategy used as well as the part that each person and 
group/institution had in this project is described in Figure III.35.  
 
Figure III.35 - Scheme of the overall strategy for the production of antibody against 
human ferroportin-1. All institutions involved in the project are indicated, as well as the part 
that each person had in the production and validation of the antibodies. 
 
Briefly, for each epitope of interest, the nucleotidic sequence was cloned 
in frame to generate two different fusion proteins per epitope: one fused with 
glutathione-S-transferase (GST) originating the peptides GST-Fpn1’, 2’ and 3’; 
one fused with dihydrofolate reductase (DHFR) with a histidine tag, originating 
the peptides (6xHis)-DHFR-Fpn1’, 2’ and 3.’ The GST-Fpn1 fusion proteins 
were used for immunization of two New Zealand rabbits per epitope through a 
total of five injections. Blood was collected from each animal before and during 
the immunization process for title and specificity analysis of antibody production 
previous to the final bleeding and animal sacrifice. At last, the anti-serum of the 
final bleeding was affinity-purified using the (6xHis)-DHFR-Fpn1 fusion proteins 
and then tested on different cell lines overexpressing human Fpn1. 
Preliminary specificity tests were performed by immunoblotting, using 
fusion protein DHFR-Fpn1’/2’/3’ mixed with total extract of BMDM and testing 
crude anti-serum of the blood collected during the immunization process at 
different time points. As can be observed on Figure III.36, each antibody tested 
recognized the respective fusion-protein. Also, the title of antibody in the crude 
135 
anti-serum increased during the immunization process as expected. The 
antibody produced against epitope huFpn2’ (anti-huFpn2’) appears to have the 
strongest title whereas the one raised against huFpn3 (anti-huFpn3’) has the 
lowest, reacting also unspecifically with other proteins.  
 
Figure III.36 - Specificity tests of crude antibodies raised against human ferroportin-1 
using fusion protein. Immunoblotting analysis to evaluate the title and specificity of the crude 
anti-serum during the immunization process. Purified fusion protein (6xHis)-DHFR-Fpn1’ (A, 
10ng), (6xHis)-DHFR-Fpn2’ (B, 10ng) or (6xHis)-DHFR-Fpn3’ (C, 10ng) were mixed with total 
extract of murine BMDM (15µg), separated by SDS-PAGE and then immunoblotted using crude 
serum of rabbit before immunization (non-immunized serum, NIS) and after immunization in 
different time points: bleed 1(day 28), bleed 2 (day 49) and bleed 3 (day 63). The position and 
size in kilodaltons (kDa) of the molecular weight markers are indicated on the right. Vertical 
dashed lines indicate repositioned gel lanes.  
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In order to test if the antibodies would recognize the whole human Fpn1 
protein, membrane extracts were prepared from transfected CHO cell line 
overexpressing human Fpn1 cDNA coding the full-length protein. On Figure 
III.37A, we can observe that only the crude anti-huFpn1’ recognized a protein 
with a molecular weight compatible with the one predicted for human Fpn1. As 
a positive control, the affinity purified antibody raised against murine Fpn1 (anti-
mFpn1’) was also tested on CHO extracts. This antibody was raised against the 
same epitope as anti-huFpn1’ and was characterized extensively 269, 
recognizing specifically murine Fpn1 and also cross-reacting with the human 
protein when overexpressed. Both anti-huFpn1’ and anti-mFpn1’ recognized the 
same band, providing further support to the specificity of anti-huFpn1’.  
After affinity purification, all three antibodies raised against human Fpn1 
recognized the same protein as the anti-mFpn1’, supporting the specificity of 
reaction (Figure III.37B). The different intensity of reaction as well as time of 
exposure showed that anti-huFpn1’ has the highest title whereas anti-huFpn3’ 
presents the lowest title. Noteworthy, anti-huFpn3’ reacted with an unspecific 
protein with higher molecular weight (indicated by “*”) than human Fpn1. 
Comparison between affinity purified anti-huFpn1’ and anti-mFpn1’ shows that, 
despite similar specificity in this overexpression model, the antibody raised 
against the human epitope has the highest title as expected (FigureIII.37C). 
Figure III.37 - Specificity tests of antibodies raised against human ferroportin-1 using 
CHO cell line. CHO cells were transfected with a plasmid containing full-length human Fpn1 
cDNA and incubated 18h for protein expression before protein extraction. Crude membrane 
extracts (M) were then prepared and analyzed by Western blot using different antibodies (A-B) 
Comparison between crude antibodies (A) or affinity-purified antibodies raised against huFpn1’, 
2’ and 3’ epitopes (B) on membrane extracts of CHO cells overexpressing or not human Fpn1 
protein. The purified antibody raised against murine Fpn1’ (mFpn1’) epitope (equivalent to 
huFpn1’) was used as a positive control. (C) Comparison between affinity purified antibodies 
raised against huFpn1’ and mFpn1’ epitopes, using CHO membrane extracts overexpressing or 
not human Fpn1. The position and size in kilodaltons (kDa) of the molecular weight markers are 
indicated on the right. Vertical dashed lines indicate repositioned gel lanes. Antibodies tested, 
dilutions and exposure time of films are indicated at the bottom. Red Ponceau staining was 
used as a control for total protein loading between samples. *Unspecific band. 
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For further confirmation of the specificity of antibodies raised against human 
Fpn1, HUH7 cell line was used as a human hepatocyte model which, unlike 
CHO, was previously reported to express endogenous human Fpn1 319. In such 
model, the intracellular trafficking of overexpressed human Fpn1 was expected 
to be normal and basal levels of endogenous human Fpn1 would also be 
expected. Nonetheless, in order to increase the expression of human Fpn1, 
HuH7 cells were also transfected with the plasmid coding the full-length human 
Fpn1 cDNA previous to analysis by immunoblotting. As observed in Figure 
III.38, the affinity purified anti-huFpn1’ recognized the overexpressed human 
Fpn1 in transfected HuH7 cells. However, the lower transfection efficiency in 
HuH7 cell line lead to a diminished expression of human Fpn1 in these cells 
when compared with transfected CHO cell line. The affinity purified anti-huFpn2’ 
and anti-huFpn3’ antibodies failed to detect human Fpn1 in HuH7 cells (data not 
shown), likely due to the lower title of the antibody combined with the lower 
transfection efficiency. 
Figure III.38 - Specificity tests of an antibody raised against human ferroportin-1 using 
HuH7 cell line. HuH7 cells were transfected with a plasmid containing full-length human Fpn1 
cDNA and incubated 18h for protein expression before protein extraction. Crude membrane 
extracts (M) were analyzed by immunoblotting using the affinity purified anti-huFpn1’. Crude 
membrane extract of CHO cells overexpressing human Fpn1 was used as a positive control. 
The position and size in kilodaltons (kDa) of the molecular weight markers are indicated on the 
right. Vertical dashed lines indicate repositioned gel lanes. Red Ponceau staining was used as a 
control for total protein loading between samples. *Unspecific band. 
  
For confirmation of the specificity of the band detected by the different 
antibodies, both CHO and HuH7 cells overexpressing human Fpn1 were treated 
or not with Hepc (700nm, 3h), followed by immunoblotting analysis using anti-
huFpn1’ antibody. The activity of Hepc was tested on iron-treated murine 
macrophages (J774A1) and confirmed by immunoblotting using the anti-mFpn1’ 
antibody (data not shown). Additionally, the anti-huFpn1’ antibody cross-reacted 
with murine Fpn1 in these same samples, detecting the same band as the anti-
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mFpn1’ antibody. However, the anti-huFpn1’ antibody presented less avidity as 
well as less specificity, providing higher background in the detection (data not 
shown). As can be observed on Figure III.39, Hepc induced a downregulation of 
the protein detected by the anti-huFpn1’ antibody in both CHO and HuH7 cells 
overexpressing human Fpn1, confirming that this protein corresponds to human 
Fpn1. Noteworthy, this antibody detected an unspecific band in HuH7 
membrane extracts with higher molecular weight than human Fpn1.  
 
Figure III.39 - Hepcidin effect on human ferroportin-1 expression in transfected CHO and 
HuH7 cell lines. Cell line CHO and HuH7 were transfected with plasmid containing full-length 
human Fpn1 cDNA, incubated 18h for protein expression and then untreated or treated with 
Hepc (Hepc, 700nM, 3h). Crude membrane extracts (M) of HuH7 (left) and CHO (right) were 
then analyzed by immunoblotting using the affinity purified anti-huFpn1’ antibody. The position 
and size in kilodaltons (kDa) of the molecular weight markers are indicated on the right. Vertical 
dashed lines indicate repositioned gel lanes. *Unspecific band.  
Despite the results obtained in CHO and HuH7 cells, the final specificity 
test for antibody validation is to detect endogenous expression in non-
transfected cells. Human THP-1 monocytic cells were differentiated into 
macrophages using the activator PMA, followed by treatment or not with iron 
(described to increase Fpn1 expression, as a positive control) and Hepc. All 
three affinity purified antibodies raised against human Fpn1 were tested on 
membrane extracts of THP-1 macrophages. Unlike the tests on CHO cell line, 
different detection patterns were generated by each antibody displaying 
different unspecific bands (indicated by “*”). The gray arrowhead indicates one 
band detected by the anti-huFpn1’ antibody that has a molecular weight 
compatible with human Fpn1 and seems to increase with iron and decrease 
upon Hepc treatment as expected (Figure III.40). However, the detection was 
weak and may reflect low human Fpn1 protein level in these cells despite PMA 
activation and iron treatment. Indeed, a posterior and unrelated experiment 
confirmed using qPCR that the basal level of human Fpn1 mRNA was low in 
THP-1 derived macrophages (Mean Ct = 28,5). Therefore, further tests on 
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endogenous human Fpn1 detection using a different cell model are necessary 
to complete the validation of the antibodies produced. 
Figure III.40 - Specificity tests of antibodies 
raised against human ferroportin-1 THP-1 
macrophages. Comparison between affinity 
purified antibodies raised against huFpn1’, 2’ 
and 3’ epitopes using membrane extracts of 
PMA-induced THP-1 macrophages stimulated 
or not with iron (FeNTA, 100µM, 18h) and 
Hepc (700nM, 3h). The arrowhead indicates a 
possible band for endogenous expression of 
human Fpn1 in THP-1 macrophages. The (*) 
indicates unspecific bands. The position and 
size in kilodaltons (kDa) of the molecular 
weight markers are indicated on the right. 
Vertical dashed lines indicate repositioned gel 
lanes. Antibodies tested and respective 
dilutions used are indicated at the bottom. Red 
Ponceau staining was used as a control for 
total protein loading between samples.  
 
4. Discussion and conclusion 
In this study, three different antibodies were produced against human 
Fpn1, recognizing different epitopes. Specificity tests on cell lines 
overexpressing human Fpn1 show that, despite presenting different avidity 
and/or title, all three antibodies can recognize the same protein and with a 
molecular weight compatible with human Fpn1. Cross-reaction with the same 
protein by the antibody raised against mFpn1’ epitope gives further support to 
the specificity of the band detected by the three antibodies raised against 
human Fpn1. Noteworthy, despite the cross-reaction of anti-mFpn1’ antibody 
with human Fpn1, the power of detection of human Fpn1 by the anti-mFpn1’ 
antibody was lower in comparison with the antibodies generated against human 
Fpn1 and were exclusive of transfected cells overexpressing human Fpn1.  
The decrease of the putative human Fpn1 band intensity observed in 
Hepc-treated CHO and HuH7 cells overexpressing human Fpn1 provides 
further confirmation on the specificity of anti-huFpn1’ antibody detection in this 
system. The incomplete degradation of human Fpn1 after Hepc treatment in 
these samples could be explained by the overexpression system itself, in which 
the concentration of Hepc used could have been insufficient to induce complete 
degradation of human Fpn1 protein levels. Additionally, the overexpression 
system may also lead to a significant amount of intracellular human Fpn1 
(cellular trafficking) that would not be available for Hepc binding. As a 
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consequence, the intracellular human Fpn1 would not be degraded and would 
be detected in the crude membrane extracts.  
Preliminary tests on THP-1 macrophages, which were reported elsewhere 
to endogenously express human Fpn1 85,278, revealed unspecific reaction by the 
three antibodies tested, recognizing bands with higher or lower molecular 
weight than human Fpn1. Only the anti-huFpn1’ antibody reacted against a 
protein with a molecular weight compatible to human Fpn1, increasing mildly 
with iron and decreasing upon Hepc treatment on iron-treated cells, which 
suggests that it could correspond to human Fpn1. However, the weak reaction 
and at the limit of detection indicate low expression of human Fpn1 in these 
cells, which could also explain the unspecific bands detected. Indeed, posterior 
experiments confirmed the low human Fpn1 mRNA basal level in these cells. 
The low human Fpn1 expression in THP-1 derived macrophages may result 
from the fact that these are immortalized cells, which are therefore prone to 
store iron in order to promote their proliferation in culture. For this reason, we 
concluded that THP-1 macrophages are not a good model and further studies in 
primary cells such as human peripheral blood macrophages stimulated with 
different conditions know to modulated Fpn1 expression (iron overload, iron 
deficiency, hypoxia, erythrophagocytosis, Hepc) are thus necessary to complete 
the characterization of these antibodies and to conclude on their specificity on 
systems with endogenous expression of human Fpn1. In addition, given the fact 
that some antibodies against human Fpn1 were tested in THP-1 macrophages 
in chapter 1, it is possible that the lack of specific detection in those 
experiments could also be an artifact of the low expression of human Fpn1 in 
these cells and should also be re-tested in primary cells. 
5. Authorship 
The project of antibody production was designed and organized by Doctor 
François Canonne-Hergaux in a large network involving different participants, 
groups, and institutions as described in Figure III.35.  
All the validation results presented in this chapter were produced by the author 
of the thesis, with exception to the ones shown in Figure III.36 which were 
performed by Lorenne Robert.  
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1. Discussion 
In atherogenesis, the infiltration of immune mononuclear cells is an early 
and continuous event associated with the development and progression of the 
atherosclerotic lesions. An association between iron and cardiovascular risk has 
been proposed, in which the iron status of the immune cells within the lesion, 
and particularly in macrophages, could be decisive for its development and 
progression into an unstable or stable atherosclerotic plaque 214,218,234.  
In the present study, we focused on the expression of specific iron 
metabolism proteins on the three main immune cell types that are found in the 
atherosclerotic lesions: lymphocytes, monocytes and macrophages.  
1.1. Ceruloplasmin and immune cells in atherosclerosis 
We demonstrated that human lymphocytes and monocytes express both 
isoforms of Cp (GPI-Cp and sCp) 320, an acute phase protein with oxidase 
activity that is essential for iron export through Fpn1, but that also oxidizes other 
substracts such as LDL 51,256. Additionally, the results obtained suggested that 
Cp expression and regulation in these cells is likely to be cell-specific, 
particularly in activated cells. Moreover, the expression of both Cp isoforms was 
also confirmed in murine macrophages.  
In ATH, the accumulation and oxidative modification of LDL is believed to 
be the primordial factor in atherogenesis, activating ECs to produce chemokines 
and pro-inflammatory cytokines that will promote the recruitment of monocytes 
and lymphocytes to the site of lesion. The synthesis of Cp by the main immune 
cell types found in the atherosclerotic plaque may therefore constitute an 
additional mechanism contributing to LDL oxidation. As an acute phase protein, 
the production of pro-inflammatory cytokines by activated ECs and infiltrated 
immune cells will significantly upregulate local Cp expression. Indeed, in 
addition to the previous report of sCp upregulation by IFNγ in monocytes 274, we 
showed that IFNγ also promotes expression of sCp by lymphocytes. Moreover, 
our results confirmed previous reports by other authors in which M1 polarized 
macrophages significantly express Cp.  
Interestingly, when analyzing the effect of M1 polarization on the different 
Cp isoforms, we observed that GPI-Cp mRNA remains mostly unchanged 
whereas sCp mRNA was significantly upregulated by the combined pro-
inflammatory conditions LPS/IFNγ. The same differential upregulation was 
observed in the mixed phenotype Mox/M1, but not in the downregulation of Cp 
in Mox macrophages, thus indicating that it is exclusively induced by pro-
inflammatory conditions. This differential regulation of GPI-Cp and sCp in 
murine macrophages points to a major role of sCp local expression at site of 
inflammation. This role is most likely linked to iron loading onto Tf and/or Lf 
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molecules instead of cellular iron export, considering the lack of GPI-Cp mRNA 
upregulation along with Fpn1 downregulation in pro-inflammatory conditions. 
A previous study showed that monocyte-derived sCp can oxidize LDL 256, 
demonstrating how local Cp upregulation by inflammatory conditions can 
promote LDL oxidation and thus contribute to the progression of the plaque. 
Moreover, in addition to Cp-mediated LDL oxidation, Cp was also reported to 
enhance SMC- and EC-mediated LDL oxidation by a superoxide-dependent 
mechanism 261. Accordingly, co-localization of Cp and oxLDL in the enlarged 
intima of pro-atherosclerotic areas was previously demonstrated 260, supporting 
the hypothesis that local Cp production by immune cells (lymphocytes, 
monocytes and macrophages) within the plaque might be associated with 
increased LDL oxidation and thus contribute to increased susceptibility to VD 
260. Interestingly, an association between high Cp activity and increased oxLDL 
levels was reported in patients with acromegaly, a pathology associated with 
increased mortality due to cardiovascular causes 258, which reinforces the 
hypothesis of increased Cp levels could constitute a risk factor for developing 
VD. 
1.2. Ferroportin-1 and its partners in murine macrophages 
Given the key role of macrophages in ATH progression and how iron 
accumulation in atherosclerotic lesions has been associated with macrophages 
and macrophage-derived foam cells, the study focused on the expression of 
iron metabolism proteins in murine macrophages and, in particular, on the ones 
involved in iron export.  
As one of the main aims of this study, we studied the potential partners of 
Fpn1 in murine macrophages. The results obtained showed that, as observed in 
human lymphocytes and monocytes, murine macrophages also express both 
Cp isoforms. Moreover, we demonstrated that GPI-Cp partially co-localizes with 
Fpn1 in lipid rafts microdomains in iron-treated macrophages, which indicates 
that GPI-Cp is at least in part involved in iron export in these cells 320. However, 
the partial co-localization also suggested indicated that another ferroxidase, 
including sCp, could be additionally interacting with Fpn1 in iron-treated BMDM. 
APP was recently reported to possess ferroxidase activity and to interact with 
Fpn1 promoting iron export in neurons 139 and its expression was previously 
reported in human monocytes and macrophages 262. Herein, we showed that 
APP is expressed in murine macrophages, being strongly upregulated by iron 
and recruited to the DRM fractions enriched in lipid raft proteins, where its 
expression overlaps with Fpn1. A model of Fpn1 interaction with GPI-Cp, sCp 
and APP during iron export was therefore suggested in murine macrophages 
(Figure III.19), in which APP could influence iron export despite presenting or 
not ferroxidase activity.  
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Nonetheless, further studies are necessary in order to clarify the 
ferroxidase partners of Fpn1 in macrophages and how these proteins and iron 
export are modulated by different conditions, particularly iron deficiency and 
hypoxia that were not explored in this study. 
1.3. Macrophage polarization and iron export in atherosclerosis 
Iron export has been pointed out as a key event on the resistance to 
macrophage-derived foam cell formation 239,248. Characterizing how the proteins 
involved in macrophage iron export are modulated under pro-atherogenic 
conditions is therefore essential to understand the role of iron in atherogenesis.  
An association between macrophage iron overload and the development 
of an unrestrained pro-inflammatory M1 phenotype was recently reported 184. 
M1 macrophages, which were previously reported to constitute the main 
macrophage subpopulation in advanced and unstable plaques 321, are 
characterized by increased iron retention and high production of pro-
inflammatory cytokines, chemokines and ROS, which promote the recruitment 
of more immune cells in a vicious cycle that perpetuates the pro-inflammatory 
environment of the plaque 169. On the other hand, the increased ROS 
production contributes to the oxidative intraplaque environment in which 
accumulation of oxLDL continuously induce the expression of adhesion 
molecules, chemokines and pro-inflammatory cytokines by ECs. Accordingly, 
recent observations point to an important role of Hepc-mediated macrophage 
iron overload in the progression of atherosclerotic lesions into vulnerable 
plaques. Noteworthy, in addition to macrophages, lymphocytes and monocytes 
were also reported to produce Hepc in response to pro-inflammatory conditions 
(TNFα and IL-6, respectively) 74,322 and may therefore contribute to Hepc local 
production in atherosclerotic lesions. Furthermore, increased serum Hepc and 
iron macrophage were associated to increased MCP-1 release and vascular 
damage in patients with metabolic syndrome 237, pointing to a role for circulating 
Hepc in addition to local Hepc in atherogenesis.  
The present study showed that exposure of macrophages to oxLDL (Mox 
activator) upregulated Il6 and Hamp1 mRNA in Mox macrophages, indicating 
that intraplaque environment rich in oxLDL may contribute to the production of 
pro-inflammatory cytokines and Hepc promoting local inflammation and 
intracellular iron accumulation. Our results are supported by Li et al study 
showing that J774 macrophages exposed to oxLDL presented increased 
production of ROS and synthesis of pro-inflammatory cytokines and Hepc 240. 
Remarkably, despite the transcriptional upregulation of Fpn1, we showed that 
murine Mox macrophages presented basal Fpn1 protein level. Although the 
upregulation of Hamp1 mRNA induced by oxLDL in BMDM is unlikely to be 
reflected at protein level due to the low basal Hamp1 mRNA level in these cells, 
this mechanism is preserved in other models and was also observed in primary 
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human macrophages. The higher level of expression of HAMP in these cells 
suggests that Hepc might be upregulated at protein level in human Mox 
macrophages, promoting Fpn1 downregulation at cell surface and impairing iron 
export. Considering this, it is plausible to consider that Mox macrophages in 
vivo may present Fpn1 downregulation and impaired iron export due to 
increased Hepc production. Additionally, we also showed that a combined 
environment of oxLDL and pro-inflammatory stimuli (LPS/IFNγ, M1 activators) 
induces a mixed Mox/M1 macrophage phenotype in which Fpn1 in 
transcriptionally downregulated, suggesting impairment of iron export and 
subsequent iron accumulation in these cells. Moreover, significant Il6 
upregulation in Mox/M1 macrophages similar to the one observed in M1 
phenotype further suggests increased Hepc production and Hepc-mediated 
Fpn1 downregulation in these cells.  
According to Kadl et al, the following macrophage subpopulations were 
observed in LdlR-/- mice aortic lesions: 39.2% M1, 34.4% Mox, 21.8% M2, 9.6% 
Mox/M1 and 2.3% Mox/M2 of the total F4/80+/CD11b+ aortic cells 249. 
Considering that iron export is impaired in M1 and Mox/M1 macrophages 
(transcriptional Fpn1 downregulation) and likely to be impaired also in Mox 
macrophages (Hepc upregulation and basal levels of Fpn1 protein expression), 
a significant part of approximately 49% to 83% of the total macrophage 
population at the aortic lesions likely presents intracellular iron accumulation 
along with increased production of pro-inflammatory cytokines and Hepc. These 
results along with the recent publications on Hepc fundamental role in plaque 
progression are in agreement with the iron hypothesis proposed by Sullivan, in 
which macrophage iron accumulation likely induced by Hepc under pro-
inflammatory conditions could contribute to plaque destabilization and disease 
progression 234.  
However, the iron hypothesis was recently questioned by a study 
conducted by Kautz et al in which mice deficient for ApoE and heterozygous for 
the Fpn1 mutation ffe (ApoE-/-Fpn1+/ffe) that promotes macrophage iron overload 
were used in order to evaluate the possible effect of macrophage iron overload 
in ATH progression. In this study, no significant differences were observed on 
the lesions area when comparing ApoE-/-Fpn1+/ffe and ApoE-/- mice, which lead 
the authors to conclude that there was no significant association of macrophage 
iron overload and ATH progression 323. Interestingly, in another experimental 
model in which macrophage iron overload was induced by local overexpression 
of Hepc, no significant differences were observed concerning the area of 
lesions. However, analysis of plaque composition releaved increased 
macrophage infiltration along with decreased SMC and collagen content. In 
addition, the plaques also presented increased oxLDL content, but no difference 
in plaque total lipid content 240. All these features indicated that Hepc 
overexpression and subsequent macrophage iron trapping promoted the 
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development of unstable atherosclerotic plaques that are more vulnerable to 
rupture, without necessarily correspond to larger lesions. It is therefore 
reasonable to question if such alterations in the composition of the 
atherosclerotic plaques would also have been found in the study conducted by 
Kautz et al, despite the lack of significant changes in the area of lesions.  
1.4. Comparison between Mox and Mhem/M(Hb) macrophages 
The recent polarized macrophage phenotypes of Mhem and M(Hb) 
characterized by low intracellular iron and resistance to foam cell formation are 
also in agreement with the iron hypothesis, in which macrophage iron depletion 
was proposed to protect against foam cell formation. Both Mhem and M(Hb) are 
found in intraplaque hemorrhage areas in vivo and can be reproduced in vitro 
by incubation of monocytes with Hb:Hp or heme during their differentiation into 
macrophages (6-7 days). These macrophages are characterized by high levels 
of HO-1, low intracellular ROS and increased expression of cholesterol 
exporters.  
Although there are some differences in the molecular mechanisms 
described in Mhem and M(Hb) phenotypes, low intracellular ROS is a common 
feature essential for the increased cholesterol efflux and protection against 
foam cell formation. While in Mhem, HO-1 activity is essential for reducing 
intracellular ROS, in M(Hb) it is the upregulation of Fpn1 and increased iron 
export that is associated with reduced ROS production and subsequent 
protection against foam cell formation 246,248,324. However, both HO-1 activity 
and increased iron export seem to be interconnected and the results herein 
presented support it.  
In fact, exposure to heme or Hb:Hp activates a cellular response against 
“heme stress” in which Nrf2 plays a key role and, among other target genes, 
upregulates Hmox1, Fpn1 and Fth1 transcription. As observed in our results, 
while HO-1 upregulation is easily reflected at protein level in Mox macrophages, 
Fpn1 and H-Ft translation is regulated by the IRE/IRP system and kept at basal 
level by low intracellular iron levels. The HO-1 activity on heme catabolism in 
Mhem/M(Hb) macrophages generates higher intracellular iron levels to promote 
IRP1 dissociation from the IREs and subsequent significant induction of Fpn1 
and H-Ft protein synthesis. Intracellular iron can then be stored in Ft molecules 
and/or be exported by Fpn1 out of the macrophage, reducing the intracellular 
LIP and preventing the formation of ROS, thus leading to LXR activation and 
subsequent upregulation of cholesterol exporters ABCA1/ABCG1.  
Thus, one of the key differences between Mhem/M(Hb) and Mox 
phenotypes (Figure IV.1) is likely the lack of an abundant intracellular iron 
source during Mox differentiation that would promote the significant 
upregulation of Fpn1 protein and later on lead to LXR activation, triggering the 
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upregulation of cholesterol exporters and reducing intracellular lipid content. 
Noteworthy, LXR activation was recently associated with decreased Hepc 
expression 325, which could constitute an additional mechanism for protection 
against foam cell formation in Mhem/M(Hb).  
In addition, in the absence of heme, the increased HO-1 levels found in 
Mox macrophages will not be translated in increased production of heme 
catabolism end-products such as biliverdin/bilirubin and CO that possess known 
anti-oxidant and anti-inflammatory properties. As a consequence, IL-10 
induction will not be induced in Mox macrophages, which also contributes to the 
distinction between Mox and Mhem/M(Hb) macrophages. 
Figure IV.1 - Schematic illustration of the main differences between Mox and Mhem/M(Hb) 
macrophages. At early phase of polarization, both Mox and Mhem/M(Hb) activators trigger 
Nrf2 pathway, leading to significant mRNA upregulation of Hmox1 and Fpn1 (officially known as 
Slc40a1). Unlike Mhem/M(Hb) macrophages, despite the massive HO-1 upregulation, the 
absence of heme during Mox polarization leads to the lack of an abundant LIP in order to 
promote significant Fpn1 translation. As a consequence, iron export in Mox macrophages likely 
remains at basal levels and may even be impaired by Hepc upregulation. On the contrary, 
increased Fpn1 protein levels lead to increased iron export in Mhem/M(Hb), reducing ROS 
formation and triggering the LXR-mediated resistance against foam cells formation. In addition, 
heme catabolism by HO-1 in Mhem/M(Hb) macrophages leads to the formation of biliverdin and 
CO, which have known anti-oxidant and anti-inflammatory properties, such as triggering the 
production of IL-10, a cytokine essential for Mhem/M(Hb) polarization and resistance to foam 
cell formation. 
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2. Conclusion  
In summary, in this study we characterized the expression of proteins 
involved in iron metabolism in immune cells with particular focus on the ones 
involved in iron export. We demonstrated that, in addition to sCp, lymphocytes, 
monocytes and macrophages also express the membrane isoform GPI-Cp that 
was previously detected mostly in CNS cells, where its activity was shown to be 
essential for cellular iron export mediated by Fpn1 270. In murine macrophages, 
we showed that GPI-Cp partially co-localizes with Fpn1 in lipid rafts 
microdomains and could participate in the Fpn1-mediated iron export. 254. 
However, we proposed that besides Cp, APP could be also interacting with 
Fpn1 and contributing to iron export in macrophages under iron overload 
conditions. Further research is currently necessary to clarify the role of APP in 
macrophage iron export. 
In the context of ATH, in addition to the serum circulating Cp, the three 
immune cell types (lymphocyte, monocytes and macrophages) present in 
atherosclerotic lesions express both Cp isoforms and likely contribute to local 
Cp accumulation in atherosclerotic lesions. Such Cp activity in the lesion could 
contribute to the local oxidation of LDL, providing a potential mechanism for the 
association between high Cp levels and increased cardiovascular risk 257-259.  
The effect of oxLDL on iron metabolism proteins expression in 
macrophages was then investigated. We demonstrated that despite Nrf2 
activation induced by oxLDL, Mox macrophages are not protected from foam 
cell formation as are Mhem/M(Hb) macrophages, showing lipid accumulation, 
basal levels of Fpn1 at cell surface along with upregulation of pro-inflammatory 
cytokines and Hepc. In addition, simultaneous exposure of macrophages to 
oxLDL and LPS/IFNγ showed that Mox polarization is not dominant over M1, 
and the resulting Mox/M1 phenotype was closer to M1 than Mox, with increased 
IL-6 expression, downregulated Fpn1 expression combined with increased H-Ft 
expression. These results suggests that macrophages exposed to an 
environment rich in oxLDL and pro-inflammatory cytokines are prone to 
accumulate both lipids and iron while secreting high levels of pro-inflammatory 
cytokines and Cp, which will further promote the local inflammation and LDL 
oxidation.  
In general, the results presented in this study are in agreement with the 
iron hypothesis proposed initially by Sullivan 214,234, in which macrophage iron 
trapping induced by Fpn1 transcriptional and/or post-transcriptional 
downregulation induced by Hepc could promote the development of unstable 
atherosclerotic plaques and thus contribute to the progression of the disease. 
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3. Future perspectives 
One fundamental aspect for many of the questions generated during this 
study relies on the validation of a specific antibody against human Fpn1. The 
results presented in chapter 4 about our home-made antibodies showed 
specific detection in overexpressed Fpn1 system, but low title and unspecific 
detection when tested on THP-1 macrophages, likely due to low Fpn1 
expression in this cell model. Completing the validation tests on primary human 
cells that endogenously express Fpn1 under different experimental conditions is 
therefore essential for any further investigation involving Fpn1 expression in 
human cells. In addition, recent publications indicate that one commercial 
antibody previously tested in chapter 1 could be a specific tool for detecting 
human Fpn1 and should therefore be re-tested in an appropriate human primary 
cell model. 
Another major priority would be to clarify the iron regulation of Cp in 
BMDM and to characterize GPI-Cp/Fpn1 and APP/Fpn1 co-localization in 
hypoxia/iron deficiency conditions. In addition, performing iron export studies 
combined with specific Cp isoforms or APP knockdown would be important in 
order to confirm their role in iron export in BMDM and extent those studies to 
human macrophages. Characterization of the role of Cp isoforms in iron export 
in human lymphocytes would also complete our own study as well as the recent 
work by Pinto et al 290. 
One additional and interesting experiment would be to test if increasing 
macrophage LIP previous to oxLDL exposure would affect the level of Fpn1 
protein expression in Mox macrophages as we proposed in this study. Also, 
further characterization of human Mox and Mox/M1 macrophages at both 
mRNA and protein level, including quantification of secreted cytokines and 
Hepc, would also be important to understand how the results obtained in this 
study would be confirmed in human cells.  
Since macrophage characterization in human atherosclerotic plaques is 
mostly focused in M1 and M2 phenotypes, it would be interesting to 
characterize the different polarized macrophage populations (M1, M2, Mox, 
Mox/M1, Mox/M2, M4 and Mhem/M(Hb)) in human stable and unstable 
atherosclerotic lesions at different stages of development in order to understand 
how the different specific macrophage phenotypes could be associated with the 
plaque progression and destabilization. Additional characterization of Fpn1 
expression in intraplaque macrophages and search for its correlation with iron 
and lipid accumulation associated with specific macrophage phenotype markers 
would also bring further insight on the iron hypothesis.  
Finally, analysis of the effect of statins and other promising therapeutic 
agents such as Metformin (Mhem activator), LXR and Nrf2 activators on the 
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expression of Fpn1, Hepc and cholesterol exporters in macrophages would also 
be important for the identification of potential therapeutic strategies for ATH. 
Overall, with these experiments, we would like to answer the questions 
generated in this study concerning Cp and APP role in Fpn1 iron export in 
immune cells. Furthermore, we would aim to complete the work on macrophage 
polarization and iron export in atherogenesis and thus contribute to understand 
the role of iron as a risk factor in ATH as well as possibly identify future 
therapeutical targets for this disease. 
152 
  
153 
 
 
 
 
 
 
 
V. Supplemental Data 
 
 
  
154 
 
  
155 
1. Introduction 
Like macrophages, hepatocytes play a key role in iron homeostasis being 
the main iron storage cell in the human body. Previous reports had only 
reported the expression of the soluble isoform of Cp in hepatocytes. In the 
results of chapter 1, we used the hepatocarcinoma cell line HepG2 as a 
hepatocyte model and showed that these cells express both Cp isoforms. In 
addition, the immunostaining of GPI-Cp in non-permeabilized cells showed a 
pattern of detection very similar to the one observed on GPI-Cp staining in non-
permeabilized murine macrophages (BMDM, chapter 2). Furthermore, we 
showed that GPI-Cp partially co-localizes with Fpn1 in lipid rafts microdomains 
in iron-treated BMDM.  
2. Aims 
In this study, we aimed to clarify if Cp expression in HepG2 would be 
modulated by iron as observed in murine macrophages. Additionally, we 
investigated the distribution of GPI-Cp in lipid rafts microdomains at cell surface 
of HepG2 cells.  
3. Results 
 
3.1. Ceruloplasmin is not modulated by iron in HepG2 cells 
This observation was further confirmed by immunoblotting analysis of 
cytosolic and crude membrane extracts of HepG2 cells untreated and iron-
treated with increasing concentrations of FeNTA (50-200µM), where no 
significant effect was observed on GPI-Cp (M) nor on sCp (C) isoforms 
expression level (Figure V.1A). A slight difference in electrophoretic migration 
was observed between the Cp specie detected in membrane-associated Cp 
(GPI-Cp) and the cytosolic Cp (sCp), indicating a slight molecular weight 
difference as previously reported 135. Again, downregulation of TfR1 was 
observed in iron-treated HepG2 crude membrane extracts, confirming 
successful iron uptake by these cells (Figure V.1B).  
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Figure V.1 - Effect of iron on 
ceruloplasmin expression in 
HepG2. (A) Immunoblotting of Cp 
in cytosolic (C) and crude 
membrane (M) extracts of HepG2 
cells untreated and treated with 
increasing concentrations of iron 
(FeNTA, 50-200µM). (B) 
Immunoblotting of TfR1 in 
membrane extracts isolated from 
HepG2 cells untreated or treated 
with FeNTA (50-200µM). 
Downregulation of TfR1 in iron-
treated HepG2 extracts confirms 
successful iron uptake by these 
cells, despite no observed effect of 
iron on Cp expression levels (A). 
 
 
3.2. GPI-anchored Cp is localized in lipid rafts in HepG2 cells  
As observed in figure V.2A, the dot-like pattern of Cp staining at cell 
surface of HepG2 cells suggested that this protein could be present in 
microdomains such as lipid rafts, known to be enriched in GPI-anchored 
proteins. To test this hypothesis, immunoblotting analysis of Cp was performed 
in iodixanol gradient fractions prepared from HepG2 cells untreated and iron-
treated. In both conditions, as determined by the subcellular fractionation on 
iodixanol gradient, the localization of Cp and flotillin-1 (a marker for lipid rafts in 
hepatocytes) overlapped notably in the lightest fractions 1 and 5 (Figure V.2B). 
Such observation indicated the presence of some of the detected Cp in the 
fractions enriched in lipid raft-associated proteins (DRM). Non-rafts membranes 
(NDRM) containing TfR1 were mostly defined as the denser material (fractions 
6 to 12) and were shown to contain high amount of Cp.  
Analysis of Cp species detected in DRM and NDRM fractions, a slight 
difference in eletrophoretic migration is observed in figure V.2B. According to 
the nature of the fractions and to our previous observations in membrane 
versus cytosolic extracts (see Figure V.1A), we concluded that the GPI-Cp 
isoform is present in DRM (black arrowhead) whereas the cytosolic isoform is 
strongly detected in NDRM (gray arrowhead). After FeNTA treatment, a 
decrease of TfR1 expression was observed, confirming downregulation of this 
receptor by iron overload as expected. However, no effect was observed in Cp 
expression levels nor its localization, indicating that Cp expression and 
distribution is not modulated by iron overload conditions in human hepatocytes.  
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Figure V.2 - Ceruloplasmin localizes in 
lipid raft microdomains at cell surface 
of HepG2 cells. (A) Immunofluorescence 
staining of Cp (green) in non-
permeabilized HepG2 cells. Nuclei are 
stained with DAPI (blue). The white bars 
represent 25 μm. (B) Immunoblotting 
detection of Cp, Flotillin1 (Flot-1; raft 
marker) and TfR1 (non-raft marker) in 
detergent resistant membrane (DRM) and 
non-detergent resistant membrane 
(NDRM) fractions isolated from iron-
treated (FeNTA, 100 µM) and untreated 
HepG2 cells. Human serum-purified Cp 
(hCp) was used as a positive control for 
Cp detection. Red Ponceau (RP) staining 
was used for control of total protein 
loading. The positions and sizes in 
kilodaltons (kDa) of the molecular weight 
markers are indicated on the left. Vertical 
dashed lines indicate repositioned gel 
lanes.  
 
 
4. Discussion and conclusion 
The hepatocyte is a key cell in iron homeostasis, being the major iron 
store in the human body and also the main producer of some proteins important 
in iron metabolism. One of those proteins is Cp, which is an abundant plasma 
protein reported to be produced and secreted by hepatocytes. Our results in 
chapter 1 showed that HepG2 cells express GPI-Cp in addition to the soluble 
isoform of Cp. Herein, we investigated if GPI-Cp was indeed localized in lipid 
rafts microdomains as suggested by Cp surface staining in HepG2 cells. Our 
results confirmed that GPI-Cp and the hepatocytes raft marker Flot-1 are highly 
enriched in the lightest DRM fractions, indicating that GPI-Cp is localized in lipid 
rafts microdomains. This subcellular localization suggests that, in addition to 
sCp, GPI-Cp could also contribute to promote iron release through Fpn1 in 
hepatocytes. Despite the fact we were not able to clarify Fpn1 expression in 
HepG2 cells (Figure III.8-9), Fpn1 has been described at the cell surface of 
hepatocytes in hepcidin-deficient mice 55. Moreover, lack of Cp activity in 
aceruloplasminemia patients or Cp-/- induces progressive and significant iron 
accumulation in several organs, in which the liver and, in particular, hepatocytes 
are highly affected 51,63. However, neither Cp expression nor its distribution in 
DRM fractions were affected by iron overload conditions in HepG2 cells. 
Hepatocytes are cells committed mostly to iron storage, promoting unrestricted 
NTBI uptake and storage. The massive iron accumulation in the liver of HH or 
secondary iron overload patients shows that these cells favor iron uptake rather 
158 
than release. Therefore, it is not surprising that iron overload conditions would 
not modulate Cp expression in these cells. In addition, as mentioned before, 
other authors reported that APP is also expressed in liver, where it would 
equally contribute to liver ferroxidase activity along with Cp. In fact, App-/- mice 
presented iron accumulation in this organ, more specifically in hepatocytes 139. 
However, further studies are needed in order to clarify the role of Cp and APP 
as ferroxidases promoting iron export in hepatocytes.  
On the other hand, GPI-Cp expression in hepatocytes may not be limited 
to its putative role in iron export. Hepatocytes store significant amounts of 
intracellular iron, presenting therefore increased risk of oxidative stress. Indeed, 
the ROS production and oxidative damage originated by free hepatic iron were 
already reported as being highly mutagenic and carcinogenic 326. In these cells, 
the expression of both Cp isoforms may also have an important anti-oxidant role 
in order to preserve membrane integrity and cellular function against iron-
mediated oxidative stress. We observed a higher basal level of expression of 
both Cp isoforms in HepG2 compared with BMDM, which may reflect the higher 
risk of oxidative damage on hepatocytes compared with macrophages.  
Finally, one should keep in mind that HepG2 is n hepatocarcinoma cell 
line and, in this context, cellular iron homeostasis in these cells could be 
regulated in order to favor the intracellular iron demands to promote cell 
proliferation. Studies of Fpn1 expression in breast cancer cells show that its 
expression is inversely correlated with cell proliferation 187. In HepG2, the 
expression of proteins involved in iron release such as Cp or Fpn1 could be 
regulated in a different way compared with primary hepatocytes. Therefore, 
further research in primary hepatocytes in culture as well as in tissue 
hepatocytes using histological techniques are needed to clarify the role and the 
regulation of the proteins involved in iron export in hepatocytes. 
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